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Abstract 
Background: Coagulation factor XIII (FXIII) is a key enzyme in stabilising 
blood clots by cross-linking fibrin molecules together, amongst other effects 
on fibrinolysis and matrix protein stabilisation. The human FXIII-A V34L 
sequence variant leads to increased activation rates, forming clots with 
thinner fibrin fibres and smaller pores, and has been reported to show 
protective effects against thrombotic diseases like venous thromboembolism. 
However, the complete mechanism(s) underpinning this effect has hitherto 
remained elusive.  
Aim: To establish a murine FXIII-A L34V model and study the role of this 
sequence variant, as well as that of FXIII itself, in thromboembolic disease. 
Methods: FXIII-A Knock-Out (FXIII-/-, already available in the laboratory), 
FXIII-A 34Val (generated by MRC Harwell for Leeds) and FXIII-A 34Leu 
(common variant, wild-type) mice were compared in their growth, plasma 
FXIII activation rates (biotin incorporation assay), turbidity for clot structure, 
fibrinogen concentrations (ELISA assay) and FXIII-A antigen levels (western-
blotting). Whole blood clotting and lysis was measured by rotational 
thromboelastometry (ROTEM). Whole blood clot contraction, erythrocyte 
extrusion (haemoglobin) and two-hour clot weights were quantified. For 
pulmonary and cerebral embolism models, FeCl3 vascular injury was 
performed on inferior vena cava and carotid artery, respectively. Lungs or 
brains were optically cleared and imaged with a light sheet microscope. 
Pulmonary emboli volume and count were quantified using software, while 
cerebral emboli were quantified manually. 
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Results: No significant differences between 34Leu and 34Val mice growth, 
whole blood contraction, serum haemoglobin, clot weight, ROTEM, plasma 
FXIII-A and fibrinogen levels were observed. FXIII-/- mice plasma contained 
no FXIII-A antigen, showed negligible fibrin cross-linking activity and had 
similar levels of fibrinogen as FXIII sufficient mice. FXIII-/- clots were less 
firm, easier to lyse, slower to form, retained fewer red blood cells, were 
lighter and formed thicker fibres than FXIII sufficient clots. 34Leu mice 
plasma showed increased FXIII-A activation rates over 34Val mice plasma. 
Increasing FXIII activation rates (34Leu > 34Val > FXIII-/-) increased both 
pulmonary emboli count and volume, while the trend in cerebral embolism 
differences was inconclusive.  
Conclusion: The murine FXIII-A 34Leu variant showed increased activation 
rates over the 34Val variant and altered thromboembolisation, particularly in 
the venous circulation. Potentially, increased FXIII activation may enhance 
venous thromboembolism by protecting emboli against fibrinolysis during 
their transit to the lungs. In the high shear stress arterial environment, effects 
of mechanical stabilisation by FXIII may counterbalance any effects on 
fibrinolysis. These studies show a potentially important role for FXIII-
mediated clot stabilisation and protection against fibrinolysis that impact on 
thromboembolic diseases. Pulmonary embolism dependence on FXIII could 
be clinically relevant, where FXIII inhibition would act as prophylaxis for 
patients with a high risk of pulmonary embolism. 
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1.1 Cardiovascular diseases and thrombosis 
Cardiovascular disease (CVD) is the number one cause of death globally, 
accounting for 31% of global deaths, reaching 17.9 million cardiovascular 
related deaths worldwide in 2016 (WHO, 2017). The major contributor to 
cardiovascular disease is thrombosis: 85% CVD associated deaths are due 
to heart attack and stroke, while venous thromboembolism is responsible for 
over 500,000 deaths per year in Europe alone (Thrombosis UK, 2017) 
(Rosendaal, 2016). Thrombotic disease is not only a major killer, but also a 
critical financial burden, since 60% of patients with thrombosis get 
hospitalised and here in UK, venous thromboembolism (VTE) alone costs the 
NHS £198,000,000 (Thrombosis UK, 2017). 
Thrombosis is the pathological consequences of the formation of an 
abnormal blood clot in the blood vessel lumen, which starts to obstruct the 
blood flow and causes damage to the surrounding vessel and downstream 
tissues (Stone et al., 2017). These thrombi can also break off, travel 
downstream and block the blood flow of smaller vessels elsewhere in a 
process called embolisation (Johannessen et al., 1988). Restricted blood 
flow or disrupted endothelial integrity causes a shortage of oxygen supply to 
the surrounding tissues making it unable to carry out basic cellular 
metabolism leading to cell death and tissue ischaemia (Ferris and Friesen, 
1979). Examples of ischaemic diseases are thrombi in the brain (stroke) 
(Musuka et al., 2015), heart (myocardial infarction) (Saleh and Ambrose, 
2018) and lung (pulmonary embolism) (Lavorini et al., 2013). Arterial and 
venous thrombosis are quite distinct from each other, developing in different 
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conditions, forming different types of clots and having unique risk factors 
(Previtali et al., 2011). 
Knowledge about key pathophysiological determinants of thrombosis dates 
back to as far as the 19th century, when the German physician Rudolf 
Virchow (1821-1902) characterised thrombosis as a result of three key 
mechanistic elements: endothelial injury, stasis of blood flow and 
hypercoagulability – the so called Virchow’s triad shown in Figure 1.1 (Kumar 
et al., 2010).  
 
Figure 1.1 Virchow’s triad of thrombosis. 
The triad proposing three major elements of thrombosis: 
blood stasis, hypercoagulability and vessel wall injury. 
 
It is commonly accepted that in VTE, hypercoagulability and stasis are more 
influential components of Virchow’s triad that cause venous thrombosis than 
endothelial damage (Previtali et al., 2011). Venous thrombi are rich in red 
blood cells (RBC’s) and fibrin, and less rich in platelets. Atherothrombosis, or 
arterial thrombosis associated with atherosclerosis, however, usually pivots 
around endothelial damage. Platelets, which patrol the intact endothelium 
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and are immediately activated by endothelial damage, aggregate on the 
damaged endothelium forming the initial thrombus, thereby playing a greater 
role in arterial thrombus formation (Harker, 1998). Atherosclerosis and 
ensuing arterial thrombosis is strongly promoted by inflammation and 
hyperlipidaemia, in contrast to venous thrombosis, which is largely promoted 
by stasis and hypercoagulability (Previtali et al., 2011). 
1.2 Venous thromboembolism 
Venous thromboembolism (VTE) is the third most common thrombotic 
disease following myocardial infarction and stroke (Thrombosis UK, 2018). 
VTE includes two main clinical manifestations: deep vein thrombosis (DVT) 
and pulmonary embolism (PE), with PE following DVT in disease progression 
(Previtali et al., 2011). Venous thrombi form in low shear stress 
environments, where a reduction of laminar blood flow, stasis, is prominent 
(Kumar et al., 2010). Stasis usually occurs in patients with reduced mobility, 
since venous blood flow (especially in lower limbs) is facilitated by large 
surrounding muscle contraction which “squeeze” the blood up against the 
gravity (Verma et al., 2017). Blood vessel valves, present only in veins and 
heart, also ensure forward (and gravity defying upward) movement of blood 
(Ortega et al., 2019). In valve sinus pockets between the valve and the 
vessel wall, blood flow is the most static and oxygen supply to the 
endothelium can be insufficient due to vein endothelium being reliant on 
luminar oxygen supply. These ischaemic conditions promote endothelial 
activation and dysfunction (Esmon, 2009). Activated endothelium then 
secretes prothrombotic agents, such as von Willebrand factor (VWF), 
plasminogen activator inhibitor-1 (PAI-1), reactive oxygen species (ROS) and 
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vasoconstrictor endothelin-1 (Bovill and van der Vliet, 2011) as well as 
expresses surface adhesion molecules for white blood cell and platelet 
recruitment (Budnik and Brill, 2018). At the same time, distressed and 
dysfunctional endothelial cells produce lower amounts of thromboresistance 
mediators, such as antithrombin, Tissue factor pathway inhibitor (TFPI) and 
vasodilator nitrous oxide (NO) (Aird, 2005) further leading towards 
hypercoagulability. This hypercoagulable state may exist due to many 
different inherited and acquired factors usually causing an imbalance 
between procoagulant and anticoagulant mechanisms (Thomas, 2001). 
Common risk factors for hypercoagulability include surgery (Ulrych et al., 
2016), cancer (Heit, 2007), oestrogen elevation (Tchaikovski and Rosing, 
2010), anticoagulant deficiencies (Esmon, 2009), obesity (Stein and 
Goldman, 2009) and pregnancy (Simcox et al., 2015). Early detection of 
venous thrombosis development is essential, since lifestyle changes 
(Rosendaal, 2005) combined with anticoagulation are very effective at 
preventing further thrombotic episodes (Ageno and Huisman, 2000). It has 
recently been suggested that targeting local inflammation in venous flow 
could be a safer DVT prevention strategy than targeting coagulation 
mechanisms themselves, which imposes a high risk of bleeding (Budnik and 
Brill, 2018). 
1.3 Atherothrombosis  
Atherothrombosis is a diffuse process starting in early childhood, progressing 
through the adult life and finally manifesting as stroke, coronary artery 
disease (CAD) or peripheral arterial disease (Viles-Gonzalez et al., 2004). 
Morbidity and mortality of atherothrombosis is unpredictable and its 
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prevalence is high, even with the efficient antithrombotic therapies available 
(Leys, 2001). Effectiveness of directly inhibiting coagulation factors, such as 
factor Xa and thrombin has been well established for thrombosis prevention, 
however being such a multifactorial, lifelong disease, atherothrombosis is still 
extremely widespread and difficult to treat. (Viles-Gonzalez et al., 2004) 
Arterial thrombosis develops in an environment where blood flow rates and 
shear stress are high (Sakariassen et al., 2015). Arterial thrombosis is 
initiated due to atherosclerotic plaque growth and rupture, which exposes 
collagen fibres from the deeper layers of the vessel wall and promotes 
platelet aggregation/activation and fibrin clot formation (Otsuka et al., 2016). 
Platelets bind to the exposed collagen fibres via glycoprotein von Willebrand 
factor (vWF), using GPIb receptor (Kroll et al., 1991), and directly to collagen 
via platelet surface receptors GPVI (Nieswandt and Watson, 2003) and α2β1 
(Wang et al., 2003). Upon binding, platelets get activated and spread through 
the injury area in order to cover it (Aslan et al., 2012). Activated platelets also 
release ADP, fibrinogen, calcium, factor V and vWF stored in the dense and 
alpha granules, therefore facilitating further platelet aggregation and 
coagulation (Coppinger et al., 2004, Heijnen et al., 1998). Platelet surface 
integrin αIIbβ3 binds fibrinogen, which links platelets together and further aids 
platelet activation (Vickers, 1999). Finally, fibrinogen is converted to fibrin by 
thrombin and the fibrin mesh stabilises the initial platelet plug into a blood 
clot (van Kempen et al., 2014).  
Atherosclerotic plaque formation is initiated by high levels of lipids in 
circulation, mostly low density lipoproteins (LDL) (Ference et al., 2017). Due 
to hypertension (Puddu et al., 2000, Brandes, 2014), high blood glucose 
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(Esper et al., 2008), hyperlipidaemia (Humphries, 1993) and smoking 
(Michael Pittilo, 2000, Messner and Bernhard, 2014), the arterial endothelium 
gets damaged and becomes easily permeable to lipids (Mundi et al., 2018). 
LDL molecules are then able to invade the vessel wall and deposit in the 
intima layer underneath the endothelium (Mundi et al., 2018). Damaged 
endothelium also attracts monocytes via vascular cell adhesion molecule 1 
(VCAM-1) (Ley and Huo, 2001), which then migrate through the endothelium 
in order to reach the lipid depositions (Gerhardt and Ley, 2015). Activated 
monocytes oxidise the LDL by secreting free radicals (Xing et al., 1998), 
differentiate into macrophages and ingest the oxidised LDL (oxLDL) 
(Bobryshev et al., 2016). Macrophages eventually fill up with oxLDL and 
become large foam cells, which are no longer able to carry out phagocytosis 
and therefore commit apoptosis (Tabas, 2010). Dying macrophage contents 
lead to further deposition of cell debris and oxLDL within the vessel wall 
(Tabas, 2010). Smooth muscle cells from the nearby tunica media also 
respond to the local cytokines, produced by endothelial cells, smooth muscle 
cells and fibroblasts (Wang et al., 2017), by migrating to the intima layer, 
proliferating over the growing fatty streak and forming the fibrous cap around 
it (Rudijanto, 2007). Growing atherosclerotic plaques eventually result in 
stenosis, a significantly obstructed blood flow, and may rupture therefore 
exposing plaque contents to the bloodstream, including tissue factor (Annex 
et al., 1995, Moreno et al., 1996), which is expressed by the foam cells. 
Tissue factor in turn initiates the extrinsic pathway of the coagulation 
cascade (Drake et al., 1989, Ardissino et al., 1997). Thrombin, ADP and 
collagen fibres present in the plaque activate platelets, initiate their 
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aggregation and thrombus formation (Badimon and Vilahur, 2014). The 
resulting thrombus occludes the blood flow even further, or completely, and 
may embolise downstream occluding smaller arteries (Badimon and Vilahur, 
2014). Most known and lethal forms of arterial embolism are cerebral 
embolism (stroke) and myocardial infarction (Lyaker et al., 2013). 
1.4 Immune system in coagulation 
In recent decades, the traditional understanding of haemostasis being 
regulated only by the coagulation cascade and platelet activation has been 
increasingly challenged. New evidence keeps surfacing that activation of the 
immune system has a strong influence on blood coagulation and thrombotic 
pathology. Leukocytes can be a strong factor in inducing coagulation via the 
expression of tissue factor (Shantsila and Lip, 2009) secretion of 
procoagulant cytokines (Pham, 2006, Meier et al., 1985) and release of 
nuclear damage-associated molecular patterns from activated apoptotic 
leukocytes (Maugeri et al., 2014, Chow et al., 2010). What is more, the 
leukocyte cell surface provides a site for assembly and activation of 
coagulation factors (Tracy et al., 1985). The integral part of 
immunothrombosis, however, is attributed to neutrophil extracellular trap 
(NETs) formation. NETs occur upon neutrophil activation and recruitment to 
the vessel wall, when neutrophil nuclear contents are secreted in a form of a 
web-like structures comprised out of DNA, histones and intracellular granular 
components (Brinkmann et al., 2004). NETs have been shown to be 
abundant in DVT thrombi and to be important in DVT development, since 
NET disruption (Brill et al., 2012) and neutrophil (von Bruhl et al., 2012) 
depletion experiments have shown to inhibit venous thrombus formation. 
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NETs have also been shown to provide a scaffold of FXIII activation (von 
Bruhl et al., 2012), promote platelet adhesion as well as induce endothelial 
cell activation (Xu et al., 2009) and thrombomodulin-dependent protein C 
activation (Ammollo et al., 2011) due to histone toxicity. Additionally, 
neutrophil elastase has been shown to degrade anticoagulants, such as 
tissue-factor pathway inhibitor (TFPI) (Massberg et al., 2010). These 
processes initiate thrombus formation, platelet activation and promote further 
leucocyte recruitment into the clot via interactions with platelets and 
adhesion molecules on endothelial cells (Swystun and Liaw, 2016).  
On the other hand, phagocytic leukocytes promote fibrinolysis (Simon et al., 
1993) and thrombus resolution via clearance of coagulation factors (Swystun 
and Liaw, 2016) and activated platelets (Hoffmeister, 2011). Through these 
combined mechanisms, deregulated activation of leukocytes is a major 
player in thrombosis and vascular pathology. Recently, modulation of 
leukocyte interactions with other cell types and leukocyte-derived 
procoagulant secretion has been an attractive target for developing novel 
antithrombotic treatments (Swystun and Liaw, 2016). 
1.5 Coagulation cascade 
The coagulation cascade is an enzymatic chain reaction involved in blood 
clotting and is traditionally divided into a coagulation-initiating tissue factor 
(extrinsic) pathway (Mackman et al., 2007), and a coagulation-amplifying 
contact surface (intrinsic) pathway (Wu, 2015). The tissue factor (TF) 
pathway begins with TF being expressed by a variety of intravascular cells, 
such as endothelial cells, monocytes as well as extravascular cells, such as 
fibroblasts, pericytes and smooth muscle cells (Drake et al., 1989). Under 
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normal, healthy circumstances, intravascular TF expression can be 
counteracted by TFPI present on the endothelium (Callander et al., 1992). 
However, during inflammation or endothelial damage, TF expression on 
intravascular cells can increase and TF may also become available to the 
blood on now exposed extravascular cells, which evokes a procoagulant 
stimulus (Butenas et al., 2009). When exposed to the circulating blood, TF 
will bind and activate serine protease factor VII (Rao and Rapaport, 1988). 
The contact pathway, on the other hand, is initiated by negatively charged 
surfaces and platelet secreted polyphosphates following endothelial damage 
and platelet activation. Coagulation factor XII is activated upon binding to the 
exposed negatively charged collagen (van der Meijden et al., 2009, Naudin 
et al., 2017) as well as misfolded protein aggregates, nucleic acids and 
platelet secreted polyphosphates (Naudin et al., 2017). Subsequently, FXIIa 
activates FXI, which, in turn activates FIX (Gailani and Renne, 2007). FIXa 
then couples with its cofactor FVIIIa and forms a tenase complex with FX 
(Autin et al., 2005). Tenase complex assembly results in efficient FX 
activation, which is also enhanced by the presence of negatively-charged  
phosphatidylserine derived from platelet membranes (Lentz, 2003). FX 
activation is also carried out by TF:FVIIa complex (Chaudhry and Babiker, 
2019), therefore making FX activation a step where two pathways merge into 
a “common” coagulation pathway (Figure 1.2). Coagulation factor Xa is a 
prothrombin activating factor, which upon coupling with its cofactor FVa and 
forming a prothrombinase complex, converts inactive prothrombin into the 
active thrombin enzyme (Allen et al., 2000). Once thrombin is activated, it 
activates FXI, FVIII and FV, creating a positive feedback loop and amplifying 
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the coagulation even further (Jesty and Beltrami, 2005). Most importantly, 
activated thrombin catalytically  converts fibrinogen into fibrin, and activates 
FXIII (Narayanan, 1999). Fibrin then polymerises and self-assembles into a 
fibrin mesh, whereas FXIIIa covalently cross-links the fibrin mesh, making it 
structurally robust and much more resistant to fibrinolysis. A summarising 
simple schematic can be seen below (Figure 1.2). FX (Owens and Mackman, 
2010), prothrombin (Heldebrant and Mann, 1973) and FXIII (Muszbek et al., 
1999) activation requires Ca2+ ions being present. 
  
12 
 
 
Figure 1.2 Coagulation cascade schematic. 
Orange coloured coagulation factors constitute the contact surface pathway, 
which is initiated by blood being exposed to a negatively-charged surface like 
collagen or activated platelet membrane. Green coloured factors constitute 
the tissue factor pathway, which starts with exposure to tissue factor-bearing 
cells and activity. Both pathways then converge into a common pathway, 
which ultimately results in a stable fibrin clot. Dotted arrows denote 
coagulation factor conversion, while thick arrows illustrate the activity of 
coagulation factors. 
 
1.6 Fibrinogen 
Fibrinogen (initially named Factor I), is a structural protein, which upon 
conversion to fibrin polymerises and comprises the grid of the clot. 
Fibrinogen circulates at a concentration of 1.5-4.0 mg/mL and has a half-life 
of 4 days (Asselta et al., 2006). The fibrinogen (Fbg) molecule is comprised 
of three different polypeptide chains (Aα, Bβ, and γ) organized as dimers (6 
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chains in total) around a central N-terminal E-region and has two outer D C-
terminal regions (Figure 1.4, A) (Mosesson, 2005). Thrombin cleaves 
fibrinopeptides A and B located in the E-region and so converts fibrinogen 
into fibrin (Scheraga, 1983). Cleavage of fibrinopeptide A (FpA) on the α-
chain, which happens first, exposes the A “knob” on the E-region, which is 
able to non-covalently bind the A hole in the D-region of another fibrin 
molecule (Weisel and Litvinov, 2013). This spontaneous process is called 
half-staggered fibrin polymerisation and results in protofibril formation (Figure 
1.4, B) (Fowler et al., 1981). Next, thrombin cleaves fibrinopeptide B (FpB) 
on the β-chain, which releases the αC-region of the α-chain and opens the 
αC-chains up (Figure 1.4, C) (Weisel and Litvinov, 2013). The now exposed 
B “knobs” are able to bind the B holes on the D-region as well (Litvinov et al., 
2007), further reinforcing the D-E-D interactions that underpin fibrin 
polymerisation. The released and exposed αC-chains are able to 
spontaneously bind αC-chains of other fibrinogen molecules incorporated in 
nearby protofibrils. This results in a lateral aggregation of protofibrils and 
assists fibrin fibre formation (Figure 1.4, D) (Weisel and Litvinov, 2013). 
Fibrin protofibrils aggregate into ~130 nm wide fibrin fibres (Li et al., 2016b), 
which are extremely tensile and can sustain a 2.8-fold extension without 
being permanently lengthened and a 4.3-fold extension before rupturing (Liu 
et al., 2006). These numbers make fibrin one of the most extensible proteins 
observed, and one of the most elastic biological polymers known in nature, 
with almost comparable characteristics to spider silk.  
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1.7 Fibrinolysis 
The fibrinolytic system is centred around the proteolytic activity of plasmin. 
Plasmin enzymatically degrades fibrin into multiple soluble degradation 
products. The inactive proenzyme plasminogen is converted into active 
plasmin by activator enzymes, a key step in fibrinolysis regulation and 
modulation (Rijken and Lijnen, 2009). Two main physiological plasminogen 
activators are tissue-type and urokinase-type plasminogen activators (t-PA 
and u-PA respectively) (Chapin and Hajjar, 2015). The main plasminogen 
activator out of both serine proteases is t-PA, however u-PA exerts 
complementary actions as well (Gurewich, 2016). t-PA is a fibrin specific 
plasminogen activator, which needs fibrin to be present in order to form a 
ternary complex with plasminogen and activate it efficiently (Kim et al., 
2012). t-PA inhibition is key in reducing plasmin generation. This function is 
carried out by serine protease inhibitors (serpins) plasminogen activator 
inhibitor 1 and 2 (PAI-1 and PAI-2 respectively), which block the 
plasminogen activator active site (Carter and Church, 2009). Fibrin 
degradation is also inhibited by thrombin-activatable fibrinolysis inhibitor 
(TAFI) (Plug and Meijers, 2016). Plasmin and, more efficiently, thrombin (in 
presence of its cofactor thrombomodulin) converts circulating inactive TAFI 
precursor into its active form (Miljic et al., 2010). Activated TAFI reduces 
fibrinolysis by removing the C-terminal lysine residues of fibrin (Marx et al., 
2004), that are involved in binding the lysine-binding sites on plasminogen 
and t-PA (Zhao et al., 1998, Boffa et al., 1999). Finally, studies on 
complement C3 have suggested that it also prolongs fibrinolysis and is 
cross-linked to fibrin by FXIII (Richardson et al., 2013). However, the 
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mechanism by which the inhibition of fibrinolysis takes place has not yet 
been fully elucidated.  
α2-AP also plays a very important role in the regulation of fibrinolysis (Rijken 
and Uitte de Willige, 2017). The antifibrinolytic effect of α2-AP comes from 
blocking the active site of the plasmin molecule (Abdul et al., 2016, Wiman et 
al., 1979). α2-AP circulates at 70 µg/mL and is predominantly synthesized 
and secreted by the liver (Moroi and Aoki, 1976, Wiman and Collen, 1977). 
However, it has been shown that the kidney (Menoud et al., 1996) and the 
brain (Kawashita et al., 2013) could also be sites of α2-AP production. α2-AP 
is cross-linked via Gln2 and Gln14 residues in α2-AP and Lys303 residue in 
the α-chain of fibrin (Kimura and Aoki, 1986, Tamaki and Aoki, 1982, 
Ichinose et al., 1983). Other less commonly cross-linked sites in α2-AP are 
the Gln34, Gln431 and Gln459 residues (Lee et al., 2000). The process of 
α2-AP and fibrin cross-linking occurs quickly: α2-AP cross-linking is nearly 
maximal  when α-chain polymerization begins to occur (Tamaki and Aoki, 
1981). Interestingly, the same study has shown that the cross-linking of α2-
AP ceases at about 30% of incorporation, corresponding to approximately 
one α2-AP molecule per 25 molecules of fibrin. The cross-linking rate has 
been shown to rise with increasing FXIIIa concentrations, but the maximal 
incorporation rate does not change (Tamaki and Aoki, 1981). Remarkably, a 
common FXIII-A sequence variant, V34L, which is more rapidly activated by 
thrombin and calcium than the more frequent FXIII-A (34Val) variant, shows 
higher α2-AP incorporation rates when compared to 34Val variant. This has 
been shown in both plasma samples of healthy human subjects (Schroder 
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and Kohler, 2000) as well as in purified recombinant protein systems (Duval 
et al., 2016). 
1.8 Role of FXIII 
Clots that are self-assembled from fibrin as described earlier are initially 
mechanically weak and highly susceptible to fibrinolysis. Coagulation factor 
XIII (FXIII) plays an essential part in blood clot formation, by making the clot 
much more resistant to fibrinolysis and enhancing its structural stability 
(Ariens et al., 2000). The structural stability of the haemostatic clot is greatly 
increased by FXIII forming isopeptide bonds (Figure 1.4, D) between two γ-
chains (γ-γ) (Chen and Doolittle, 1971), two α-chains (α-α) (Cottrell et al., 
1979) or far less regularly, two α- and γ-chains of fibrin (Standeven et al., 
2007) (Siebenlist and Mosesson, 1996). FXIII cross-linking transglutaminase 
reaction always occurs between glutamine and lysine residues (Chen and 
Doolittle, 1971, Matsuka et al., 1996, Sobel and Gawinowicz, 1996). FXIII 
catalytically active Cys314 residue, located in a catalytic core of FXIII-A, is 
carrying the cross-linking reaction out by replacing the ammonia of a 
glutamine residue on one protein (e.g. fibrin) molecule with an amino group 
on a lysine residue on another protein molecule, and subsequently creating a 
covalent isopeptide bond between these two residues (Figure 1.3).  
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Figure 1.3 Schematic of transglutaminase reaction of FXIII. 
Cys314 residue of FXIIIa reacts with glutamine on one protein 
molecule (black oval), binding it and releasing ammonia (NH3) in 
the process. Then amino group of lysine residue on adjacent 
protein molecule is covalently bound to the glutamine residue, 
forming a ε-(γ-glutamyl)lysyl bond between and FXIIIa is released. 
 
Modification of fibrin by FXIII occurs in an orderly sequence; FXIII cross-
linking favours γ-chains and occurs 10‐fold faster than that of α-chains 
(Lorand et al., 1998). This is extremely important for the protofibril 
longitudinal strength in the developing clot (Lorand, 2005) and is achieved 
through the tight end‐to‐end alignment of fibrin molecules (Lorand et al., 
1998). FXIII also covalently cross-links fibrinolysis inhibitors such as α2-
antiplasmin (α2-AP) (Sakata and Aoki, 1980), thrombin activatable fibrinolysis 
inhibitor (TAFI) (Valnickova and Enghild, 1998) and plasminogen activator 
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inhibitor (PAI) (Ritchie et al., 2000) to the α-chain, which greatly increases 
fibrin resistance to lysis. The strongest antifibrinolytic effect comes from α2-
AP cross-linking and a particular study has even suggested that  all of the 
FXIII antifibrinolytic effect comes solely from α2-AP cross-linking (Fraser et 
al., 2011). Consequently, plasmin (main fibrinolytic enzyme) is inactivated by 
now local, cross-linked α2-AP and clot lysis is impaired. Cross-linking of α2-
AP also increases its retention in the clot over time, especially during the 
platelet-induced clot retraction stage (Rijken et al., 2016).  
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Figure 1.4 Schematic of the conversion of fibrinogen into fibrin, and fibrin fibre formation. 
Fibrinogen molecule contains a central E-, two distal D-regions and two αC-domains (A). FpA is cleaved by thrombin and the 
exposed A knobs bind A holes on adjacent fibrinogen molecule D-regions, forming protofibrils (B). Next, FpB is cleaved, releasing 
the αC-domains, and allowing α-chains to open up (C). These then bind α-chains of the other fibrin molecules in other protofibrils, 
laterally aggregating and forming fibrin fibres (D). Finally, activated FXIII covalently cross-links (denoted in “=” sign) two γ-chains, 
two α-chains together, as well as fibrinolysis inhibitors to the α-chain of fibrin, thus increasing the strength of the fibrin mesh.
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1.9 FXIII deficiency 
The importance of FXIII can be observed in patients with FXIII deficiencies 
and developing numerous bleeding disorders. FXIII deficiencies can be two-
fold: a lack of B-subunit (and in turn A-subunit) and a lack of FXIII-A alone 
(Duval, 2012). Severe FXIII deficiency leads to impaired fibrin cross-linking, 
less resistance to fibrinolysis and mechanical instability of clots, resulting in 
various clinical bleeding symptoms, such as umbilical cord bleeding and 
intracranial bleeding (Biswas et al., 2014), impaired wound healing (Lauer et 
al., 2002) and miscarriage in pregnancy (Inbal and Muszbek, 2003). Protein 
(including FXIII) deficiencies can be classed as congenital or acquired, as 
well as protein deficiency due to indirect mutations affecting expression or 
function of FXIII. 
Congenital FXIII deficiencies are usually inherited as autosomal recessive 
disorder and are mostly encountered in areas of high consanguinity, such as 
rural Middle Eastern regions (Dorgalaleh et al., 2017). The most common 
signs of FXIII deficiency are mucosal bleeding, pre- and post-medical 
intervention bleeding and predisposition to haemorrhage. More severe cases 
include intracranial bleeding and haemarthrosis (Hayward, 2018, Pitkanen et 
al., 2017). Brain haemorrhage is a leading cause of mortality in FXIII 
deficiency, followed by neonatal umbilical cord bleeding (Malkhassian and 
Sharma, 2019). Currently the prevalence of congenital FXIII deficiency in the 
general population is 1 per 2 million. An early detection of the disorder in 
heterozygous patients is very important, since the bleeding risk can be 
effectively managed and morbidity prevented (Biswas et al., 2014). 
Prophylaxis in maintaining FXIII levels above 3-5% by administering patients 
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10-20 U/kg FXIII every 4 to 6 weeks is preventing life-threatening 
spontaneous bleeding (Lorand et al., 1993). 
Acquired FXIII deficiencies are mostly caused by heightened FXIII 
consumption and immune-mediated inhibition. Increased consumption and 
decreased synthesis have been identified as two possible mechanisms to 
reduce FXIII levels by 20% to 70% (Jain and Acharya, 2018). Certain 
autoantibodies have been shown to inhibit the cross-linking sites on fibrin 
monomers (Komaromi et al., 2011). Due to acquired FXIII deficiencies being 
rare, research published on the matter is not extensive, but published reports 
show data on acquired FXIII deficiency in haemorrhagic stroke, liver cirrhosis 
and inflammatory bowel disease (Malkhassian and Sharma, 2019).  
1.10 FXIII Structure 
Plasma FXIII is a 325-kDa non-covalent heterotetrameric (A2B2) 
protransglutaminase comprising of two catalytic FXIII-A (83.3 kDa) and two 
carrier FXIII-B (76.5 kDa) subunits (Ashcroft et al., 2000). Plasma 
concentration of the A2B2 is approximately 22 μg/mL and its half-life is around 
9-14 days (Karimi et al., 2009, Fickenscher et al., 1991). Cellular FXIII 
consist only of the A-subunit dimer, however in plasma, two B-subunits act 
as hydrophilic shells providing stability for hydrophobic A subunits in the 
aqueous environment of the blood (Duval, 2012). The A-subunit molecular 
structure has been identified by X-ray crystallography (Yee et al., 1994), but 
B-subunit tertiary structure is still largely unknown. Therefore, the perceived 
structure of the complete heterodimeric A2B2 FXIII molecule is only 
hypothetical and has largely been based on EM studies (Carrell et al., 1989) 
and, more recently, by elegant AFM studies (Protopopova et al., 2019). Each 
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FXIII-B plasma carrier peptide consists of ten repetitive “sushi” domains that 
are held together by double internal disulphide bonds (Carrell et al., 1989). In 
the circulation, the B-subunit binds to fibrinogen, helping FXIII to get close to 
fibrinogen and exert its effects on clot stabilisation (Souri et al., 2015). The 
tetramer structural model of FXIII based on crystallography (Yee et al., 
1994), AFM (Protopopova et al., 2019) and EM studies (Carrell et al., 1989) 
consists of globular A- and strand-like B-subunits oriented symmetrically to a 
central axis (Figure 1). The first 37 amino acid residues at the N-terminus of 
an A subunit comprise a 4 kDa activation peptide (AP), which, upon Arg37-
Gly38 cleavage by thrombin, is released alongside the FXIII-B subunit and 
converts inactive FXIII to its active (FXIII-A2, FXIIIa) form (Gupta et al., 
2016). FXIII activation by thrombin also requires Ca2+ to be present as a 
cofactor (Lorand, 1986). In circulation FXIII-B exists in approximately equal 
amount as a bound A2B2 constituent as it is in freely circulating form 
(Ichinose et al., 1986). Around 99% of FXIII-A, however, exists in A2B2 
complex (Katona et al., 2014). 
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Figure 1.5 Structural model of the FXIII A2B2 tetramer.  
FXIII-A subunit, B-subunit and activation peptide (AP) duos are arranged 
around a central axis of symmetry. Hydrophobic A-subunits (red) including 
AP’s (yellow) are enclosed by flexible, hydrophilic B-subunits (grey). 
 
1.11 FXIII A and B subunits 
FXIII-A is expressed in megakaryocytes, monocytes and macrophages 
(Adany et al., 1987, Weisberg et al., 1987, Muszbek et al., 1988), primarily in 
the bone marrow (Wolpl et al., 1987). A classical secretion pathway signal 
sequence has not been detected in the FXIII-A gene and the extracellular 
secretion mechanism is presently unknown (Thomas et al., 2016, Cordell et 
al., 2010). FXIII-A is also stored in platelet cytoplasm as a homodimer (FXIII-
A2) and gets externalised upon platelet activation by thrombin and collagen 
(Kattula et al., 2018, Bagoly et al., 2012, Mitchell et al., 2014). FXIII-A2 dimer 
is also stored in a variety of different cells ranging from monocytes, 
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monocyte-derived macrophages to dendritic cells, chondrocytes, osteoblasts, 
and osteocytes (Nurminskaya and Kaartinen, 2006, Muszbek et al., 2011). 
The full protein sequence of FXIII-A comprises 731 amino acids, with the first 
37 forming the activation peptide. FXIII-A molecule can be divided into five 
structural regions, with starting from N-terminus an activation peptide (amino 
acids 1-37), β-sandwich (38-184), catalytic core (185-515), β-barrel 1 (516-
628) and β-barrel 2 (629-727) (Yee et al., 1994). The catalytic core is the 
functional domain, which carries out the transamination function of FXIII. The 
three most important amino acids involved in catalytic activity are called the 
“catalytic triad” and comprise of Cys314, His373 and Asp394 (Yee et al., 
1994). Cys314 is normally hidden by the activation peptide and by Tyr560 of 
the β-barrel 1 domain, but gets exposed during activation (Komaromi et al., 
2011).  
FXIII-B is a glycoprotein consisting of 10 tandem sushi domains, each 
comprising of approximately 60 amino acids and each containing a pair of 
disulphide bonds (Carrell et al., 1989). Singh et al. performed individual 
cysteine mutations and demonstrated that all of the 20 disulphide bonds are 
important for FXIII-B secretion, function and structural stability (Singh et al., 
2019). The first two N-terminal sushi domains are associated with FXIII-A2, 
while domains 4 and 9 are involved with the antiparallel interaction of two 
FXIII-B subunits (Souri et al., 2008a, Katona et al., 2014). Individual FXIII-B 
molecules associate together to form dimers, as shown in AFM (Protopopova 
et al., 2019), however it is not yet understood how and when they dissociate 
in order to bind to the FXIII-A molecules to form A2B2. Locating the FXIII-B 
finding site on the FXIII-A molecule could elucidate the association 
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mechanism and could potentially be useful in formulating a more efficient 
FXIII-A delivery to FXIII-B molecules in FXIII-A deficient patient’s blood and 
prolong supplemented FXIII-A half-life (Bagoly and Muszbek, 2019). 
Interestingly, FXIII-B subunits that are unable to dimerise but possess 
functional sushi domains 1 and 2 can still form A2B2 heterotetramers (Souri 
et al., 2008a, Katona et al., 2014). FXIII-B is synthesised in and secreted by 
hepatocytes (Nagy et al., 1988, Wolpl et al., 1987, Muszbek et al., 1988) and 
contains a 20 amino acid leader sequence, which indicates a classical 
secretion pathway (Ichinose, McMullen et al. 1986) (Webb, Coggan et al. 
1989). FXIII-B circulates in excess and presumably assembles into the A2B2 
complex at the site of A-subunit release, however the mechanism by which 
this occurs has not yet been elucidated in detail. FXIII-B has been shown to 
accelerate fibrin cross-linking by binding to the γ-chain of the fibrinogen 
molecule and by facilitating the formation of a complex between fibrinogen, 
FXIII and thrombin (Souri et al., 2015). In circulation, plasma FXIII binding to 
fibrinogen is primarily mediated by the interaction between fibrinogen γ-chain 
C-terminal region and FXIII-B subunit (Siebenlist, Meh et al. 1996). FXIII-B is 
crucial for the stability of FXIII-A in circulation and it has been shown that the 
half-life of plasma FXIII-A is exceptionally low (~3 days) in a patient with 
FXIII-B deficiency (Saito et al., 1990). Recombinant FXIII-B injection in FXIII-
B-/- mice increased plasma FXIII-A levels (Souri et al., 2008b), clearly 
indicating a role for FXIII-B in stabilising the FXIII-A subunit in circulation. 
However, FXIII-B deficiency still results in normal FXIII-A levels inside cells, 
such as monocytes, macrophages and platelets (Souri et al., 2015). 
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1.12 FXIII activation 
FXIII A2B2 heterotetramer activation is a two-step process (Figure 1.6). The 
first step involves thrombin cleaving the peptide bond between residues 
Arg37 and Gly38 releasing the activation peptide from the N-terminus of 
FXIII-A (Lorand and Konishi, 1964). The second step is FXIII-B dissociation, 
which is dependent on Ca2+ ions being present (Turner et al., 2004) 
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Figure 1.6 Schematic representation of FXIII activation. 
FXIII is activated in two steps: activation peptide (AP) cleavage by thrombin, and B-subunit dissociation from the FXIII-A dimer in 
the presence of calcium. Both steps are enhanced by the presence of polymerising fibrin, ensuring that FXIII activation occurs at 
the time of fibrin polymerisation. Activated FXIII-A dimer then covalently cross-links fibrin polymers and strengthens the mesh. 
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Polymerising fibrin has been shown to reduce the concentration of thrombin 
needed to activate plasma FXIII by ~100 fold (Greenberg et al., 1987). 
Platelet FXIII-A2 activation required 50% of the thrombin concentration 
required to activate plasma FXIII A2B2, however activation was not enhanced 
by the presence of fibrin (Greenberg et al., 1987). This suggests that B-
subunit inhibits A-subunit cleavage in the absence of fibrin. Interestingly, only 
non-cross-linked fibrin polymers induce this enhancing effect and could serve 
to ensure that FXIIIa generation subsides after FXIII activity is not required 
anymore (Lewis et al., 1985). The fact that fibrin polymers and not monomers 
increase FXIII activation serves the purpose of minimising FXIII activation 
prior to the formation of FXIII substrate: polymerising fibrin (Lewis et al., 
1985). Because thrombin-mediated AP cleavage timely coincides with 
fibrinopeptide A cleavage and fibrin polymerisation, cleaved fibrin could be a 
true promoter of FXIII-A AP cleavage (Janus et al., 1983). Later, it was 
shown that polymerising fibrin enhances activation of FXIII-A by forming a 
complex with FXIII-A, which is processed by thrombin much more efficiently 
than the uncomplexed plasma FXIII (Naski et al., 1991). The increase comes 
from a greatly increased thrombin affinity to FXIII, with a 30-fold decrease in 
Michaelis constant (Naski et al., 1991). Interestingly, the complex of 
thrombin, fibrin and FXIII does not only enhance FXIII activation, but also 
fibrin fibrinopeptide B cleavage, which progresses to fibrin α-chain release 
and fibrin fibre formation (Naski et al., 1991). What is more, FXIII-B subunit 
has been shown to facilitate FXIII binding to fibrinogen (Siebenlist et al., 
1996). In light of these findings it is clear, that colocalization of fibrin, 
thrombin and FXIII is extremely important and follows a timely manner of 
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activation and inhibition in order to ensure the stepwise process of the 
formation of the final blood clot.  
FXIII-B dissociation from FXIII-A dimer is dependent on Ca2+ ions being 
present (Turner et al., 2004). Intracellular FXIII-A2 is activated with thrombin 
and Ca2+ just as the plasma FXIII-A2B2 (Muszbek et al., 1993), however it 
can also be slowly activated by Ca2+ alone without thrombin induced 
proteolysis (Polgar et al., 1990). Upon activation with thrombin and calcium, 
plasma FXIII-A2B2 and FXIII-A2 dissociate into active monomers (Anokhin et 
al., 2017), while B subunits form a dimeric FXIII-B2 (Protopopova et al., 
2019). These novel findings are in line with the crystal structure of activated 
cellular FXIIIa (Stieler et al., 2013) and with molecular dynamics simulations, 
suggesting that after the activation of plasma FXIII, the A2 inter-subunit 
interface is weakened (Gupta et al., 2016, Dodt et al., 2016). In equilibrium 
~25% of A- and B-subunits dissociate while ~75% remain as a complex 
(Protopopova et al., 2019, Katona et al., 2014).  
1.13 FXIII cross-linking effects 
Both γ-chain and α-chain cross-linking reactions have distinct effects on fibrin 
polymerisation, fibre formation and mechanical properties of fibre network. 
Complete cross-linking of fibrin fibres greatly increases their stiffness and 
elasticity (Helms et al., 2012). The γ-chain cross-linking greatly enhances the 
structural robustness of the clots (Standeven et al., 2007). Moreover, γ-chain 
cross-linking enhances fibrin fibre elasticity via altered force-extension 
relationship of the protofibrils, and slightly reduces fibre extensibility as well 
(Houser et al., 2010). The mechanical robustness following FXIIIa cross-
linking also becomes apparent at the fibre and whole clot level, however this 
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appears more dependent on α-chain cross-linking (Collet et al., 2005). It has 
been shown that in experimental conditions where γ-chain cross-linking is 
abolished, clot fibres affected by α-chain cross-linking are thicker and take 
less time to thicken (Duval et al., 2014). Also, α-chain cross-linking couples 
constituent protofibrils in a more compact manner and therefore stiffens the 
fibrin fibre (Piechocka et al., 2017, Kurniawan et al., 2014). In addition, α-
chain cross-linking is responsible for fibre straightening and increased fibre 
resistance to fibrinolysis in the absence of α2-antiplasmin (Duval et al., 
2014). Clots which undergo α-chain cross-linking also retain a significantly 
larger proportion of red blood cells when the clots contracts (Byrnes et al., 
2015, Aleman et al., 2014). Interestingly, this effect is only mediated by 
plasma FXIIIa and not platelet FXIIIa (Kattula et al., 2018). FXIIIa cross-
linking activity also affects the process of clot contraction itself. It has been 
shown that inhibiting FXIIIa activity reduces both the extent and velocity of 
clot contraction (Tutwiler et al., 2016). Cross-linking of TAFI and PAI to fibrin 
α-chain greatly increases fibrin resistance to lysis (Sakata and Aoki, 1980). 
Consequently, plasmin (main fibrinolytic enzyme) is inactivated by now local, 
cross-linked α2-AP and clot lysis is impaired. Cross-linking of α2-AP also 
increases its retention in the clot over time, especially during the platelet-
induced clot retraction stage (Rijken et al., 2016).  
1.14 FXIII-A V34L  
A common human FXIII-A sequence variant (valine mutated to leucine at 
residue 34, V34L) has been shown to demonstrate increased FXIII activation 
rates through increased proteolysis of FXIII-A by thrombin and earlier release 
of the activation peptide (Ariens et al., 2000). These events result in 
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increased cross-linking activity during the first 30 min after FXIII activation by 
thrombin, however full pre-activation of both 34Val and 34Leu variants 
equalised their cross-linking activity output, showing that cross-linking activity 
increase for 34Leu variant only comes from increased activation rate and the 
mutation does not increase the enzymatic activity of FXIII-A itself 
(Wartiovaara et al., 2000). FXIII-A V34L has also been shown to lead to the 
formation of clots with denser, thinner fibrin fibres, smaller pore sizes (Ariens 
et al., 2000) and higher resistance to lysis (Collet et al., 2000), which is 
deemed prothrombotic. Clinical studies of FXIII-A V34L have indicated, 
however, that the 34Leu variant associates with a protective effect in most 
thrombotic diseases such as coronary artery disease (Voko et al., 2007), 
myocardial infarction (Shafey et al., 2007) and deep vein thrombosis (Wells 
et al., 2006), while it has been associated with an increased risk of 
thrombotic microangiopathies (Sucker et al., 2009), aneurysmal 
subarachnoid haemorrhage (Ladenvall et al., 2009) and Alzheimer’s disease 
(Gerardino et al., 2006).  
1.15 FXIII-A V34L sequence variant in arterial and venous 
thromboembolism 
In the last two decades, multiple studies have shown that the FXIII-A V34L 
variant is protective against deep vein thrombosis (DVT) (Wells et al., 2006, 
Pourgheysari et al., 2014), stroke (Elbaz et al., 2000), coronary artery 
disease (CAD) (Voko et al., 2007) and myocardial infarction (Shafey et al., 
2007).  
The first large meta-analysis including 12 studies provided evidence that 
FXIII-A V34L variant has a significant protective effect in VTE with an odds-
32 
 
ratio (OR) of 0.63 for homozygote patients (Wells et al., 2006). Later, a study 
from Iran with 267 subjects also found a protective V34L effect (OR: 0.107). 
Additionally, a recent study has shown that FXIII supplementation stabilized 
venous thrombi in DVT and led to fewer PE episodes in mice, suggesting 
that FXIII cross-linking activity indeed protects by stabilising otherwise 
weaker clots, which become less prone to embolisation (Shaya et al., 2019). 
Furthermore, a 120 patient study in PE has shown that reduced FXIII-A 
levels are more prominent in PE patients, lower FXIII-A levels increase 
occlusion rates and PE patients have weaker clots (Kucher et al., 2003). This 
in a sense suggests that FXIII-A activity could be protective against PE, 
making a faster activated 34Leu FXIII-A variant potentially protective. 
A large meta-analysis of 16 studies involving 12,399 subjects has shown that 
the FXIII-A V34L variant is protective against CAD with a homozygous OR of 
0.89 (Voko et al., 2007). The same year, another research team published a 
meta-analysis of 12 studies with 8743 patients on FXIII-A V34L in acute 
myocardial infarction. This meta-analysis showed an OR of 0.79 for 
heterozygous Val/Leu patients, and a not statistically significant OR of 0.83 
for homozygous patients. This non-significant result may be due to a 
relatively low frequency of the homozygous genotype. 
The association of FXIII-A V34L with atherothrombotic ischemic stroke (AIS), 
however, remains controversial. In 2000, a French study on 456 patients 
concluded a protective effect (homozygous 34Leu OR: 0.57) of the 34Leu 
variant in ischaemic stroke (Elbaz et al., 2000). Later, a study in Italy showed 
an opposite (increase) in stroke risk (homozygous 34Leu OR: 1.25) with the 
34Leu variant (Rubattu et al., 2005). There are several other studies showing 
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an inconclusive or absent association with ischaemic stroke, such as a 664 
patient study in Austria (Endler et al., 2003) showing homozygous 34Leu 
OR: 1.02. Also a large meta-analysis, consisting of 8,800 patients from 16 
studies found a lack of association between the 34Leu sequence variant and 
acute ischaemic stroke, with Leu/Leu vs. Val/Val OR: 0.90, 95% CI=0.73-
1.11 (Li et al., 2012). However, a subsequent study has shown that despite 
34Leu sequence variant not increasing the occurrence of ischaemic stroke, it 
increased the severity of the outcome, making a fatality from acute ischaemic 
stroke three times more likely than compared with 34Val patients (Shemirani 
et al., 2014). The latter study suggested that a lack of association with 
occurrence does not paint the full picture of FXIII effects on ischaemic stroke, 
and that it still remains an area for further investigation.  
1.16 Models of thrombosis 
Different to humans, murine FXIII-A 34Leu allele represents the most 
common (wild-type) sequence variant in mice and the only existing variant in 
laboratory mice. There is 86.9% homology between the murine and human 
FXIII-A subunits and 77.5% between B subunits allowing comparisons 
between murine 34Val and 34Leu variants to be relevant for human 
physiology and pathology. Therefore, in order to compare 34Leu and 34Val 
FXIII-A variants in mice, I will utilise novel L34V mFXIII-A genetically 
modified mice and a recombinant version of this murine sequence variant for 
my PhD studies. 
For in vivo investigations, there are various murine models for thrombosis, 
which utilise different modalities to initiate thrombosis in mice. Some employ 
optical and chemical means or their combinations, such as laser induced 
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(Hechler et al., 2005) or photochemical vascular injuries (Eitzman et al., 
2000), while others utilise procoagulant injections, such as collagen-
epinephrine (Maurice et al., 2006). A commonly used stenosis model is also 
used for inducing venous thrombosis (Payne and Brill, 2017), while a FeCl3 
vascular injury model is a commonly utilised model for arterial thrombosis 
(Neeves, 2015). 
The stenosis model, in which a suture is ligated around the inferior vena 
cava, obstructing the flow by ~90% (Brill et al., 2011), is particularly suited to 
reproduce natural mechanisms involved in venous thrombotic pathology, 
where blood flow is restricted, becomes static and hypercoagulable. 
However, the downside of this model is the time and skill required in order to 
properly control the experiment, since achieved thrombus sizes as well as 
total occlusion rates are variable (Diaz et al., 2012). It has also been reported 
that side branches of occluded vessel also influence the reproducibility of the 
model (Brandt et al., 2014). 
A complete occlusion (stasis) model is also utilised in thrombus generation, 
where suture is ligated completely around the inferior vena cava and reliably 
generates a venous thrombus (Diaz et al., 2012). However, even though 
stasis model results in good reproducibility and mimic human DVT formation, 
stasis model was not used due to formed thrombus occluding the vessel fully 
and not producing emboli during the formation of the thrombus. Equally, if 
the sutures were later opened in order to let the thrombus travel 
downstream, embolisation would not be studied since the emboli would not 
be created from blood shear stress evoked on the forming thrombus, but 
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rather letting the formed thrombus itself travel downstream, yielding little 
information on thrombus stability and dislodging dynamics.  
The FeCl3 injury model is a simpler, more accessible method, however, the 
mechanism(s) by which this agent induces thrombosis are far less 
understood and less likely to reflect human pathophysiology (section 5.1). 
However, as a highly reproducible model for intravascular clot formation, the 
model remains valuable depending on the aim of the study.  
As primary responders to endothelial damage and exposed subendothelial 
constituents, platelets are a rich component of arterial (“white”) thrombi, while 
venous thrombi are far less populated by platelets, but rather rich in red 
blood cells and are named “red” thrombi (Lippi and Favaloro, 2018). For 
studies focussed on clot stability, the FeCl3 vessel injury model remains 
highly suitable as the resulting clot structure is largely representative of 
thrombi in either the arterial or venous circulation. FeCl3 generated clots are 
suitable in studying fibrin polymerisation effects since they contain numerous 
fibrin fibres, as observed with scanning electron microscope (SEM) both by 
our research team (Figure 1.7) and others (Eckly et al., 2011).  
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Figure 1.7 SEM pictures of inferior vena cava thrombus generated with 
FeCl3 injury. 
Fibrin fibres are covering red blood cells. Credit: surgical procedure by Dr 
Cédric Duval, imaging by Dr Fraser Macrae. 
 
However, for studies focussed on how thrombosis is triggered, the FeCl3 
model may be less suitable. In the FeCl3 vascular injury model, FeCl3 is 
carefully applied by gently touching the vessel wall with a FeCl3 pre-soaked 
piece of filter paper. As firstly described by Kurz et al. (1990), FeCl3 causes 
redox-induced injury to the endothelial cells lining the vessel wall, leading 
to exposure of tissue factor on the luminal side of vessel (Li et al., 2013) and 
the consequent initiation of the extrinsic pathway of the coagulation cascade 
(Li et al., 2016a). The intra-vessel thrombus that is produced by this injury is 
also expected to embolise, thereby contributing to occlusion of downstream 
vessels and causing thromboembolic disease (Schoenwaelder and Jackson, 
2015). Figure 1.8 illustrates the principle of FeCl3 injury model. Emboli 
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coming from the inferior vena cava travel to lungs and result in pulmonary 
embolism, while emboli originating from the carotid artery result in ischaemic 
stroke. The FeCl3 injury model is the most widely used and most 
reproducible thrombosis model developed to date (Neeves, 2015).  
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Figure 1.8 Illustration of FeCl3 vascular injury. 
FeCl3 soaked filter paper is placed onto the vessel wall (orange rectangular), FeCl3 diffuses through the wall to damage the 
endothelium (red rectangle), which denudes to expose subendothelial layers. The blood is exposed to tissue factor expressed by 
subendothelial cells such as fibroblasts and smooth muscle cells, which initiates coagulation leading to fibrin formation. Endothelial 
damage also exposes negatively charged collagen fibres, which facilitates platelet (white disks) recruitment and initiates the contact 
pathway of coagulation leading to further generation of a fibrin (blue sticks) mesh and incorporation of red blood cells (red disks) 
into the thrombus. Parts of the local thrombus then dislodge and embolise further downstream. 
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1.17 Study rationale and hypotheses 
In light of the published literature on the V34L FXIII-A variant, with its 
reported protective capabilities against thrombosis, and effects on clot 
structure and coagulation/fibrinolysis dynamics, it was decided that a closer 
look at this FXIII-A variant needs to be taken using an in vivo model of 
thrombosis. The mechanisms of action of V34L in thrombotic disease has not 
yet been fully elucidated, and there are no other reports yet utilising a 
transgenic L34V animal model to study thrombosis. The first aim in my PhD 
studies was to confirm that known activation rate differences between human 
FXIII-A 34Val and 34Leu variants are reflected in analogous murine FXIII 
variants. Following activation rate comparison, my next aim was to study the 
effects on clotting, in order to investigate whether FXIII activation rate 
changes result in expected coagulation alterations as described in previous 
human FXIII studies. Finally, the main question to address in my PhD studies 
was whether murine thromboembolic diseases manifest differently with 
34Leu and 34Val variants. In order to do so, both arterial and venous murine 
thromboembolism models were established and used to investigate the 
effects these FXIII-A variants have in thromboembolic pathology. 
The main hypotheses of the PhD studies were: 
1) Murine FXIII-A 34Leu variant is activated faster than the 34Val variant 
and result in more fibrin cross-linking activity. 
2) Clots affected by mFXIII-A 34Leu variant will have thinner fibres, be 
more resistant to fibrinolysis, firmer, retain more red blood cells and 
take less time to clot than the 34Val variant affected clots. 
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3) Established differences in clot firmness, stability and resistance to 
lysis between murine 34Leu and 34Val variants will manifest in 
different dislodging, embolisation dynamics and will reflect in 
occurrence rates and severities of thromboembolism, presumably 
34Leu variant protecting against venous thromboembolism, as 
reported in human clinical studies. 
1.18 Aims 
To establish a murine FXIII-A V34L model and study its role in 
thromboembolic disease. 
1.19 Objectives 
My specific project objectives were: 
1) To generate a murine FXIII-A L34V cDNA construct using site-
directed mutagenesis and express it in E. coli alongside the Wild-Type 
(34Leu) variant. 
2) To compare activation rates of murine 34Leu and 34Val variants in 
vitro utilising a biotin incorporation assay. 
3) To characterise the newly generated L34V genotype mice (MRC 
Harwell) and establish it’s phenotype for comparison to Wild-Type 
(34Leu) mouse. 
4) To utilise mFXIII-A 34Leu, 34Val and Knock-Out (FXIII-A -/-) mice in 
studying their whole blood and plasma coagulation parameters, such 
as plasma FXIII-A antigen and fibrinogen levels, clot contraction 
dynamics, RBC retention, clot firmness and lysis parameters. 
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5) To establish murine FeCl3 vascular injury models for studying both 
arterial and venous thromboembolism. 
6) To optimise organ optical clearing and optical sectioning 
methodologies using organic solvents and light sheet microscopy. 
7) To establish an efficient and reliable emboli quantification method 
using Imaris image analysis software and use it to compare both 
venous and arterial thromboembolism dynamics between the mice 
variants. 
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Chapter 2 Methods 
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2.1 mFXIII-A gene PCR amplification 
Primers used in mFXIII-A gene PCR amplification were designed using a 
primer design program on Thermo-Fisher Scientific website 
https://www.thermofisher.com/order/custom-oligo/enterSequences.  
Full designed primer sequences can be found in section 3.3.1. PCR primers 
were then ordered from Thermo-Fisher Scientific and resuspended in ddH2O 
at 100 µM.  
A) from a DNA vector: 
A mix of 20 ng pCMV-SPORT6 vector (Source Bioscience, 
Nottingham, UK) containing a WT mFXIII-A gene, 1 μL of 10 mM 
dNTP mix (Thermofisher), 125 ng of both forward and reverse 
primers, 5 µL of 10X reaction buffer and 2.5 U Platinum® Taq DNA 
Polymerase High Fidelity (Invitrogen) was prepared, and 50 µL of the 
mix added into the thermal cycler (MJ Research; Waltham, MA, USA). 
PCR cycling parameters were followed according to Platinum® kit 
manufacturer’s instructions which can be found in section 3.3.1. 
Successful amplification was checked and DNA fragment extraction 
was performed using agarose gel electrophoresis (section 2.2). 
B) from a bacterial colony: 
PCR mix for one reaction included 1 µL of 20 µM primer mix, 25 µL of 
MyTaq™ Red Mix (Bioline, London, UK), 24 µL of ddH2O and a pen 
point sized smear of E. coli from an agar plate. PCR mixes were then 
added into the thermal cycler (MJ Research) and run according to 
MyTaq™ Red Mix manufacturer’s guidelines. Cycling parameters 
used can be found in section 3.3.1. 5 µL PCR reactions were then run 
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in the agarose gel (section 2.2) in order to confirm successful DNA 
transformation into E. coli.  
2.2 Agarose gel electrophoresis 
Agarose gel runs utilise an electric field to separate negatively charged DNA 
molecules inside an agarose gel mesh based on their size.  
2 g of agarose (Bioline, London, UK) was added into 200 mL TAE buffer 
(40mM Tris, 20mM acetic acid and 1mM EDTA) and the mix was 
microwaved until boiling point, mixed and boiled again. 10 µL of 10 mg/mL 
ethidium bromide (Sigma-Aldrich, Dorset, UK) was added to the mixture, 
mixed and poured into the gel making frame. The frame was then left to cool 
at 4°C until agarose mixture solidified into gel. The gel was transferred into a 
gel tank and 5 µL of DNA samples, premixed with 6X gel loading dye 
(appendix 3), as well as 10 µL HyperLadder™ 1kb molecular weight 
standard (Bioline, London, UK), were loaded into the gel. For DNA band 
extraction up to 45 µL of the samples were used. A 100 V current was 
applied for 1 h. Gels were imaged using G:Box XR5 imager (Syngene, 
Cambridge, UK) and Genesys (California, US) software. 
2.3 DNA recovery from agarose gel 
DNA recovery is based on the ability of DNA to bind to silica membranes in 
the presence of chaotropic salts and to be eluted with water. 
Agarose gel parts containing the DNA band of interest were identified under 
UV light and cut out using a scalpel. Wizard SV® Gel and PCR Clean-Up 
System kit (Promega; Wisconsin, USA) was then used to extract the DNA 
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from agarose gel, following kit manufacturer’s instructions for using vacuum 
pump.  
2.4 TA cloning 
TA cloning technique (also known as “T” or “rapid” cloning) utilises DNA 
topoisomerase I to insert a DNA sequence ending in adenine (A) nucleotide 
on the 3’ end into a recipient vector having complementary thymine 
nucleotide (T) tail (Figure 2.1). The technique utilises the Taq DNA 
polymerase, which unlike most DNA polymerases does not carry out 3' to 5' 
proofreading activity. During PCR, the lack of proofreading activity results in 
Taq DNA polymerase adding a single A on the 3’ end of the gene insert, 
which is ready to bind the T on the recipient vector. Post TA cloning, the 
resulting double stranded circular DNA allows for increased efficiency in DNA 
restriction by restriction enzymes.  
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Figure 2.1 Explanatory schematic of a TA cloning technique.  
Gene insert sequence ends in adenine (A) nucleotide on the 3’ end, while 
recipient vector contains thymine (T) nucleotide on the recipient 3’ end. 
Complementary sequence match allows gene fragment to be inserted into 
the vector by DNA topoisomerase I. 
 
TOPO TA cloning kit (Thermo-Fisher Scientific) was used to perform TA 
cloning. 1 µL of 10 ng/µL pCR2.1-TOPO (further: pCR 2.1) vector, ddH20, 
salt solution (inside the kit) and 0.5-4.0 µL PCR product were mixed in a final 
volume of 6 µL and incubated at 4°C for at least 30 min. Ratios of 3:1, 1:1 
and 1:3 of gene insert (PCR product) to pCR 2.1 vector were used in order to 
increase bacterial transformation success rate. Equation 2.1 was used to 
calculate the amount of insert DNA in ng needed for a 1:1 insert:vector ratio 
in the ligation reaction: 
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Gene insert amount needed =
10 ng of vector ∗  Insert length in base pairs
Vector length in base pairs
 
Equation 2.1 Gene insert amount calculation for insert vector ligation. 
 
2.5 E. coli Transformation, Growth and Glycerol Stock 
2.5.1 Transformation 
Lysogeny Broth (LB) Agar (LabM; Bury, UK) (5 g/L Yeast extract, 5 g/L NaCl, 
12 g/L Agar, 10 g/L Tryptone, topped up with ddH20) was autoclaved at 
121°C for 15 min, cooled down to 50°C and 100 μg/mL ampicillin (Sigma-
Aldrich), or 50 μg/mL kanamycin (Sigma-Aldrich) was added. 20 mL of LB 
agar was then poured into 10 cm sterile petri plates (Corning, High 
Wycombe, UK) and left to solidify for 30 minutes. SOC medium 
(Thermofisher) was then defrosted and heated to 42°C in a thermal bath. 
Competent bacteria cells were thawed on ice for 30 minutes. 50 µL of 
bacterial cells were then added to 50 mL falcon tubes (Greiner bio-one, 
Stonehouse, UK) together with up to 20 µL of DNA. The reaction tube was 
gently swirled and incubated on ice for 30 min. Bacteria there then “shocked” 
by incubating the transformation tubes at 42°C for 45 seconds and placing 
on ice for 2 minutes. 500 µL of warm SOC media (Thermofisher) was then 
added to the tubes and incubated at 37°C, shaking at 220 rpm for 1 hour. 
Three different volumes of transformed bacteria (50 µL, 150 µL and 300 µL) 
were spread on each agar plate surface until dry. Plates were wrapped in 
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paraffin film and incubated overnight at 37°C. In the morning, grown colonies 
were observed and plates were stored at 4°C. 
2.5.2 Transformation quality assurance 
Post agar plate culturing (section 2.5.1), half of each selected bacterial 
colony was taken to perform a PCR reaction (section 2.1 B), and run through 
the agarose gel (section 2.2) in order to confirm that 2196 base pair mFXIII-A 
DNA insert was successfully inserted in the vector and transformed.  
2.6 Bacterial growth 
LB (LabM; Bury, UK) (5 g/L Yeast extract, 5 g/L NaCl, 10 g/L Tryptone, 
topped up with ddH20) for bacterial growth was first made and 100 µg/mL of 
ampicillin, or 50 µg/mL kanamycin, was added to 5 mL of LB broth in 50 mL 
falcon tubes. Multiple individual colonies from the transformation (section 
1.9.1) step, which have been confirmed to contain an insert (section 2.5.2), 
were added into separate 50 mL tubes and incubated for 4 hours at 37°C, 
220 rpm. 1.6 ml of each culture growth was then distributed equally into three 
50 mL tubes containing 5 mL LB broth + antibiotic and incubated at 37°C, 
220 rpm for 16 hours. In cases of bulk growth for higher DNA extraction 
yields, each 5 mL culture growth was added into their own 250 mL LB broth 
+ antibiotic mixes instead. At each 37°C, 220 rpm step, tubes or flasks used 
were not sealed shut in order to allow airflow.  
1 mL of grown bacteria culture was added into a 2 mL tube and mixed with 1 
mL of Glycerol (Fisher Scientific, Loughborough, UK). Glycerol stock tubes 
were stored at -80°C for later use. 
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2.7 DNA extraction 
The overnight bacterial growth cultures were spun down using a Rotanta 460 
Lab Benchtop centrifuge (Hettich, Massachusetts, USA) at RT, 4650 g for 3 
min and product pellet was processed using the QIAprep® Spin Miniprep Kit 
(Qiagen, Manchester, UK), according to the manufacturer’s instructions. The 
extraction was carried out using centrifugation steps and Nuclease-free 
water for DNA elution. The concentrations of DNA acquired were determined 
using a Nanodrop ND 1000 spectrophotometer (Fisher Scientific) at A280nm. 
Purified DNA was stored at -20°C for future restriction digestion and vector 
ligation. Some of the plasmid DNA was sent for sequencing (section 2.11) in 
order to assess the integrity of the gene sequence. In cases of bulk DNA 
extraction from 250 mL bacterial growth media, PureYield™ Plasmid 
Maxiprep System (Promega) was used instead, following manufacturer’s 
instructions for vacuum use. The kit allows endotoxin clearance from the cell 
lysate and purifies DNA based on binding to a silica membrane, washing 
through with ethanol and eluting the DNA product in water. 
2.8 Restriction digestion 
Restriction enzymes cleave double stranded DNA at specific restriction sites, 
thereby allowing both a gene insert and a recipient vector to be primed for 
ligation.  
10µL restriction reaction mixes consisted of 1 µg vector DNA, 20 U restriction 
enzyme and 1X CutSmart Buffer (New England Biolabs). Restriction reaction 
was carried out in a thermal cycler (MJ Research) at 37°C for 1 hour then 
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stored at 4°C until further use. Experiment specific restriction digest details 
can be found in section 3.3.3. 
2.9 Gene – vector ligation 
Gene insert and vector post restriction digestion were run onto and extracted 
from an agarose gel and were ligated together in quantity ratios of 5:1, 3:1, 
1:1, 1:3 and 1:5. Ligation reaction consisted of: 100 ng of vector, X ng of 
insert according to the insert:vector ratio, 1.0 U T4 ligase and 1X T4 buffer 
(Promega) to reach a total volume of 20 µL. Equation 2.1 (section 2.4) was 
used to calculate the amount of insert DNA in ng needed for a 1:1 
insert:vector ratio in the ligation reaction. The ligation mix was stored 
overnight at 4°C. Experimental specific ligation details can be found in 
section 3.3.3. 
2.10 Site-directed mutagenesis 
Site-directed mutagenesis utilises designed PCR primers, which contain a 
desired nucleotide swap. The resulting PCR product sequence thereafter 
contains the introduced mutation.  
Primers used in side-directed mutagenesis were designed using a primer 
design program on the Agilent website (www.agilent.com/store/ 
primerDesignProgram.jsp). Primer sequences can be found in section 3.3.5. 
SDS-PAGE purified primers were then ordered from Thermo-Fisher Scientific 
and resuspended in ddH2O at 100 µM. QuikChange II Site-Directed 
Mutagenesis Kit (Agilent Technologies, Stockport, UK) was used to perform 
mutagenesis on mFXIII-A gene in pLIVE expression vector (section 3.3.5). A 
mix of 20 ng pLIVE vector (containing mFXIII-A gene), 1 μl of 10 mM dNTP 
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mix, 1X reaction buffer, 125 ng of both forward and reverse primers and 2.5 
U PfuUltra High-Fidelity DNA Polymerase (Agilent) was prepared and 50 µL 
of the mix added into the thermal cycler (MJ Research; Waltham, MA, USA). 
PCR cycling parameters were followed according to the QuikChange® kit 
manufacturer’s instructions and can be found in section 3.3.5. Following the 
PCR reaction, 1 µL of 10 U/μL Dpn I restriction enzyme was added to the 
PCR mix for 1 hour at 37°C in order to digest the parental DNA in the mix. 
2.11  DNA sequencing 
DNA sequencing was performed after most PCR amplification, site-directed 
mutagenesis and ligation product transfection experiments. Sequencing 
confirmed, that each step of the recombinant mFXIII-A construct formation 
was performed using a correct mFXIII-A gene sequence without any newly 
introduced, unwanted mutations in the gene.  
Sequencing was carried out by DNA Sequencing and Services, Dundee 
University, UK (https://www.dnaseq.co.uk/). 30 µL of 80-200 ng DNA and 3.2 
pmole of each primer were sent per reaction. Sequences of primers used 
can be found in section 3.3.6. Sequence checking was performed using 
Clustal Omega DNA sequence alignment tool: 
(http://www.ebi.ac.uk/Tools/msa/clustalo/). 
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2.12  Expression and purification of recombinant GST-mFXIII-
A protein from E. coli 
2.12.1 Expression 
10 µL of BL21-GOLD (DE3) E. coli cells transformed with pGEX-6P-1 34Leu 
or 34Val GST-mFXIII were grown from glycerol stock overnight at 37°C, 225 
rpm in starter cultures, comprising of 180 mL autoclaved Terrific Broth (12 
g/L Tryptone, 24 g/L Yeast Extract, 8 mL/L Glycerol), 20 mL autoclaved 
phosphate buffer (23.2 g/L KH2PO4, 164 g/L K2HPO4-3H2O), 200 µL of 100 
mg/mL ampicillin.  
The following day, 200 mL starter cultures were transferred into 1800 mL of 
autoclaved Terrific Broth, 200 mL phosphate buffer, and 2 mL of 100 mg/mL 
ampicillin mix and left incubating at 37°C, 180 rpm. When the resulting 2.2L 
culture reached the absorbance of 1.0 OD at A620 (measured with 
PowerWave HT spectrophotometer, Biotek; Swindon, UK), 2.2mL of 1M 
Isopropyl β-D-1-thiogalactopyranoside (IPTG; Sigma-Aldrich) was added, 
temperature was reduced to 30°C and the culture was left to shake overnight 
at 180 rpm. Adding IPTG allowed the release of a gene repressor from the 
lac operon and initiated mFXIII-A gene transcription.  
Following overnight culturing, bacteria were centrifuged at 4,500 g, 4°C, for 
10 min using an Avanti J-26XP Series High-Speed Centrifuge (Beckman 
Coulter; High Wycombe, UK). Culture supernatants were then discarded and 
pellets resuspended in 180 mL ice cold PBS (Sigma-Aldrich; 140 mM NaCl, 
10 mM phosphate buffer, 3 mM KCl, pH 7.4). The samples were centrifuged 
at 4,500 rpm, 4°C for 30 min and pellets were dry-frozen at -20°C until 
purification. 
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2.12.2 Purification 
Purification of Glutathione S-transferase (GST) tagged mFXIII-A protein was 
performed using GSTrap FF Glutathione Sepharose column (GE Healthcare 
and Life Sciences, Little Chalfont, UK) and the process was carried out as 
follows: 
Frozen culture pellets from the expression stage were resuspended in 176 
mL ice cold PBS for 120 min at RT, stirring at 200 rpm using a magnetic 
stirrer. 1.76 mL of 100 mg/mL Lysozyme (Sigma-Aldrich) as well as 177.6 µL 
of 1 M Dithiothreitol (Thermofisher) were added into the resuspension 
solution and left to stir for another 30 min at RT, 200 rpm in order for cell 
lysis to take place. Next, 177.8 µL of 2 mg/mL Aprotinin, 177.8 µL of 1 mM 
Pepstatin A (Sigma-Aldrich), 444 µL of 4 mM Leupeptin (Sigma-Aldrich) and 
0.138 g of Benzamidine hydrochloride (Sigma-Aldrich) were added and the 
lysate was stirred gently for another 30 min at 4°C, 200 rpm while the 
protease inhibitors helped to stop endogenous proteases cleaving mFXIII-A. 
Protease inhibition proceeded by adding 444 µL of 100 mM PMSF 
(Thermofisher), 898 µL of 10% Sodium Deoxycholate (Sigma-Aldrich) and 
stir-incubating the lysate for another 30 min at RT, 200 rpm. Solubilisation of 
GST-mFXIII-A was then aided by forcibly adding 9 mL of 20% Triton X-100 
(Sigma-Aldrich) and stirring the solution at 4°C, 200 rpm. 94.5 µL of 10 
mg/mL DNaseI (New England Biolabs) and 945 µL of 1 M MgCl2 (Sigma-
Aldrich) were added and the solution was stirred at 4°C for 10 min. DNA 
degradation was stopped by adding 2.29 mL of 0.5 M EDTA (Sigma-Aldrich). 
Samples were centrifuged at 22,000 g at 4°C for 20 min using Avanti J-26XP 
Series High-Speed Centrifuge (Beckman Coulter), 2 g of Streptomycin 
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Sulphate (Sigma-Aldrich) was mixed into the supernatant and the solution 
was centrifuged on the same settings once more. The final supernatant was 
topped up to 300 mL with PBS, filtered through 0.22 µm Express™PLUS 
filter (Merck Millipore; Watford, UK), degased and loaded onto GSTrap FF 
Glutathione Sepharose column overnight using ÄKTAprime (GE Healthcare 
and Life Sciences) system (section 3.3.7). The lysate bottle was covered with 
ice blocks over the duration of loading. The following morning the GSTrap FF 
column was stored horizontally at 4°C until late afternoon, then 16 mL GST 
Equilibration buffer (buffer list can be found in section 3.3.7) containing a vial 
of 500 units PreScission™ Protease (Fisher Scientific) mix was slowly 
injected into the column and left incubating overnight at 4°C in a horizontal 
position. The PreScission™ step was skipped when the desired purification 
product was GST-bound mFXIII-A fusion protein. The following day, the 
column was connected to ÄKTAprime for elution (section 3.3.7). mFXIII-A (as 
well as GST) fractions were collected, pooled, concentrated using 30,000 
MWCO Vivaspin 20 Columns (Sigma-Aldrich) at 4°C, 4,500 g in a Rotanta 
460 Lab Benchtop centrifuge (Hettich, Massachusetts, USA). The final 
protein concentration was measured using BCA assay (section 2.14). 
Aliquots of desirable volumes of both mFXIII-A-34Val and mFXIII-A-34Leu 
were stored at -80°C until further use. 
2.13 SDS-PAGE gels 
The SDS-PAGE gel technique uses an electric field to separate proteins in a 
Bis-Tris gel mesh. Proteins are not innately equally charged, therefore 
negatively charged sodium dodecyl sulfate (SDS) molecule is first mixed with 
the proteins, so they move towards the positive electrode in a size-
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dependent manner regardless of their charged amino acid count. SDS binds 
to the proteins in proportion to their relative molecular mass making 
separation by size accurate. 
5 µg protein samples containing 1X NuPAGE™ Sample Reducing Agent and 
1X NuPAGE™ LDS Sample Buffer (Thermofisher; Loughborough, UK) were 
first heated denatured at 70°C for 10 min, incubated on ice for 2 minutes and 
centrifuged briefly at 14,500 g in an Eppendorf MiniSpin Plus (Hamburg, 
Germany) microcentrifuge. 500 mL of 1X NuPAGE™ MES (Thermofisher) 
buffer was prepared and poured into the gel tank. 20 µL of denatured protein 
samples alongside 10 µL of Precision Plus Protein™ Dual Color Standards 
(Bio-Rad Laboratories; California, USA) were run in NuPAGE™ 4-12% Bis-
Tris Gel (Invitrogen; California, USA) for 1 hour at 200V. Post run, gels were 
washed with double distilled water (ddH20) and stained with GelCode Blue 
Stain (Thermofisher) for 1 hour at room temperature. The gel was then left 
washing in a shaking ddH20 filled box for an hour, with ddH20 being changed 
every 15 minutes. The final wash step was left overnight at 4°C and the gel 
was imaged the following day using G:Box XR5 imager (Syngene) and 
Genesys (California, US) software. 
2.14 BCA assay 
The bicinchonic acid assay (BCA or Smith assay) allows quantification of the 
total protein amount in the sample. During the BCA assay, Cu2+ is added to 
the sample, which is reduced to Cu+ ions by peptide bonds in protein. Cu+ is 
then chelated by added bicinchoninic acid and the resulting product complex 
is purple (562 nm). Since both copper related reactions are dependent on the 
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amount of protein present in the sample, total protein concentration can be 
determined by comparing sample colour intensity to a protein standard. 
The samples were diluted 1:10 in ddH2O in a 96 well plate (Greiner Bio One 
Ltd; Stonehouse, UK) and standards were prepared in serial dilutions of 
1000 µg/mL bovine serum albumin (BSA) protein (1000, 800, 600, 400 and 
200 µg/mL) (Sigma-Aldrich). 25 µL of each standard and samples were 
dispensed to the plate wells and ddH2O was used as a blank. All samples 
and standards were loaded in duplicate. 200 µL of 50:1 ratio of 
bicinochoninic acid:copper II sulphate solution (Bicinchoninic Acid Kit for 
Protein Determination; Sigma-Aldrich) was added to plate wells and 
incubated at 37°C for 30 minutes. The plate was read on a Bio-Tek 
Powerwave plate reader at 562 nm and the standard curve was determined 
by plotting the concentration of the standards against the absorbance minus 
the blank absorbance value. mFXIII-A elution sample total protein 
concentration was derived by relating sample absorbance to the standard 
curve.  
2.15 Recombinant mFXIII-A activation rate assay 
The FXIII-A activation rate assay is based on the quantification of the amount 
of GST-activation peptide (GST-AP) cleaved by thrombin from the GST-
mFXIII-A fusion protein at different time-points. Fusion protein is expressed 
with a GST bound to the N-terminus of FXIII-A, therefore, when thrombin 
cleaves off the 37 residue activation peptide, the 26 kDa GST is removed as 
well. This GST-AP loss over time is observed on the SDS-PAGE gel. 
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0.5 mL Eppendorf tubes were labelled for 0, 1, 2, 5, 10, 20, 40, 60 and 120 
minute time-points and 10 µg (15 µL) of recombinant GST-mFXIII-A diluted 
in Tris-Buffered Saline (TBS; 50 mM Tris-Cl, 150 mM NaCl, pH 7.4) was 
added into the tubes. 5 µL of activation mix consisting of 100 mM CaCl2 and 
2.5 U/mL murine thrombin was then added to all time-point tubes as quickly 
as possible, tubes were vortexed and put onto 37°C heat block. At each 
time-point, 10.5 µL of stop solution (7.5 µL of 4x Loading Buffer + 3 µL of 10x 
Reducing Agent) was added into corresponding tubes, which were put onto a 
90°C heat block for 10 minutes. Time-point “0” tubes contained stop solution 
prior to adding the activation mix to serve as negative control. After heating, 
the tubes were put on ice awaiting SDS-PAGE gel run. The SDS-PAGE run 
was carried out as described in Methods section 2.13 while loading all 30 µL 
of each sample. 
Band intensities of the 83 kDa species (activated FXIII-A) were measured 3 
times using GeneTools software (Syngene; Bangalore, India), and the 
averages were used as data. Band intensities were blanked by subtracting 
time-point 0 values from each time-point value. Band intensity values were 
also divided by the intensity of the ~65 kDa host cell protein band at 
respective time-points in order to normalise each time-point value, and adjust 
for differences in loading amounts. Adjusted intensity amounts were plotted 
against time and the natural logarithmic function (y= ln(xa) + c) was fit to the 
chart using Excel (Microsoft; Redmond, WA, USA). The exponents (“a”) of 
both variants were treated as rate and 34Leu activation rate was expressed 
as % value of 34Val average rate. Paired two-tailed student’s T-test was 
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carried out using Prism 7 (GraphPad; San Diego, CA, USA). Experiments 
were carried out 3 times. 
2.16 Mice variants and animal husbandry 
All procedures were approved by the University of Leeds Ethics Committee 
and performed under the Home Office Animals (Scientific Procedures) Act 
1986. Mice were kept in individually ventilated cages, same gender per cage, 
no more than 5 mice per cage after weaning, on 12h light and dark cycles, at 
20-22°C with 55-60% humidity. 
C57BL/6 background FXIII-A Knock-Out (F13A1-/- or FXIII-/-) mice were 
obtained by backcrossing 10 generations of CBA/129 F13A1-/- (Lauer et al., 
2002) and C57BL/6 WT mice. 
C57BL/6 background FXIII-A L34V (34Val) mice were obtained from 
Genome Editing Mice for Medicine (GEMM; MRC Harwell Institute, Oxford, 
UK). These mice were generated using CRISPR/Cas9 gene editing method. 
C57BL/6 background Wild-Type FXIII-A (34Leu) mice were obtained from 
MRC Harwell Institute (Oxford, UK). 
Experiments on mice were performed at their age of 7 weeks (± 3 days). 
2.17 Murine blood collection and plasma preparation 
Mice, aged 7 weeks (± 3 days), were first anaesthetised with 3% isoflurane 
and 2% oxygen gas mix. 450 µL of blood was then drawn from the exposed 
inferior vena cava (IVC) into a 50 µL 109 mM trisodium citrate (Sigma-
Aldrich) solution. Immediately after blood taking, animals were sacrificed by 
cervical dislocation. Blood was then immediately used for whole blood 
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experiments, while plasma was collected by centrifuging whole blood (14,000 
g, 10 min).  
2.18  Growth curve 
Both Wild-Type mFXIII-A (34Leu) and mFXIII-A-L34V (34Val) variant mice 
were weighed weekly for 10 weeks, starting on day 21 since birth. There 
were 10 mice, 5 per gender in each group.  
Mice were statistically compared using unpaired student’s T-test (Prism 7 
software). 
2.19 Blood clot contraction, serum haemoglobin and clot 
weight 
At first, glass tubes (BIO/DATA corp.; Horsham, PA, USA) were siliconised 
for 10 minutes using Sigmacote® siliconising reagent (Sigma-Aldrich; St. 
Louis, MO, USA) and rinsed with ddH2O. Clotting of FXIII-/-, 34Val and 
34Leu mice blood (n=10) was then initiated in the glass tube using: 460 µL 
whole blood diluted with saline 1/4 and 40 µL of the activation mix consisting 
1 pM final tissue factor PPP-Reagent (Thrombinoscope B.V.; Maastricht, 
Netherlands) and 10 mM final CaCl2 (Fisher Scientific; Hampton, NH, USA). 
Clot formation and contraction were left to occur at 37°C for 2 hours. The 
experiments were performed in duplicate assessing two glass tubes per 
mouse. 
2.19.1 Clot contraction  
Photographs of clots were taken at time-points 0, 30, 60, 90, and 120 
minutes. Images were analysed using ImageJ software (publicly available; 
creator: Wayne Rasband) and clot volumes derived using the Equation 2.2. 
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Total solution in the glass tube volume was known (500 µL) and digital 
clot/solution volumes were calculated from the images using diameter (d) 
and height (h) measures as well as a cylinder volume.  
 
𝐴𝑐𝑡𝑢𝑎𝑙 𝑐𝑙𝑜𝑡 𝑣𝑜𝑙. (µ𝐿) =
𝑚𝑒𝑎𝑠𝑢𝑟𝑒𝑑 𝑑𝑖𝑔𝑖𝑡𝑎𝑙 𝑐𝑙𝑜𝑡 𝑣𝑜𝑙. (𝑃𝑖𝑥𝑒𝑙𝑠ଷ)  𝑥  𝑡𝑜𝑡𝑎𝑙 𝑎𝑐𝑡𝑢𝑎𝑙 𝑠𝑜𝑙𝑢𝑡𝑖𝑜𝑛 𝑣𝑜𝑙. (500 µ𝐿)
𝑚𝑒𝑎𝑠𝑢𝑟𝑒𝑑 𝑡𝑜𝑡𝑎𝑙 𝑑𝑖𝑔𝑖𝑡𝑎𝑙 𝑠𝑜𝑙𝑢𝑡𝑖𝑜𝑛 𝑣𝑜𝑙. (𝑃𝑖𝑥𝑒𝑙𝑠ଷ)
 
 
Equation 2.2 Equation for clot volume calculation from images. 
 
𝑫𝑖𝑔𝑖𝑡𝑎𝑙 𝑣𝑜𝑙. (𝑃𝑖𝑥𝑒𝑙𝑠ଷ)  = 𝜋 (𝑑2)
2
ℎ 
Equation 2.3 Cylinder volume equation. 
Cylinder volume equation used to calculate digital volumes of clots and 
blood from images taken. Both the diameter (d) and height (h) was 
measured in pixels. 
  
Clot volumes from FXIII-/-, 34Val and 34Leu mice (n=10) were statistically 
compared using Two-Way ANOVA and Tukey's multiple comparisons tests 
(Prism 7 software). 
2.19.2 Clot supernatant haemoglobin 
At time-points 0, 30, 60, 90, and 120 minutes, 20 µL of gently resuspended 
supernatant was diluted with 30 µL ddH2O, vortexed and kept at room 
temperature for 20 minutes. Water entering red blood cells via osmosis burst 
the cells open extruding haemoglobin into the solution. Resulting solutions 
were then transferred to Greiner 384 Well Plate (Sigma-Aldrich; St. Louis, 
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MO, USA) and read at wavelengths 380 nm, 415 nm and 450 nm. 
Supernatant haemoglobin amounts were then derived using the adapted 
Harboe method Equation 2.4 (Malinauskas, 1997).  
 
𝐻𝑏 (𝑔/𝑑𝐿) =
(1/𝑑)(167.2𝐴ସଵହ − 83.6𝐴ଷ଼଴ − 83.6𝐴ସହ଴)D
1000
 
𝑑 = 𝑝𝑎𝑡ℎ𝑙𝑒𝑛𝑔𝑡ℎ 𝑖𝑛 𝑐𝑚 (0.2 𝑐𝑚) 
𝐷 = 𝑠𝑒𝑟𝑢𝑚 𝑑𝑖𝑙𝑢𝑡𝑖𝑜𝑛 𝑓𝑎𝑐𝑡𝑜𝑟 (
2
5
) 
Equation 2.4 Equation for clot supernatant haemoglobin calculations. 
 
Time-point 30, 60, 90 and 120 min values were divided by time-point 0 
values and multiplied by a 100 in order to express haemoglobin values as % 
of initial value. Haemoglobin values were normalised in order to compensate 
for natural variation in red blood cell and haemoglobin levels in mice. 
Haemoglobin values between mice variants were compared using Two-Way 
ANOVA and Tukey's multiple comparisons tests (Prism 7 software). n=10. 
2.19.3 Clot weight 
After 120 minutes of whole blood clotting, supernatant was removed and 
clots were dried and weighed. Clot weights between mice variants were 
compared using One-Way ANOVA and Tukey's multiple comparisons tests 
(Prism 7 software). n=10 (n=9 for FXIII-/-, because the clot of the first FXIII-/- 
mouse clot was lost and not weighed). 
  
62 
 
2.20  Thromboelastometry 
Rotational thromboelastometry is performed by rotating a pin, which is 
submerged into the whole blood sample. As blood clots, it becomes more 
viscous and increasingly resists the rotating pin. Measurement of this 
resistance is used to derive coagulation metrics of the blood sample.  
Thromboelastometry was performed using freshly collected FXIII-/-, 34Val 
and 34Leu (n=10) mouse blood (section 2.17), ROTEM® Pup & Pin mini cups 
(Tem Innovations GMBH; Munich, Germany), EXTEM® (tissue factor and 
heparin inhibitor), STARTEM® (CaCl2), FIBTEM® (platelet inhibitor 
cytochalasin D) kit solutions, 20 nM mouse tPA (2B Scientific; Heyford, UK) 
and ROTEM® delta thromboelastometer. Three different conditions were run 
for each blood sample: a normal clotting condition, a clotting / lysis condition 
and a clotting condition with platelet inhibition (Table 2.1).  
Table 2.1 ROTEM® conditions and reagent volumes used 
 
 
First all the reagents were added at the base of the cup and on the opposite 
sides so that reagents would not mix. Then, blood was added, pipetted up 
and down once and immediately slid into the ROTEM measurement 
Condition Reagent Volume (µL)
EXTEM 7.0
STARTEM 7.0
Blood 105.0
EXTEM 7.0
STARTEM 7.0
Blood 103.3
Murine tPA 1.7
EXTEM 7.0
FIBTEM 7.0
Blood 105.0
Clotting / Lysis
Clotting
Platelet inhibition
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machine. ROTEM measurements were recorded for at least 2.5 hours. 
Clotting Time (CT), Mean Clot Firmness (MCF) and Lysis Time (LT) were 
derived from ROTEM charts.  
Each of these parameters were analysed between mice variants using One-
Way ANOVA and Tukey's multiple comparisons tests (Prism 7 software). 
n=10 (n=6 for FIBTEM FXIII-/-, because 4 clots have not formed). 
2.21  Mice plasma experiments 
Plasma from 10 Wild-Type mFXIII-A (34Leu), 10 mFXIII-A-L34V (34Val) 
mice and 9 mFXIII-A FXIII-/- mice were analysed in multiple in vitro and in 
vivo assays. A single FXIII-/- male mouse was omitted from all analyses due 
to its mFXIII-A antigen levels being similar to 34Leu and 34Val mice, most 
likely due to a genotyping error. 
2.22  Plasma FXIII antigen levels 
Plasma FXIII activity is dependent on the amount of FXIII present, therefore 
western blotting was used to determine mFXIII-A antigen levels in 34Leu, 
34Val and FXIII-/- mice plasma. A high molecular weight (HMW) IgG band 
was used as a loading control. Samples constituting of 10 µL 1/200 plasma, 
3.75 µL of NuPAGE™ LDS Sample Buffer and 1.5 µL of 10X NuPAGE™ 
Sample Reducing Agent (Thermofisher; Loughborough, UK) were denatured 
at 70°C for 10 min, and run in NuPAGE™ 4-12% Bis-Tris Gels (Invitrogen, 
California, USA) as per section 2.13, alongside 10 µL of Precision Plus 
Protein™ Dual Color Standard (Bio-Rad Laboratories, California, USA). A 
200 V current was applied for 90-120 min. Sample bands were then 
transferred onto Odyssey® (LI-COR Biosciences; Lincoln, NE, USA) 
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nitrocellulose membrane in a sandwich apparatus (Bio-Rad Laboratories) for 
90 min stirring in ice cold Odissey® Transfer Buffer (LI-COR Biosciences). 
Membranes were treated with Odissey® Blocking Buffer for 1 hour at RT, 
then incubated with primary antibody mix of Rabbit anti-FXIIIA #17223-1-AP 
(Proteintech Group, Inc; Rosemont, IL, USA) diluted 1/500 in Odissey® 
Blocking Buffer + 0.2% Tween20 and shaking overnight at 4°C, 100 rpm. 
Membrane washing was performed three times with TBS-T (0.1% v/v 
Tween20, Sigma-Aldrich) and once with TBS, then incubated in secondary 
antibodies mix of IRDye 680RD Goat anti-Rabbit IgG and IRDye® 800CW 
Donkey anti-Mouse IgG (LI-COR Biosciences; Lincoln, NE, USA) diluted 
1/20,000 in Odissey® Blocking Buffer + 0.2% Tween20, for 1 hour at RT in 
the dark, with shaking at 150 rpm. Another 3x TBS-T and 1x TBS washing 
step was carried out and membranes were imaged using LI-COR Odyssey® 
CLx Imaging System.  
FXIII antigen levels from western blot images were expressed as FXIII 
antigen band fluorescence over HMW IgG band fluorescence. The 
corresponding ratios from each of the mouse variants were compared using 
One-Way ANOVA and Tukey's multiple comparisons statistical tests (Prism 7 
software). n=10 (n=9 for FXIII-/-). The experiment was carried out once. 
2.23  Plasma fibrinogen levels 
Coagulation and FXIII activity is heavily dependent on fibrinogen levels, 
therefore mouse plasma fibrinogen antigen levels were quantified using 
Mouse Fibrinogen Antigen ELISA Kit (MyBioSource; San Diego, CA, USA) 
and following manufacturer’s instructions, using plasma dilution 1/100,000.  
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Fibrinogen levels between mouse variants were compared using One-Way 
ANOVA and Tukey's multiple comparisons statistical tests (Prism 7 
software). n=10 (n=9 for FXIII-/-). The experiment was carried out once. 
2.24  Plasma FXIII biotin incorporation assay 
Biotin incorporation assay is based on the principle that FXIII covalently 
cross-links amines and therefore incorporates 5-(biotinamido) pentylamine 
into fibrin. The amount of cross-linked biotin is detected by adding 
streptavidin-alkaline phosphatase conjugate, which binds the incorporated 
biotin and is able to carry out the sample colorimetric change in presence of 
phosphatase substrate. Finally, the amount of sample absorbance is 
measured, which directly correlates with FXIII activity. 
Biotin incorporation assay was used to determine cross-linking activity of 
FXIII in 34Leu, 34Val and FXIII-/- plasma. The assay is based on FXIII-
catalysed cross-linking of 5-(biotinamido) pentylamine to fibrinogen coated to 
a microtiter plate well, and by measuring the phosphatase activity after 
incubation with a streptavidin-alkaline phosphatase conjugate (Ariens et al., 
2000). 
96 Well MaxiSorp Nunc-Immuno™ microtiter plates (Thermo Fisher 
Scientific; Waltham, MA, USA) were coated with 100 µL of 40 μg/mL human 
fibrinogen (MilliporeSigma; Burlington, MA, USA) for 40 minutes at RT. 
Plates were then emptied, and non-specific binding was blocked by adding 
300 µL of 1% Bovine Serum Albumin (Sigma-Aldrich; St. Louis, MO, USA) / 
TBS pH 8.3 (40 mM Tris, 140 mM NaCl), for 90 minutes at 37°C. Plates were 
then washed 4 times with 300 µL of TBS pH 8.3 and 10 µL mouse plasma 
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(diluted 1/50 in TBS pH 8.3) added to the plates. Cross-linking was initiated 
with 90 µL master mix consisting of 0.1 mM DL-Dithiothreitol (Sigma-Aldrich; 
St. Louis, MO, USA), 270 nM EZ-Link™ pentylamine-biotin (Thermo Fisher 
Scientific; Waltham, MA, USA), 10 mM CaCl2 (Fisher Scientific; Hampton, 
NH, USA) and 1 U/mL murine alpha-thrombin (Haematologic Technologies, 
Inc.; Essex, VT, USA). Reaction was stopped at time-points 0, 5, 10, 15, 20, 
25, 30 minutes by adding 200 µL 200 mM EDTA. After all reactions were 
completed, the plates were washed 4 times using 300 µL TBS-T (0.1% 
Tween® 20, Sigma-Aldrich; St. Louis, MO, USA). Plate incubation with 100 
µL of 2 mM streptavidin alkaline phosphatase (Thermo Fisher Scientific; 
Waltham, MA, USA) in 1% BSA/TBS-T solution was then carried out for 1 
hour at 37°C. Plates were washed 4 times with 300 µL TBS-T, before adding 
100 µL of phosphatase substrate in a form of 1 mg/mL p-nitrophenyl 
phosphate (Thermo Fisher Scientific; Waltham, MA, USA) in 1M 
diethanolamine (Sigma-Aldrich; St. Louis, MO, USA) solution. Once 
absorbance (405 nm) of any plate wells reached an OD of ~0.7, the reaction 
was stopped using 100 µL of 4M NaOH (Sigma-Aldrich; St. Louis, MO, USA).  
Absorbance values were blanked against T = 0 values and plotted against 
time (min). Linear regression trendlines intercepting 0 (y = kx) were fitted to 
the mean absorbance values (0, 5, 10, 15 and 20 min) for each mFXIII-A 
variant and their gradients “k” were compared. All gradient values were 
calculated as % of mean 34Val values and expressed as % activation. 
Differences were compared using One-Way ANOVA and Tukey's multiple 
comparisons statistical tests (Prism 7 software). n=10 (n=9 for FXIII-/-).  
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2.25  Plasma turbidity 
Turbidity assay is based on changes in light scattering of initially transparent 
soluble fibrinogen sample, which becomes increasingly translucent as 
fibrinogen, upon conversion to fibrin, polymerises into the insoluble fibrin 
matrix. Important metrics of fibrin polymerisation can be derived from the 
plasma turbidity curve. An example schematic of fibrin polymerisation curve 
and parameters associated can be seen below (Figure 2.2). 
 
Figure 2.2 Fibrin polymerisation curve example schematic. 
Lag time (LgT) is the portion of the fibrin polymerisation curve, which denotes 
the time it takes for the absorbance to start increasing. Vmax is the maximal 
velocity of absorbance increase seen in the steepest, linear portion of the 
curve. MaxOD is the highest OD value the curve achieves. 
 
Murine plasma was first diluted 2:3 with of TBS (40 mM Tris, 140 mM NaCl, 
pH 7.4) and 40 µL dispensed into Greiner 384 well plate. 10 µL of activation 
mix (0.5 U/mL murine thrombin, 200 mM CaCl2 in TBS) was then added to 
the well in order to initiate clotting. Immediately after initiation of clotting, 
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plates were mixed for 3 seconds and read at 340 nm every 12 seconds for 
220 minutes using a PowerWave HT Microplate Spectrophotometer. 
Absorbance values were blanked against initial values and plotted against 
time (sec). Maximum absorbance (MaxOD) and maximum clotting velocity 
(Vmax) data were analysed using One-Way ANOVA and Tukey's multiple 
comparisons tests (Prism 7 software). Fibrin polymerisation lag time (LgT) 
data was analysed using non-parametric Kruskal-Wallis and Dunn's multiple 
comparisons tests. n=10 (n=9 for FXIII-/-).  
2.26 In Vivo thromboembolism model 
2.26.1 Vascular injury, organ harvest and optical clearing 
Mice were weighed and anaesthetised by intraperitoneal injection (12.5 µL x 
body weight in grams) of 100 mg/mL ketamine / 0.6 mg/mL atropine / 20 
mg/mL xylazine. 200 µL of fluorophore (100 µg of AlexaFluor647-Fbg / 10 g of 
total mouse weight) was then injected via the tail vein. Carotid artery or 
inferior vena cava (IVC) were then isolated, and 10% or 2.5% FeCl3 
(respectively) soaked 1.5 mm x 4.5 mm filter paper (Whatman; Maidstone, 
UK) was applied for 3 minutes. The IVC was injured with a less concentrated 
FeCl3 because higher concentration resulted in an excessive number of 
emboli in the lung. After 3 minutes, the filter paper was removed, the blood 
vessel was washed with saline and the mouse was kept in the dark for 
further 57 minutes. The mouse was then slowly perfused through the heart 
with 20 mL PBS (+ 50 U/mL heparin), 15 mL 4% (PFA) and 10 mL of FITC-
Albumin gelatin (0.8 mg/mL FITC-Albumin in 2% w/v gelatin). Immediately 
after perfusion the mouse was placed under ice for at least 30 min for the 
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gelatin to solidify. All subsequent steps were performed in the dark. Lungs or 
brain were harvested and put in into 4% PFA overnight, at 4°C, shaking at 
220 rpm. The next day, the organs were dehydrated in 20%, 40%, 60%, 80% 
and 100% methanol solution for an hour each, shaking at 200 rpm, at RT. 
Organs were left overnight in 100% methanol. The following day, right and 
left lungs were surgically separated while the brains were processed as 
whole organ. Optical clearing began with incubating organs in 66% 
Dichloromethane (DCM; Sigma-Aldrich, Dorset, UK) / 34% Methanol for 3 
hour at RT, shaking at 220 rpm. Organs were then incubated in 100% DCM 
solution for 15 min twice at RT, shaking at 220 rpm. Finally, organs were 
transferred into Benzyl Ether (DBE 98%; Sigma-Aldrich, Dorset, UK) and 
incubated at least for 72 hours at RT until imaging.  
2.26.2 Light sheet fluorescence microscopy 
Light sheet microscope is able to optically section the sample into sheets 5 
µm thick by illuminating a single plane at the time. Perpendicular to excitation 
plane, the emitted light is collected at the objective and images are stored as 
a stack, capturing the whole sample, ready to be analysed as a full-sized 
reconstruction. 
The light sheet OLYMPUS (Tokyo, Japan) MVX10 Research Macro Zoom 
Microscope hardware laser power was set to 25%, and the 0.63x OLYMPUS 
MVPLAPO 2 XC objective set to 3.5 scale with lens protector on. The sample 
pool was filled with ECi (Sigma-Aldrich), which has the same refractive index 
as DBE. The cleared sample was mounted onto the sample holder and 
immersed into the microscope sample pool. The microscope was set to work 
with 470 nm and 630 nm wavelengths, at 0.63x optical zoom, 50% sheet 
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width from both sides, 5 µm sheet thickness and ECi medium. First, the 
sample was centred in the field of view, focused on the green channel and 
then on the red channel (by correcting the chromatic aberration). Once both 
colours were in focus, the software laser was adjusted to the lowest power 
(usually 30-70% green and 100% red laser power) which still covers the 
whole 0 – 65k signal intensity spectrum. Next, coordinates of the top and the 
bottom of the sample were selected. The software was instructed to separate 
stacks by colour channels (“splitting by filter”), so that the microscope first 
images the organ in one colour channel and then the other. The imaging 
resulted in two separate image stacks for green channel (vasculature) and 
red channel (emboli). Finally a top down cross section animation was created 
in the imaging software ImSpector 5.1.1 (LaVision BioTec GmbH, Bielefeld, 
Germany) (Schonle, 2006).  
2.26.3 Imaris image reconstruction and analysis 
The image stack was loaded onto Imaris 9.2.1 software (Bitplane; Belfast, 
Northern Ireland) and an initial 3D image was generated. First, both colour 
channels were adjusted for min intensity of 0 and max intensity of 65535. 
Base colours of FITC-hydrogel and AlexaFluor647-fibrinogen were set to blue 
(Red: 1.0 / Green: 1.0 / Blue: 0.0) and yellow (Red: 0.0 / Green: 0.2 / Blue: 
0.5) respectively. Next, gamma was set for both colours so the vasculature 
and emboli were visible, but the background and artefacts were not. Yellow 
gamma was defaulted to 0.1, while blue gamma defaulted to 1.0 before any 
adjustments. At this point both the image and the 3D rotating animation were 
exported.  
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Next, volumetric analysis of the emboli was performed using the “Volume” 
tool in the software. Imaris was instructed to locate yellow (emboli) surfaces 
above a certain, manually adjusted threshold, which was selected based on 
smallest clot visibility (threshold low enough, so the smallest visible clots 
were selected, but particles that were invisible by eye, were not being 
selected yet). It was possible to asses and clarify whether the software 
selection was satisfactory, because surface marking happened in real time, 
while adjusting the selected intensity threshold. By marking the emboli 
surfaces, the software was then able to calculate emboli count and volumes 
(µm3). 50 µm3 was selected as a cut off size for emboli, because smallest 
capillaries in the brain and lung are ~4-5 µm in diameter, therefore a sphere 
able to occlude such capillary is ~50 µm3 in volume. The software then 
marked the surfaces in silver (Figure 2.3) based on selected intensity 
threshold. 
Emboli counts and volumes from each mouse variant were compared using 
One-Way ANOVA and Tukey's multiple comparisons tests (Prism 7 
software). n=10. 
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Figure 2.3 Imaris software marking the surfaces of emboli post light 
sheet microscope imaging. Yellow AlexaFluor647 channel indicates 
fibrinogen fluorescence. High intensity yellow emboli were marked by silver 
surface marking tool. Marked emboli were later analysed for their count and 
volume. Surrounding vessels were made brighter for presentation purposes. 
 
2.26.4 Manual emboli counting 
Manual, as opposed to software, emboli counting was employed on brain 
sample 3D models recreated in Imaris software, because of numerous highly 
fluorescent artefacts present in brain images, which masked a great 
proportion of lower intensity emboli. Since the software could not distinguish 
the origins of fluorescent spots, visible emboli were counted by eye while 
ignoring the fluorescent smears originating from artefacts.  
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The AlexaFluor647 channel was set for min intensity of 0 and max intensity of 
65535. Gamma was set to 5, so everything was clearly visible (vasculature, 
artefacts and emboli). The organ was zoomed in to an extent so that it 
occupies the most space on the screen while being fully visible as a whole. 
“Grid” function was then set up in a way that an approximately 8x10 squares 
of the grid overlaid the organ image. Emboli in each square were counted 
using a handheld Tally Counter.  
Emboli counts from each mouse variant were compared using One-Way 
ANOVA and Tukey's multiple comparisons tests (Prism 7 software). 
2.27  Statistical analysis and outliers 
All data sets were first tested for normal Gaussian distribution using Shapiro-
Wilk test for normality. If the data set passed the normality test (P>0.05), 
data was analysed using parametric tests. Otherwise, data was analysed 
using their non-parametric equivalents.  
For a single comparison between two mice variants, student’s T-test was 
used for parametric analysis and Mann-Whitney test for non-parametric 
measures. 
For comparison of three mice variants of a single variable, One-Way ANOVA 
combined with Tukey's multiple comparisons tests were used for parametric 
analysis. Otherwise non-parametric tests used were Kruskal-Wallis and 
Dunn’s multiple comparison tests. 
For comparisons of three mice variants of multiple variables or time-points, a 
Two-Way ANOVA paired with Tukey's multiple comparisons tests were used 
for parametric analysis. All datasets of multiple group comparisons were of 
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sufficient sample size and passed the normality test, therefore the parametric 
analysis equivalent was used in all multiple group, multiple variable 
occasions. 
If any experimental design variation or technical inconsistency provided 
enough confidence that a certain value could be an outlier, that value and all 
other values associated were excluded from all sets of data. Similarly, if a 
single value is abnormally high or low compared to the rest of the associated 
data set, it was considered a possible outlier. In order to assess whether it 
should be excluded, the 1.5 interquartile range Tukey’s rule (Hoaglin et al., 
1986) was used: any data point which was 1.5 times the interquartile ranges 
below the first quartile (< Q1 - 1.5 x (Q3-Q1)) or above the third quartile ( > 
Q3 + 1.5 x (Q3-Q1)), was considered an outlier.  
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Chapter 3 In vitro recombinant 
mFXIII-A work 
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3.1 Introduction 
This PhD project intended to start with in vitro recombinant FXIII-A (rFXIII-A) 
investigations. Previous studies (Ariens et al., 2000, Duval et al., 2016) had 
shown that human rhFXIII-A 34Leu is activated faster and produces clots 
with denser, thinner fibrin fibres that are more resistant to fibrinolysis than the 
more common form: FXIII-A 34Val. In these studies, the experiments 
determining these features were perfomed both in vitro with plasma human 
FXIII-A and in vivo, injecting the human rhFXIII-A into FXIII-A deficient mice. 
In this PhD project, before moving onto the main focus – in vivo murine FXIII-
A investigations, we wanted to confirm that these V34L mutation effects can 
be replicated with murine recombinant FXIII-A (mFXIII-A). Therefore, a series 
of experiments were carried out to perform mutagenesis, insert murine FXIII-
A DNA into the expression vector, express purified mFXIII-A protein and, 
finally, compare activation rates of expressed recombinant mFXIII-A 34Leu 
and 34Val in vitro. 
The WT murine FXIII-A contains Leucine at residues 34, and a Valine 
variation at this residue does not naturally occur in mice. In order to 
investigate the differences between murine Wild-Type (34Leu) and mutant 
L34V (34Val) mFXIII-A, these proteins needed to be produced in bacteria 
using recombinant expression at sufficiently high levels. E. coli bacterial cell 
line was chosen, since FXIII-A does not normally undergo any post 
translational modifications (Hansson and Stenflo, 2005). Therefore a rapid, 
low cost and high efficiency bacterial expression system was used for protein 
expression. A series of experiments were carried out to reach the protein 
expression stage and a summary of a workflow can be found in the 
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schematic below (Figure 3.1), while in depth explanation behind these 
actions are described further. 
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Figure 3.1 In vitro recombinant mFXIII-A workflow schematic. 
The WT mFXIII-A (34Leu) gene insert from pCMV-SPORT6 vector was 
amplified by PCR and ligated into pCR 2.1 vector via TA cloning. Then, the 
ligation product was restriction digested in order to cut the mFXIII-A DNA 
insert out and ligate it with pLIVE vector. Site-directed mutagenis was then 
performed on mFXIII-A in pLIVE vector in order to generate mFXIII-A 34Val 
DNA construct. Both mFXIII-A 34Leu and 34Val DNA inserts were taken 
through the steps of PCR amplification from pLIVE vector and inserted into 
pCR 2.1 vector again. This allowed the mFXIII-A inserts to be primed by 
restriction enzymes for ligation into pGEX-6P-1 expression vector. Once in 
the expression vector, both 34Val and 34Leu mFXIII-A were expressed and 
their activation rates compared. After each ligation step, E. coli were 
transformed with ligation product, cultured, lysed and their plasmid 
(containing mFXIII-A DNA) collected for sequencing, in order to confirm that 
PCR amplification has not introduced any unwanted mutations in mFXIII-A 
DNA construct. Green bar represents mFXIII-A DNA insert and purple colour 
represents recipient DNA vector. 
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Three bacterial vectors were utilised in this project: 
1. pCR 2.1, in order to insert mFXIII-A DNA in a double stranded circular 
vector and introduce restriction sites for further restriction digestion. 
2. pLIVE, a mammalian expression vector in order to transfect FXIII 
deficient mice and express mFXIII-A in vivo. 
3. pGEX-6P-1, a bacterial expression vector in order to express 
recombinant mFXIII-A and compare 34Leu and 34Val variant 
activation rates in vitro.  
Chronologically, insertions were performed in the order listed (pCR 2.1  
pLIVE  pGEX-6P-1), however, to show the reasoning behind inserting 
mFXIII-A into each vector, the explanation will start from bacterial 
expression. 
In order for E. coli to express FXIII-A protein, the bacteria needed to be 
transfected with a vector containing the mFXIII-A gene. The 4984 bp pGEX-
6P-1 bacterial expression vector (Figure 3.2) was used, which contained a 
glutathione S-transferases (GST) sequence before the FXIII-A gene 
sequence allowing bacteria to express the protein with a 26 kDa GST tag 
attached to it. Protein expressed in this fashion had increased solubility and 
could then be purified from the bacterial lysate using affinity chromatography. 
GST fusion protein was bound to the glutathione chromatography column, all 
the remaining lysate constituents washed through the column uncollected, 
and the protein of interest was then recovered by cleavage from the bound 
GST tag using PreScission (GE Healthcare; Chicago, IL, USA) protease. 
 
80 
 
 
FXIII cDNA used in the expression vector had to be inserted into a double 
stranded bacterial vector in a specific location within the vector. Therefore, in 
order for the cDNA fragment to bind the vector sequence, both have been 
prepared using restriction enzymes. A restriction enzyme is able to cleave 
DNA at a particular sequence (restriction site), and in this case it was used to 
both open up a recipient vector at particular restriction site and prepare the 
FXIII-A insert so its beginning and ending sequences match the prepared 
recipient vector pocket.  
Restriction enzymes need a circular DNA to dock onto and initially generated 
PCR amplified mFXIII-A cDNA was only a double stranded fragment (2196 
bp). pCR 2.1 was therefore used as an intermediary step between linear 
mFXIII-A cDNA fragment and a bacterial plasmid insert. PCR product was 
ligated with a pCR 2.1 vector via TA cloning method, resulting in a mFXIII-A 
cDNA being inside a double stranded vector and ready to be cut at the right 
restriction site. Correct areas of restriction were also contained within pCR 
2.1 vector itself, allowing cut products to be inserted into many different 
bacterial and mammalian expression vectors. We have utilised two different 
sets of restriction enzymes in order to prime FXIII-A cDNA and recipient 
vectors to be inserted into both a bacterial expression vector pGEX-6P-1 and 
mammalian expression vector pLIVE. 
pLIVE vector (Figure 3.2) contains a mammalian albumin promoter sequence 
before the gene insert sequence allowing the gene to be expressed in 
mammalian cells. In this project, the pLIVE vector containing mFXIII-A was 
intended to be used in transfecting live FXIII-A Knock-Out (F13A1-/- or KO) 
81 
 
mice hepatocytes (using hydrodynamic gene transfer technique) in an 
attempt to generate a L34V mutant mice. Our research group, however, 
acquired mFXIII-A L34V (34Val) genetically modified mice strain, and the 
manual transfection method with pLIVE vector was no longer required to be 
developed. The possibility of inducing FXIII-A expression and secretion 
remains unknown as the signalling peptide of the protein has not been 
identified, and the protein may be expressed through non-classical secretion 
pathways (Cordell et al., 2010).  
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Figure 3.2 pLIVE and pGEX-6P-1 vector schematics. 
Schematic of pLIVE (top) and pGEX-6P-1 (bottom) vectors indicating 
antibiotic resistance gene sites, vector sizes, mFXIII-A insertion sites 
(indicated by panning out bars) and corresponding restriction enzymes 
shown beside the bars. pBR322 ori and pUC ori are replicons for E.coli, AMP 
– ampicillin, lac – lac operon, Ptac – Tac promoter, alpha-fetoprotein 
enhancer (AFP) enhancer II region enhances albumin promoter, MCS – 
multiple cloning site. Other letter-number combinations denote restriction 
enzymes. Adapted from www.mirusbio.com and www.lifescience-market.com 
product page. 
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Finally, in order to make the comparison between WT (34Leu) and 34Val 
variant proteins, mFXIII-A gene was mutated using site-directed 
mutagenesis. pLIVE vector containing mFXIII-A Wild-Type (34Leu) gene was 
cloned using a designed primer which contained a C to G nucleotide swap, 
resulting in DNA sequence coding for mFXIII-A 34th amino acid swap. Site-
directed mutagenesis product DNA was then cloned into PCR 2.1 and, 
subsequently, into the pGEX-6P-1 vector for mFXIII-A expression in E. coli. 
Post expression, both WT and 34Val recombinant proteins were compared in 
their activation rates through activation peptide cleavage rate quantification 
by SDS-PAGE. 
 
3.2 Aims 
To generate mFXIII-A Wild-Type (34Leu) and 34Val protein variants in order 
to assess the effects of this mutation on FXIII activation rate in murine FXIII. 
 
3.3 Methods 
3.3.1 mFXIII-A gene PCR amplification 
A 2196 bp mFXIII-A cDNA sequence from pCMV-SPORT6 vector was 
amplified using PCR for insertion into pLIVE and following a method detailed 
in section 2.1. Primers used for PCR amplification of mFXIII-A cDNA as well 
as restriction sites contained within them are shown in Table 3.1. Primers 
pLIVE-F1/R1 were used to generate pLIVE inserts from pCMV-SPORT6 
vector, while pGEX6P1_F/R primers were used to clone cDNA from a pLIVE 
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vector into pGEX-6P-1 vector. The PCR cycling parameters are listed in 
Table 3.2.  
Table 3.1 PCR amplification primers and their sequences. Restriction 
sites in the sequences are highlighted and their respective restriction 
enzymes are underlined.
Primer (Recipient vector) Sequence 
pGEX6P1_F (pGEX-6P-1) 5’TCCAGTAAAGGAATTCATGTCAGATA3’ EcoRI 
pGEX6P1_R (pGEX-6P-1) 5’TGATGTTACTCGAGCCTTCTGGG3’ XhoI 
pLIVE-F1 (pLIVE) 5’ CTCAGGAGCGCTAGCAGGAT3’ NheI 
pLIVE-R1 (pLIVE) 5’ CAGCCCACTCGAGCCTTC3’ XhoI 
 
Table 3.2 mFXIII-A PCR amplification cycling parameters. 
Segment Cycles Temperature (°C) Time (s) Stage 
1 1 94 180 Denaturation 
2 35 
94 45 Denaturation 
55 60 Annealing 
68 132 Extension 
3 1 4 any Storage 
 
3.3.2 TA cloning 
Amplified mFXIII-A cDNA fragments were run on agarose gel (section 2.2), 
recovered from the gel (section 2.3) and ligated with a pCR 2.1 vector as 
indicated in section 2.4. 
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3.3.3 Restriction digestion and gene – vector ligation 
mFXIII-A insert in pCR 2.1 as well as either pLIVE or pGEX-6P-1 vectors 
were primed for future ligation by using respective restriction enzymes.  
DNA amplification using pLIVE-F1 and pLIVE-R1 primers allowed for 
subsequent restriction of the mFXIII-A insert out of pCR 2.1, using NheI and 
XhoI restriction enzymes. pLIVE vector was also digested using these 
enzymes.  
DNA amplification using pGEX6P1_F and pGEX6P1_R primers allowed for 
subsequent restriction of the mFXIII-A insert out of pCR 2.1, using EcoRI and 
XhoI restriction enzymes. pGEX-6P-1 vector was also digested using these 
enzymes. 
Restriction digestion was carried out as detailed in section 2.8, digestion 
product samples were run on agarose gel (section 2.2) and recovered from 
the gel (section 2.3). Cut mFXIII-A gene fragment and primed recipient 
expression vector were then ligated together as described in section 2.9. 
3.3.4 E. coli Transformation, Growth and Glycerol stock 
mFXIII-A cDNA insert and vector (pCR 2.1, pLIVE or pGEX-6P-1) ligation 
products were used to transform competent XL1 Blue E. coli cells (Agilent 
Technologies, Stockport, UK) as described in section 2.5.1. Transformation 
success was investigated by running the PCR on bacterial plasmid, using 
cycling parameters listed in Table 3.3 and inspecting reaction products on an 
agarose gel (detailed in section 2.2). Finally, successfully transformed 
bacterial colonies were cultured and grown for higher yields of DNA, as 
described in section 2.6. Parts of successful bacterial colonies were stored in 
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glycerol at -80°C as described in section 2.6, whilst the remainder of colonies 
were used for plasmid extraction, as detailed in section 2.7. 
Table 3.3 PCR thermal cycling parameters used in transformation 
quality assurance runs. 
Segment Cycles Temperature (°C) Time (s) Stage 
1 1 95 600 Bacteria opening 
2 35 
95 45 Denaturation 
55 60 Annealing 
68 132 Extension 
3 1 4 any Storage 
 
3.3.5 Site-directed mutagenesis 
Site-directed mutagenesis was performed on WT (34Leu) mFXIII-A 
sequence contained in pLIVE plasmid, as detailed in section 2.10. Forward 
and reverse primers for site-directed mutagenesis PCR reaction were 
designed to contain a C to G and a G to C nucleotide swap at 34th amino 
acid sequence codon (Table 3.4) enabling the L34V mutagenesis. PCR 
reaction thermal cycling parameters were used as listed in Table 3.5. 
Table 3.4 PCR primers used in site-directed L34V mutagenesis of 
mFXIII-A. Highlighted are the codons changed from the wild-type, while 
underlined are the base pair swaps designed from C to G in the forward 
primer and G to C in the reverse primer. 
Primer Sequence 
mFXIIIL34V-F 5´-GGAGCTACAAGGCGTGGTGCCAAGGGG-‘3 
mFXIIIL34V-R 5´-CCCCTTGGCACCACGCCTTGTAGCTCC-‘3 
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Table 3.5 PCR thermal cycling parameters used in L34V site-directed 
mutagenesis. 
Segment Cycles Temperature (°C) Time (s) Stage 
1 1 95 30 Denaturation 
2 12 
95 30 Denaturation 
55 60 Annealing 
68 132 Extension 
3 1 4 120 Cooling down 
 
3.3.6 DNA sequencing 
DNA sequencing (section 2.11) was performed after most PCR amplification, 
site-directed mutagenesis and ligation product transfection experiments. 
Primers below (Table 3.6) were used to sequence the mFXIII-A gene inside 
a pCR 2.1, pLIVE or pGEX-6-P1 vector. Sequencing confirmed that each 
step of the recombinant mFXIII-A construct formation was performed using a 
correct mFXIII-A gene sequence without introducing any unwanted mutations 
in the gene.  
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Table 3.6 Primers (and sequenced vectors) used in mFXIII-A 
sequencing. 
Primer (vector) Sequence 
M13 F (pCR 2.1) 5’-GTAAAACGACGGCCAG-’3 
M13 R (pCR 2.1) 5’-CAGGAAACAGCTATGAC-’3 
pGEX6P1-F (pGEX-6P-1) 5’-GCAAGTATATAGCATGGCCTTTG-’3 
pGEX6P1-R (pGEX-6P-1) 5’-TCTGACACATGCAGCTCCC-’3 
pLIVE-F1 (pLIVE) 5’-GAGATGTAAAATTTTCATGATGTTTTC-’3 
pLIVE-R1 (pLIVE) 5’-ATATGGCTCTTGGAAATGGTCA-’3 
mFXIII-A-F1 5’-AGAGTGGAATATGTCATTGGTCG-’3 
mFXIII-A-F2 5’-GCATCCTGGATACTTGCTTGT-’3 
mFXIII-A-F3 5’-GGATTCGGTGTGGAACTACC-’3 
mFXIII-A-F4 5’-TATGGAGCCAAGAAGACCCTC-’3 
mFXIII-A-F5 5’-CCATCAAGGTCCGAGGTG-’3 
 
3.3.7 mFXIII-A Expression and Purification 
E. coli transformed with pGEX-6P-1/mFXIII-A 34Val or 34Leu plasmid were 
cultured and mFXIII-A expression was carried out as detailed in section 
2.12.1. Following expression, mFXIII-A purification was carried out by lysing 
the bacteria and recovering expressed protein by affinity chromatography as 
detailed in section 2.12.2. ÄKTAprime chromatography was performed in two 
major steps: loading GST-mFXIII-A fusion protein onto GSTrap FF column 
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(Table 3.8) and elution mFXIII-A (Table 3.9). Listed steps were carried out 
using buffers listed below (Table 3.7). 
Table 3.7 Buffers used in ÄKTAprime during mFXIII-A chromatography 
run. 
Buffer Constituents 
GST Equilibration Buffer 1x PBS, 15% Glycerol, pH 7.4, 0.22 μm filtered, degased 
GST Wash Buffer 1x PBS, 0.2% Triton X-100, 15% Glycerol, pH 7.4, 0.22 μm filtered, degased 
GST Elution Buffer  H2O, 50 mM Tris-HCl, 20 mM Glutathione, pH 8.0, 0.22 μm filtered, degased 
GST Column 
Regeneration Buffer H2O, Urea 5 M, 0.22 μm filtered, degased 
 
Table 3.8 Steps of mFXIII-A loading into GSTrap FF column using 
ÄKTAprime. 
Step Flow rate Volume 
1.     Equilibration   15 mL/min 50 mL 
2.     Equilibration  15 mL/min 50 mL 
3.     Sample Loading 0.5 mL/min 250 mL 
4.     Wash 1 0.5 mL/min 60 mL 
5.     Wash 2 1.5 mL/min 170 mL 
6.     Equilibration 2.5 mL/min 250 mL 
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Table 3.9 Steps of mFXIII-A and GST elution from GSTrap FF column 
using ÄKTAprime. 
Step Flow rate Volume 
1.     FXIII-A Elution (Equil. Buffer) 1ml/min 35ml 
2.     GST Elution (Elution Buffer), 
Collected in 1 mL fractions 1ml/min 35ml 
3.     Equilibration 5ml/min 45ml 
4.     Urea column regeneration 5ml/min 45ml 
5.     Equilibration 5ml/min 45ml 
6.     70% EtOH column regeneration, 
Collected in 2 mL fractions  5ml/min 45ml 
7.   Equilibration 5ml/min 100ml 
 
Collected elution samples were pooled together, concentrated and 
concentrate was run in BCA assay (described in 2.14) in order to determine 
the protein content of the elution concentrate. SDS-PAGE runs were carried 
out after the mFXIII-A purification steps in order to check elution sample 
purity (section 2.13). 
3.3.8 Recombinant mFXIII-A activation rate assay 
The difference between WT and L34V mFXIII-A activation rate was 
investigated using a GST-AP cleavage assay detailed in section 2.15.  
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3.4 Results 
3.4.1 WT mFXIII-A cDNA amplification from pCMV-SPORT6 vector 
In order to confirm a successful mFXIII-A gene fragment PCR amplification, 
agarose gel electrophoresis and DNA sequencing were performed.  
 
Figure 3.3 Gel electrophoresis of PCR amplified mFXIII-A gene 
fragment. 
 
PCR amplification of mFXIII-A WT cDNA from the pCMV-SPORT6 vector, 
containing NheI/XhoI restriction sites, was successful, as seen from a clear 
single 2196 base pair DNA band (Figure 3.3). Following amplification, the 
WT mFXIII-A cDNA insert was ligated with pCR 2.1 vector and sequenced. 
mFXIII-A cDNA fragment amplified from the pCMV-SPORT6 vector showed 
no mutations and was used in further experiments. Table 3.10 shows Clustal 
Omega web tool sequence alignment of PCR product sequencing and its 
template vector. 
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Table 3.10 Clustal Omega web tool alignment of a portion CMV-SPORT6 
vector containing WT mFXIII-A sequence with a PCR amplification 
product. Full sequence available in Appendix 1. 
 
CMV-SPORT6      aagcaggatccagtaaagctgagaATGtcagatactccagcaagcacctttggggggagg 
pCR2.1 - WT     ------------------------ATGTCAGATACTCCAGCAAGCACCTTTGGGGGGAGG 
                                        ************************************ 
 
CMV-SPORT6      CGAGCAGTCCCGCCCAATAACTCCAATGCTGCAGAAGTGGACCTCCCAACTGAGGAGCTA 
pCR2.1 - WT     CGAGCAGTCCCGCCCAATAACTCCAATGCTGCAGAAGTGGACCTCCCAACTGAGGAGCTA 
                ************************************************************ 
 
CMV-SPORT6      CAAGGCCTGGTGCCAAGGGGTGTCAACCTGAAAGATTACCTGAATGTCACAGCTGTTCAC 
pCR2.1 - WT     CAAGGCCTGGTGCCAAGGGGTGTCAACCTGAAAGATTACCTGAATGTCACAGCTGTTCAC 
                ************************************************************ 
 
CMV-SPORT6      CTGTTCAAGGAGAGATGGGACAGTAACAAGATTGATCACCACACAGACAAATATGACAAC 
pCR2.1 - WT     CTGTTCAAGGAGAGATGGGACAGTAACAAGATTGATCACCACACAGACAAATATGACAAC 
                ************************************************************ 
                                                                           
 
3.4.2 WT mFXIII-A DNA ligation into pLIVE vector 
pCR 2.1 – mFXIII-A and pLIVE vector were restriction digested using Nhe I 
and Xho I. Following digestion, the products were checked with agarose gel 
run. Figure 3.4 presents an agarose gel with bands of 2237 bp for the FXIII 
WT gene fragment cut out of the 3931 bp pCR 2.1 vector and a 3375 bp 
restriction cut pLIVE vector. Clear gel electrophoresis sample bands suggest 
that restriction digest was successful and no significant undesirable 
fragments were generated. 
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Figure 3.4 Agarose gel electrophoresis of pCR 2.1 vector (+mFXIII-A) 
and pLIVE vector restriction digest samples. 
 
Following the confirmation of successful restriction digest, WT mFXIII-A 
insert cDNA was ligated with pLIVE vector. Ligation products were then 
sequenced and, as shown in Table 3.11, had no undesired mutations 
introduced. 
Table 3.11 Clustal Omega web tool alignment of WT mFXIII-A insert in 
pLIVE vector with a pLIVE+mFXIII-A DNA template. Full sequence 
available in Appendix 2. 
 
pLIVE+mFXIII-A       tttttctgctagcaggatccagtaaagctgagaATGTCAGATACTCCAGCAAGCACCTTT 
mFXIII-A             ---------------------------------ATGTCAGATACTCCAGCAAGCACCTTT 
                                                      *************************** 
 
pLIVE+mFXIII-A       GGGGGGAGGCGAGCAGTCCCGCCCAATAACTCCAATGCTGCAGAAGTGGACCTCCCAACT 
mFXIII-A             GGGGGGAGGCGAGCAGTCCCGCCCAATAACTCCAATGCTGCAGAAGTGGACCTCCCAACT 
                     ************************************************************ 
 
pLIVE+mFXIII-A       GAGGAGCTACAAGGCCTGGTGCCAAGGGGTGTCAACCTGAAAGATTACCTGAATGTCACA 
mFXIII-A             GAGGAGCTACAAGGCCTGGTGCCAAGGGGTGTCAACCTGAAAGATTACCTGAATGTCACA 
                     ************************************************************ 
 
pLIVE+mFXIII-A       GCTGTTCACCTGTTCAAGGAGAGATGGGACAGTAACAAGATTGATCACCACACAGACAAA 
mFXIII-A             GCTGTTCACCTGTTCAAGGAGAGATGGGACAGTAACAAGATTGATCACCACACAGACAAA 
                     ************************************************************ 
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3.4.3 mFXIII-A L34V mutagenesis 
A FXIII-A L34V construct was produced by site-directed mutagenesis of the 
mFXIII-A 34Leu cDNA contained in pLIVE vector using the primers listed in 
Table 3.4. The mutagenesis product was confirmed to be successful by DNA 
sequencing. DNA base pair substitution from C to G at position 103 resulted 
in L34V amino acid substitution and can be seen in Clustal Omega web tool 
alignment of mutant and WT mFXIII-A sequences (Table 3.12).   
 
Table 3.12 Clustal Omega alignment of a portion of pLIVE vector 
containing WT (34Leu) and 34Val mFXIII-A sequences. mFXIII-A L34V 
mutagenesis from WT FXIII-A in pLIVE vector with L34V point mutation 
highlighted. Underlined is the location of mFXIII-A amino acid codon number 
34. Full sequence available in Appendix 3. 
 
pLIVE-WT        tttttctgctagcaggatccagtaaagctgagaATGTCAGATACTCCAGCAAGCACCTTT 
pLIVE-L34V      ---------------------------------ATGTCAGATACTCCAGCAAGCACCTTT 
                                                 *************************** 
 
pLIVE-WT        GGGGGGAGGCGAGCAGTCCCGCCCAATAACTCCAATGCTGCAGAAGTGGACCTCCCAACT 
pLIVE-L34V      GGGGGGAGGCGAGCAGTCCCGCCCAATAACTCCAATGCTGCAGAAGTGGACCTCCCAACT 
                ************************************************************ 
 
pLIVE-WT        GAGGAGCTACAAGGCCTGGTGCCAAGGGGTGTCAACCTGAAAGATTACCTGAATGTCACA 
pLIVE-L34V      GAGGAGCTACAAGGCGTGGTGCCAAGGGGTGTCAACCTGAAAGATTACCTGAATGTCACA 
                *************** ******************************************** 
 
pLIVE-WT        GCTGTTCACCTGTTCAAGGAGAGATGGGACAGTAACAAGATTGATCACCACACAGACAAA 
pLIVE-L34V      GCTGTTCACCTGTTCAAGGAGAGATGGGACAGTAACAAGATTGATCACCACACAGACAAA 
                ************************************************************ 
  
 
3.4.4 Amplification of mFXIII-A WT and L34V DNA sequences 
from pLIVE vector and ligation with pCR 2.1 vector 
WT and L34V mFXIII-A sequences were amplified from a pLIVE vector by 
PCR and inserted into pCR 2.1 vector for further restriction digestion. 
Agarose gel electrophoresis showed clear 2259 base pair bands of both WT 
and L34V mFXIII-A DNA fragments, which was indicative of successful DNA 
amplification (Figure 3.5). Sequencing was not performed at this stage due to 
it being a necessity in the next stage regardless. 
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Figure 3.5 Gel electrophoresis of PCR amplified mFXIII-A WT and L34V 
gene fragments.  
 
3.4.5 Restriction digestion of mFXIII-A WT and L34V in pCR 2.1 
vector and ligation with pGEX-6P-1 vector 
WT and L34V mFXIII-A gene sequences were cut out of pCR 2.1 vector 
using EcoRI/XhoI restriction enzymes and inserted into the cut pGEX-6P-1 
vector. In order to confirm a successful restriction digest of gene insert out of 
pCR 2.1 vector as well as a successful pGEX-6P-1 vector digestion, agarose 
gel electrophoresis was run. 
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Figure 3.6 Agarose gel electrophoresis of pCR 2.1 vector (+mFXIII-A WT 
and L34V) and pGEX-6P-1 vector restriction digest samples. 
 
Figure 3.6 presents an agarose gel electrophoresis bands of the 2259 bp WT 
and L34V gene fragments cut out of the 3931 bp pCR 2.1 vector and a 4969 
bp restriction cut pGEX-6P-1 vector. Restriction was performed using EcoRI 
and XhoI restriction enzymes. Clear gel electrophoresis sample bands 
suggest that restriction digestion was successful and no significant 
undesirable fragments were generated. 
Following ligation of WT and L34V inserts into pGEX-6P-1 vector, 
sequencing was performed. Table 3.13 shows pGEX-6P-1/WT aligned with a 
pGEX-6P-1/L34V. Results indicated that no undesired mutations were 
introduced during both DNA amplification and ligation steps. 
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Table 3.13 Clustal Omega web tool alignment of inserted WT and L34V 
mFXIII-A sequences into pGEX-6P-1 vector.  
Included pGEX-6P-1 sequence alongside WT mFXIII-A sequence is shown 
for vector demonstration purposes. L34V point mutation is highlighted, while 
underlined is the location of mFXIII-A amino acid codon number 34. Full 
sequence available in Appendix 4. 
 
 
pGEX6P1-WT        atcctccaaaatcggatctggaagttctgttccaggggcccctgggatccccggaattcA 
pGEX6P1-L34V      -----------------------------------------------------------A 
                                                                             * 
 
pGEX6P1-WT        TGTCAGATACTCCAGCAAGCACCTTTGGGGGGAGGCGAGCAGTCCCGCCCAATAACTCCA 
pGEX6P1-L34V      TGTCAGATACTCCAGCAAGCACCTTTGGGGGGAGGCGAGCAGTCCCGCCCAATAACTCCA 
                  ************************************************************ 
 
pGEX6P1-WT        ATGCTGCAGAAGTGGACCTCCCAACTGAGGAGCTACAAGGCCTGGTGCCAAGGGGTGTCA 
pGEX6P1-L34V      ATGCTGCAGAAGTGGACCTCCCAACTGAGGAGCTACAAGGCGTGGTGCCAAGGGGTGTCA 
                  ***************************************** ****************** 
 
pGEX6P1-WT        ACCTGAAAGATTACCTGAATGTCACAGCTGTTCACCTGTTCAAGGAGAGATGGGACAGTA 
pGEX6P1-L34V      ACCTGAAAGATTACCTGAATGTCACAGCTGTTCACCTGTTCAAGGAGAGATGGGACAGTA 
                  ************************************************************ 
 
                                                                               
 
3.4.6 Protein expression and purification 
Both WT and L34V mFXIII-A proteins were expressed in E. coli and purified 
using GSTrap FF chromatography. The L34V elution graph was identical to 
that of WT, therefore only WT graph is presented below (Figure 3.7). Once 
the desired protein had been eluted from the column, samples were 
concentrated into 200 µL volume using 30,000 MWCO centrifuge membrane 
columns and protein concentrations were measured by BCA assay before 
samples were run onto SDS-PAGE gel electrophoresis. 
 
The GSTrap FF column elution chart shows mFXIII-A and GST elution from 
GSTrap FF column (Figure 3.7). The spectroscopic peak of FXIII-A fraction 
had a left shoulder indicative that purity might be compromised.  
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Figure 3.7 WT mFXIII-A elution from GSTrap FF column graph. Blue line 
shows A280nm reading, while orange rectangle shows the magnified area of 
the full elution graph. Panel A zooms in on mFXIII-A elution curve, while 
panel B focuses on GST elution. AU – absorbance unit, CV – column 
volume. 
A 
B 
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SDS-PAGE of purified WT and L34V mFXIII-A, as well as their GST-bound 
versions revealed some issues with the purification step (Figure 3.8).  
 
 
Figure 3.8 SDS page gel of mFXIII-A Wild-Type, L34V and cleaved GST 
tag.  
83 kDa WT and L34V mFXIII-A as well as WT and L34V GST-mFXIII-A 
bands are labelled green. Red ovals indicate host cell protein bands which 
were taken into the account while performing band intensity analysis for 
mFXIII-A concentration corrections. Theoretical GST size: 26 kDa. 
Reducing agent was used. 
 
 
A B 
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Apart from 83 kDa mFXIII-A band (or ~110 kDa band for GST-bound 
variants) there were many other host cell protein bands present. The 
intensity of these bands (marked in red) were quantified alongside mFXIII-A 
band intensity and concentration of mFXIII-A was adjusted based on the 
mFXIII-A fraction in the sample. The concentrations obtained from the most 
successful purification run were as follows: 
 (22% purity) WT mFXIII-A: 74.6 µg/mL  
 (69% purity) L34V mFXIII-A: 1118.8 µg/mL 
 
As for GST-bound variant gel (Figure 3.8 B) all band intensities were similar 
that we treated these samples as of similar purity, since not only the purity 
profiles were similar, but also total protein found was the same (~1.65 
mg/mL). Interestingly, out of all purification runs, the L34V variant always 
purified significantly better. It can be seen in the most successful run results, 
which are 22% purity for WT sample and 69% purity for L34V. 
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3.4.7 Recombinant mFXIII-A activation rate assay 
GST-AP cleavage assay revealed that the murine WT (34Leu) variant is 
activated significantly faster than the L34V variant. SDS-PAGE gels of both 
variants from the activation rate assay show the speed difference over two 
hour period of activation (Figure 3.9). 
 
 
Figure 3.9 SDS-PAGE gels of mFXIII-A WT and L34V activation rate 
assay. 
Top numbers depict time-points in minutes, while left numbers show 
molecular weight marker band weight values in kDa. ~110 kDa GST-mFXIII-
A fusion protein band is disappearing faster and 83 kDa activated mFXIII-A 
band is appearing faster in WT gel, showing that WT variants is being 
activated faster than the L34V variant of the protein. “HCP” denotes a ~65 
kDa host cell protein (contaminant) band that was used as a loading control. 
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Activation rates of both mFXIII-A variants were derived from SDS-PAGE 
band intensity changes and 34Leu values were expressed as % activation 
rate of 34Val. Figure 3.10 shows an example of one of the three repeat runs, 
where band intensity data was plotted, logarithmic curve fit and equation 
exponents extracted as described in section 2.15.  
 
Figure 3.10 Example logarithmic curve fit to the recombinant mFXIII-A 
activation rate assay SDS-PAGE band intensity data.   
 
Activation rate assay analysis showed that the 34Leu variant is activated at 
118% ± 29.4% of the 34Val variant activation rate and is 18% faster than 
34Val (Figure 3.11).  
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Figure 3.11 Activation rate comparison between 34Leu and 34Val 
mFXIII-A.34Leu mFXIII-A variant shows increased activation rate when 
compared to 34Val variant, * p<0.05. 34Leu activation rate was expressed as 
% of 34Val activation rate. Data shown as mean ± SEM. Statistical analysis: 
paired two-tailed student’s T-test. n=3. 
 
3.5 Discussion 
Each step of the recombinant mFXIII-A cDNA L34V mutation and protein 
expression went smoothly and DNA products were both correct in sequence 
and high in yield. However, some difficulties appeared at the last stage of the 
in vitro mFXIII-A preparation - protein purification. Numerous purification re-
runs were carried out to purify both WT and L34V mFXIII-A protein 
sufficiently, however attempts never reached the desired yield and purity. 
Judging from the SDS PAGE gel band intensity analysis, the purity of the 
protein was between 15% and 60% depending on the run. In order to 
accurately assess the amount of mFXIII-A present in the purification sample, 
the total amount of protein present (FXIII-A + host cell proteins) had to be 
determined by the bicinchoninic acid (BCA) assay. BCA assay consumed 
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close to a third of the protein yield and, therefore not enough protein would 
have been left for all planned in vitro investigations (clot formation, structure 
and mFXIIIa activity analyses). Also the final mFXIII-A concentrations were 
differing 20-fold between the variants, making accurate comparison between 
them experimentally difficult to make. The differences in purity profiles as 
well as yields simply came from runs not being done in parallel, but rather at 
different times during the PhD project. Considering low protein 
concentrations, strong difference in purity and the difficulty balancing out the 
amounts of protein to add to the assays, the comparison was considered 
unreliable. On the other hand, GST-mFXIII-A fusion purification resulted in 
34Val and 34Leu variants showing identical purity profiles and came out in 
same concentrations while run parallel to each other at the same time. 
Therefore, FXIII activation rate comparison of these sets of proteins carried 
out with more confidence. The mFXIII-A 34Val and 34Leu variant activation 
rate comparison resulted to be in agreement with previously recombinant 
human FXIII-A (rhFXIII-A) published data. mFXIII-A 34Leu variant was 
shown to be activated around 18% faster than the 34Val variant, similarly to 
human data, where 34Leu variant has been reported to be faster activated 
than the 34Val variant, both plasma FXIII-A in vitro (Ariens et al., 2000) and 
recombinant FXIII-A in vivo (Duval et al., 2016), when injected to FXIII-A 
deficient mice. This gave confidence that when moving onto ex vivo mouse 
work we would see similar trend of 34Leu variant showing sped up activation 
and, in turn, increased cross-linking activity of FXIII compared to 34Val 
variant. Duval et al., (2016) showed 43% activation rate increase with 
recombinant human FXIII-A in vitro, which is higher than 18% that we 
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observed with murine variant. The explanation could lie in low purity of our 
FXIII samples and host cell proteins interfering with thrombin activation of 
FXIII, or a possibly, that murine and human FXIII-A are distinct in their 
activation rates when comparing 34Leu and 34Val variants.  
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Chapter 4 L34V mouse 
characterisation and ex vivo work 
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4.1 Introduction 
In this chapter the FXIII-A L34V (34Val) mouse model is phenotypically 
compared to FXIII-A Wild-Type (34Leu) and FXIII-A Knock-Out (FXIII-/-) 
mice variants. Characterising the newly acquired 34Val mouse variant was 
important in order to investigate possible phenotypical differences when 
compared to 34Leu and FXIII-/- mice in terms of FXIII activation and potential 
role in thrombosis. Coagulation is a multifactorial physiological function and 
singling out one coagulation factor comparison between mice variants means 
that any other variables have to be similar or at least accounted for. 
Therefore, we decided to first look into mice growth curve in order to 
investigate whether mice are going to have similar weight and metabolic rate 
at the same age. Then, plasma FXIII and fibrinogen levels were quantified. It 
was crucial that comparison of FXIII activity was performed in mice having 
similar levels of fibrinogen and FXIII itself. FXIII activation rate, as well as 
coagulation in general, is dependent on fibrinogen concentration. Assays, 
such as thromboelastometry and turbidity, measure mechanical properties 
and formation rates of clots, and therefore, the concentration of clot building 
block (fibrinogen) had to be similar. Blotting for FXIII antigen in murine 
plasma was also performed in order to confirm that FXIII-/- mice had no FXIII 
present and their molecular phenotype matched the expected genotype. 
Next, we performed plasma FXIII biotin incorporation assay in order to 
establish that increased 34Leu activation rate replicates human phenotype 
and is more readily activated ex vivo than the 34Val variant. Ariens et al. 
(2000) have shown this rate increase to be 2-fold with plasma human FXIII-A 
(phFXIII-A) in vitro and Duval et al. (2016) have shown that rhFXIII-A 34Leu 
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variant is 81% faster activated in vivo when injected in FXIII deficient mice. 
Both of the studies show FXIII activation rate effects manifest over the 
course of the first 15 minutes and up to 1 hour, suggesting that the effects 
persist even beyond first 60 minutes. This assay was also used to confirm 
that FXIII-/- murine plasma showed no FXIII activity. Next, in light of the 
published literature on clot contraction velocity (Tutwiler et al., 2016), RBC 
retention (Kattula et al., 2018) and thrombus weight (Byrnes et al., 2015) 
being heavily correlated with FXIII activity, we looked into these three 
parameters as well by forming murine whole blood clots ex vivo, measuring 
supernatant haemoglobin levels and weighing the clots. FXIII cross-linking is 
known to mechanically strengthen fibrin mesh and cross-link fibrinolysis 
inhibitors to fibrin, so we next performed whole blood thromboelastometry 
runs, which yielded clotting time, clot firmness and lysis time comparison 
data. Thromboelastometry was also performed both in presence and 
absence of platelet inhibitor in order to investigate influence of platelets on 
these parameters. And finally, murine plasma turbidity assay was performed 
and clotting velocity, fibre thickness and clotting lag time was derived. All 
these assays were crucial in establishing the effects of cross-linking by FXIII 
ex vivo before moving on to studying the systemic effects in vivo. 
 
4.2 Aims 
To phenotypically compare the FXIII-A L34V (34Val) mouse model to FXIII-A 
Wild-Type (34Leu) and FXIII-A Knock-Out (FXIII-/-) mice variants. 
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4.3 Methods 
4.3.1 Murine blood collection and plasma preparation 
Each characterisation experiment used murine whole blood or plasma from 
FXIII-A Knock-Out (FXIII-/-), Wild-Type (34Leu) and F13AL34V (34Val) mice 
aged 7-14 weeks. The mice were kept as described in section 2.16 and bled 
as described in section 2.17. 
4.3.2 Growth curve 
Both 34Val and 34Leu mice were weighed weekly for 10 weeks, starting on 
day 21 since birth (n=10). 
4.3.3 Plasma FXIII antigen and fibrinogen levels 
Plasma from FXIII-/- (n=9), 34Val and 34Leu (n=10) mice was blotted for 
FXIII antigen quantification as described in section 2.22, while fibrinogen 
levels were measured using ELISA (section 2.23) 
4.3.4 Plasma FXIII biotin incorporation assay 
FXIII-/- (n=9), 34Val and 34Leu (n=10) mice plasma was investigated for 
their plasma FXIII cross-linking activity, using a biotin incorporation assay 
(section 2.25). 
4.3.5 Clot contraction, serum haemoglobin and clot weight 
Whole blood was taken from FXIII-/-, 34Val and 34Leu (n=10) and clotted in 
glass tubes as described in section 2.19 for 120 minutes. Every 30 minutes, 
glass tubes were photographed in order to investigate clot contraction 
(section 2.19.1), and 20 µL of resuspended clot supernatant was taken in 
order to check for extruded number of red blood cells (quantified through 
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haemoglobin measurements) as detailed in section 2.19.2. Finally, after 2 
hours, clots were dried and weighed as described in section 2.19.3. 
4.3.6 Thromboelastometry 
Whole blood from FXIII-/-, 34Val and 34Leu (n=10) mice was investigated for 
their clotting time, clot firmness and clot lysis time using a rotational 
thromboelastometry. Platelet inhibition by cytochalasin D was also performed 
in order to assess their role in clotting parameters mentioned. Section 2.20 
describes thromboelastometry in detail. 
4.3.7 Plasma turbidity  
Turbidity assay was performed on FXIII-/- (n=9), 34Val and 34Leu (n=10) 
plasma by initiating coagulation and measuring sample opacity for 220 
minutes as described in section 2.25. 
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4.4 Results 
4.4.1 Growth curve 
There was no difference between the weights of 34Leu and 34Val mice at 
any time point during 3-12 weeks (Figure 4.1). Both mice variants grew at the 
same rate and were not significantly different in weight over the 3-12 week 
time-course. 
 
 
Figure 4.1 Growth curve of 34Leu and 34Val mice.  
No difference in mice weight was observed between the two mice mFXIII-A 
variant groups. Data shown as mean ± SEM. Statistical analysis: unpaired 
two-tailed student’s T-test. n=10. 
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4.4.2 Plasma FXIII antigen and fibrinogen levels 
Western blotting revealed that there was no difference between 34Val and 
34Leu mice mFXIII-A antigen levels (1.11 ± 0.08 FXIII / IgG ratio vs. 1.06 ± 
0.24 FXIII / IgG ratio respectively). As expected, FXIII-/- mice had no FXIII 
antigen present in their plasma (Figure 4.3). Due to a genotyping error, one 
male FXIII-/- mouse showed mFXIII-A antigen levels (Figure 4.2) similar to 
34Leu and 34Val mice and therefore was excluded from further experiments 
that used plasma samples. 
 
Figure 4.2 Western blotting SDS-PAGE gels showing FXIII-/-, 34Val and 
34Leu mice plasma FXIII-A antigen and IgG levels. 
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Figure 4.3 FXIII plasma antigen levels. 
FXIII antigen levels were expressed as FXIII / IgG antigen band intensity 
ratio. Data shown as mean ± SEM. FXIII-/- mice plasma had shown to have 
no FXIII, **** p<0.0001 when compared to 34Leu and 34Val mice. 
Statistical analysis: One-Way ANOVA and Tukey's multiple comparisons 
statistical tests. n=10 (n=9 for FXIII-/-). 
 
There was no significant difference in plasma fibrinogen content between 
mice variants: 34Val: 1.32 ± 0.13 mg/mL, 34Leu: 1.42 ± 0.06 mg/mL and 
FXIII-/-: 1.39 ± 0.14 mg/mL (Figure 4.4). Female FXIII-/- mice had 36.8% less 
median plasma fibrinogen (P<0.01) than the male mice (1.12 ± 0.09 mg/mL 
vs. 1.77 ± 0.58 mg/mL respectively). 
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Figure 4.4. Plasma fibrinogen levels of 34Leu, 34Val and FXIII-/- mice.  
Plasma from 34V, 34L and FXIII-/- mice showed no difference in fibrinogen 
content. Data shown as mean ± SEM. Statistical analysis: One-Way ANOVA 
and Tukey's multiple comparisons tests. n=10 (n=9 for FXIII-/-). 
 
4.4.3 Plasma FXIII biotin incorporation assay 
Plasma FXIII biotin incorporation assay (Figure 4.5) revealed that 34Leu 
mFXIII-A variant showed 39.5% higher cross-linking activity than 34Val 
variant (100.0 ± 8.6% for 34Val vs. 139.5 ± 12.5% for 34Leu variant) despite 
both mouse strains having similar FXIII antigen levels (Figure 4.3), consistent 
with the increased activation rate (section 3.4.7) of murine FXIII 34Leu by 
thrombin. FXIII-/- mice have shown only 2.3 ± 0.5% cross-linking activity of 
34Val variant (even less compared to Wild-Type 34Leu mice), which 
confirms FXIII-/- phenotype. 
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Figure 4.5 34Val, 34Leu and FXIII-/- mice plasma mFXIII-A biotin 
incorporation rates.  
34Leu mFXIII-A variant shows significantly higher cross-linking activity than 
34Val variant, * p<0.05. FXIII-/- variant shows negligible cross-linking activity 
when compared to 34Leu and 34Val mice, #### p<0.0001. Data shown as 
mean ± SEM. Statistical analysis: One-Way ANOVA and Tukey's multiple 
comparisons statistical tests. n=10 (n=9 for FXIII-/-). 
 
4.4.4 Clot contraction, clot supernatant haemoglobin and clot 
weight 
Clot volumes between 34Val, 34Leu and FXIII-/- mice blood were not 
different at any of the time-points measured (Figure 4.6): at 60 min (78.0 ± 
12.1 µL vs. 83.4 ± 11.1 µL vs. 91.5 ± 16.3 µL respectively), 90 min (39.2 ± 
5.2 µL vs. 41.4 ± 3.1 µL vs. 35.1 ± 4.7 µL respectively) and 120 min (31.7 ± 
1.4 µL vs. 39.5 ± 2.7 µL vs. 22.8 ± 3.1 µL respectively). FXIII-/- mice 
appeared to show a steeper clot contraction curve which can be explained by 
their blood taking longer to start contracting (most samples did not form a 
clearly defined clot yet at 30 minute time-point, therefore the clot volume was 
more difficult to measure from the photographs taken). 
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Figure 4.6 34Leu, 34Val and FXIII-/- mice whole blood clot volume after 
60, 90 and 120 min of clotting. 
34Val, 34Leu and FXIII-/- mice clot contraction showed no difference at any 
of the time-points. Data shown as mean ± SEM. Statistical analysis: Two-
Way ANOVA and Tukey's multiple comparisons tests. n=10. 
 
Clot supernatant haemoglobin levels (% initial) were the same between 
34Val and 34Leu mice at 60 min (26.4 ± 2.6 % vs. 24.6 ± 3.7 % 
respectively), 90 min (33.6 ± 3.8 % vs. 31.1 ± 4.1 % respectively) and 120 
min (34.0 ± 3.3 % vs. 34.4 ± 4.6 % respectively). However clot supernatant 
haemoglobin levels were significantly higher for FXIII-/- samples: 48.7 ± 7.0 
% (60 min), 51.3 ± 3.5 % (90 min) and 52.4 ± 3.6 % (120 min) (Figure 4.7). 
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Figure 4.7 Supernatant haemoglobin amount (% initial) after 60, 90 and 
120 min of clotting. 34Val and 34Leu supernatant haemoglobin values were 
not different at any time-point. FXIII-/- supernatant values were higher 
compared to both 34Val and 34Leu variants. ** p<0.01, *** p<0.001 (FXIII-/- 
vs. 34Leu), ## p<0.01, ### p<0.001 (FXIII-/- vs. 34Val). Data shown as mean ± 
SEM. Statistical analysis: Two-Way ANOVA and Tukey's multiple 
comparisons tests. n=10. 
 
Clot weights were measured 2 hours after the initiation of clotting and 
subsequent clot contraction. There was no significant difference in clot 
weights between 34Val and 34Leu mice (31.3 ± 1.3 g and 33.5 ± 1.5 g 
respectively), however FXIII-/- clots were significantly lighter (20.5 ± 2.0 g) 
than both 34Val (p < 0.001) and 34Leu (p < 0.0001) (Figure 4.8). A larger 
than 34% increase was observed when comparing mice that are mFXIII-A 
sufficient with mice that are FXIII-A deficient due to gene knock-out. 
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Figure 4.8 Two-hour clot weights from 34Leu, 34Val and FXIII-/- murine 
blood. Clots from 34Val and 34Leu showed no difference in final clot weight, 
but were both significantly heavier than that of FXIII-/- mice. **** p<0.0001 
FXIII-/- vs. 34Leu, ### p<0.001 FXIII-/- vs. 34Val. Data bars shown as mean ± 
SEM. Statistical analysis: One-Way ANOVA and Tukey's multiple 
comparisons tests. n=10 (n=9 for FXIII-/-). 
 
4.4.5 Thromboelastometry 
As shown in Figure 4.9, under normal clotting conditions (EXTEM) no 
difference in Clotting Time (CT), Maximum Clot Firmness (MCF) and Lysis 
Time (LT) were observed between 34Val and 34Leu, however FXIII-/- clots 
were significantly slower to clot (42.6 ± 3.4 s and 41.1 ± 2.6 s vs. 64.0 ± 4.6 s 
respectively), far less stiff (56.9 ± 1.4 mm and 58.5 ± 1.0 mm vs. 17.4 ± 1.3 
mm respectively) and quicker to lyse (4183.0 ± 413.3 s and 3049.0 ± 445.9 s 
vs. 1137.0 ± 89.9 s respectively). While platelets were inhibited, no 
difference in CT and MCF were observed between 34Val and 34Leu, 
however FXIII-/- clots were significantly slower to clot (42.4 ± 3.2 s and 43.0 
± 3.1 s vs. 76.7 ± 8.0 s respectively) and far less stiff (19.9 ± 1.6 mm and 
18.8 ± 2.2 mm vs. 4.2 ± 0.7 mm respectively). In platelet inhibition FIBTEM 
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condition, MCF was strongly reduced (more than 65% reduction) when 
compared to EXTEM condition in both 34Leu and 34Val variants. Percentage 
reduction of clot firmness was even more pronounced in FXIII-/- whole blood 
(more than 75%). 
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Figure 4.9 ROTEM clot CT, MCF and LT with and without platelet activity in FXIII-/-, 34Val and 34Leu blood. Blood from 
34Val and 34Leu variants showed no difference in any of the parameters measured, however there were differences compared to 
FXIII-/- blood. In both EXTEM and FIBTEM (platelet inhibition), CT was significantly longer for FXIII-/- compared to both 34Val and 
34Leu, ** p<0.01, ### and *** p<0.001, #### p<0.0001 (A and D). In both EXTEM and FIBTEM, MCF was significantly smaller for 
FXIII-/- compared to both 34Val and 34Leu, #### and **** p<0.0001 (B and E). LT was only performed in EXTEM condition only and 
it revealed a significant decrease for FXIII-/- compared with 34Val and 34Leu, #### p<0.0001, ** p<0.01 (C). Data shown as mean ± 
SEM. Statistical analysis: One-Way ANOVA and Tukey's multiple comparisons tests. n=10 (n=6 for FIBTEM FXIII-/-).
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4.4.6 Plasma turbidity 
Mice plasma coagulation turbidity was measured in order to assess any 
differences in clotting lag time (LT), MaxOD (fibre thickness) and Vmax 
(clotting rate) between mice variants in an acellular system (Figure 4.10). 
Both the LT values (82.8 ± 8.7 s for 34Leu, 118.8 ± 24.0 s for 34Val, 81.3 ± 
9.1 s for FXIII-/-) and Vmax values (0.020 ± 0.003 OD/s for 34Leu, 0.016 ± 
0.002 OD/s for 34Val, 0.018 ± 0.003 OD/s for FXIII-/-) were not different 
between the mice variants. MaxOD values were not statistically different 
between the 34Leu (0.176 ± 0.019 AU) and the 34Val (0.145 ± 0.014 AU) or 
FXIII-/- variants (0.226 ± 0.019 AU). However, FXIII-/- MaxOD values were 
significantly higher than 34Val values (p < 0.05), suggesting that plasma from 
FXIII-/- mice forms clots that have thicker fibrin fibres. 
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Figure 4.10 34Val, 34Leu and FXIII-/- mice plasma coagulation turbidity analysis.  
Plasma coagulation turbidity was measured (A) and Lag time (B), Vmax (C), MaxOD (D) parameters quantified. Plasma from all 
mice variants showed no difference in Lag time and Vmax, however plasma from FXIII-/- mice showed a significantly larger MaxOD 
than 34Val, ## p<0.01. Statistical analysis: One-Way ANOVA and Tukey's multiple comparisons tests. Data shown as mean ± SEM. 
n=10 (n=9 for FXIII-/-).
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4.5 Discussion 
By carrying out murine characterisation work described in this chapter, the 
phenotypes of FXIII-/-, 34Leu and 34Val mice were determined in detail. 
Phenotypical properties were chosen based on their known linkage to FXIII 
activity (e.g. clot contraction, RBC retention), being a standard mouse 
characteristic (growth curve) or being directly biochemically linked to the 
coagulation (e.g. plasma FXIII, fibrinogen levels). We could not find any 
differences in growth curve, plasma FXIII antigen and fibrinogen levels 
between 34Leu and 34Val mice. This meant that we were comparing mice of 
similar metabolism rate, clot building block (fibrinogen) concentrations and 
amount of plasma FXIII itself, at the age of 7-14 weeks. Plasma FXIII antigen 
assay also confirmed that our FXIII-/- mice did not possess any FXIII in their 
plasma (apart from one wrongly genotyped male mouse (Figure 4.2), which 
was excluded from all datasets). Similar fibrinogen levels between mice 
variants were very important, due to the fact that fibrinogen is known to 
increase FXIII activation rate, and therefore any functional FXIII comparison 
is influenced by this parameter.  
Further Ex vivo investigations were carried out to in order to assess 
functional differences between 34Leu and 34Val mFXIII-A, and to see how 
previously published recombinant human FXIII-A (rhFXIII-A) V34L data 
compares to the murine variant. Even though statistically there were no 
differences in turbidity, thromboelastometry and glass tube clotting 
experiments between 34Leu and 34Val variant, there were unexpected 
trends that are worth mentioning.  
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As previously established with plasma hFXIII-A in vitro by Ariens et al. (2000) 
and in vivo by Duval et al (2016), injecting rhFXIII-A in FXIII-A deficient mice, 
human FXIII-A V34L variant (rhFXIII-A 34Leu) is activated faster than the 
34Val variant (2-fold and 1.8-fold respectively) and this translates into more 
fibrin cross-linking activity. This activation rate increase leading to more 
cross-linking activity using murine FXIII-A variant can also be seen in this 
project’s work, described in sections 3.4.7 (1.2-fold in vitro) and 4.3.4 (1.4-
fold in vivo).  
Interestingly, FXIII-/- mice plasma has shown 2.3% of 34Val FXIII cross-
linking activity as opposed to expected 0%, since FXIII-/- mice plasma 
contained no FXIII. However, this can be explained by either noise readings 
within the assay or the fact that fibrinogen is a target for the other 
transglutaminases, such as TG1 and TG2 (Murthy and Lorand, 1990, Murthy 
et al., 2000), which carry out FXIII-like cross-linking (Lorand, 2005).  
Since FXIII-/- mice plasma has shown 2.3% and 34Leu - 139.5% of 34Val 
FXIII cross-linking activity, we can assume that any difference between these 
mice in coagulation, such as fibrin fibre thickness or lysis time, would be due 
to the difference in fibrin cross-linking activity. Interestingly, our findings did 
not necessarily follow a direct correlation where increasing fibrin cross-linking 
(FXIII-/- << 34Val < 34Leu) necessarily increased or decreased some 
coagulation parameters. For example, in published literature fibrin fibre 
thickness has been shown to decrease (Lim et al., 2003) and clot lysis time 
to increase (Stepien et al., 2009) with increasing FXIII activity (Duval et al., 
2016), however, our mFXIII-A 34Leu data for clot lysis and fibre thickness 
were in between FXIII-/- and 34Val values: 34Leu fibres being 21.4% thicker 
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than 34Val (turbidity maxOD) and 34Leu clots taking 27.1% quicker to lyse 
(ROTEM Lysis Time). Although at odds with the published literature, the 
differences between 34Leu and 34Val in clot lysis time and fibre thickness 
were not statistically significant (P>0.05).  
FXIII-/- values were in agreement with previously published data, which 
shows that decreased FXIII cross-linking slows clot formation (Schroeder et 
al., 2001), decreases time to lyse (Lorand, 2000), fibrin fibres thickness (Lim 
et al., 2003), clot firmness (Jambor et al., 2009) and RBC’s retention (more 
serum haemoglobin) during clot contraction (Aleman et al., 2014), which also 
resulted in lighter clot (Byrnes et al., 2015). In addition, during clot 
contraction studies, unlike 34Leu and 34Val, most FXIII-/- clots haven’t yet 
fully formed or started retracting by 30 minute time-point, which is in 
agreement with previous literature on impaired retraction in FXIII-A deficient 
mice (Kasahara et al., 2010). In agreement with published literature (Kattula 
et al., 2018), between 30 and 60 minutes, the firmness of FXIII-/- fibrin mesh 
is increasing and reaching that of FXIII-sufficient clots, which enables 
platelets to then pull at an accelerated rate to reach similar clot volume at 60 
minute timepoint. In their study, Kattula et al. showed that the velocity of 
FXIII-/- clot contraction was higher when compared to Wild-Type (34Leu) 
clots in the 30-60 min range (Kattula et al., 2018). Past the 60 min timepoint 
FXIII-/- and FXIII sufficient clots were contracting at a similar rate, in 
agreement with the study (Kattula et al., 2018).  
Lack of differences between mFXIII-A 34Leu and 34Val variants in some 
cases could be due to less pronounced 34Leu cross-linking activity increase 
(39.5%) when compared to the human variant, that purified from plasma 
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showed a 2-fold activation rate increase in vitro (Ariens et al., 2000) and a 
81% increase in vivo, when expressed in E. coli and injected into FXIII-
deficient mice (Duval et al., 2016). This difference in activation rate increase 
could also originate from experimental differences. A previous study in FXIII-
A V34L activation rates has shown that the FXIII activity difference between 
34Leu and 34Val variants are also thrombin concentration dependent and 
increasing concentrations of thrombin mask this difference (Balogh et al., 
2000). Also the difference could lay in the fact that recombinant human FXIII, 
having a 86.9 % homology with mice variant, could perform differently when 
injected in mice as opposed to the murine variant being expressed in plasma 
naturally.  
Platelet supplementation therapy has been a common practice for increasing 
clot strength (Solomon et al., 2015) and it has been established that 
increased platelet reactivity enhances patient clot strength (Huang et al., 
2015). Platelet inhibition during our rotational thromboelastometry 
experiments showed that platelets contribute substantially to clot firmness 
(186 % increase) and the effect is even more pronounced (314 % increase) 
when FXIII has not cross-linked fibrin fibres in FXIII-/- blood. These data 
suggest that the clot stiffening effect of platelets come from their own 
mechanical actions on fibrin fibres and not through secretion of FXIII, 
because the effect is present in FXIII knock-out mice, however the influence 
of other tissue transglutaminases (e.g. TG2) coming from activated platelets 
could be in play as well. Furthermore, these data suggest that platelet 
supplementation may rescue clot stiffening when FXIII activity is lacking. 
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Another point of consideration is an ablity of granulocyte enzymes such as 
human neutrophil elastase (HNE) (Schmidt et al., 1975), cathepsin G and 
metalloproteinases to both proteolytically activate (Bagoly et al., 2012) and 
degrade FXIII (Klingemann et al., 1982). Since HNE cleavage site on FXIII-A 
subunit is the Val39-Gln40 peptide bond (Bagoly et al., 2008), it is close 
enough for Val34Leu mutation to possibly influence HNE dependent-FXIII-A 
activation rate as well. It could be worth exploring other (non-thrombin) FXIII 
activating enzymes in the future, especially since HNE activated FXIII-A 
activity has been shown to achieve fibrin cross-linking (Bagoly et al., 2008). 
All considered, the data provided in this chapter show that FXIII-A 34Val 
mice are phenotypically similar to Wild-Type (FXIII-A 34Leu) mice and can 
be used for FXIII activity comparison. FXIII-/- mice were similar in terms of 
plasma fibrinogen levels, however every other (FXIII-A dependent) 
phenotypical trait was different. Comparatively, FXIII-A activation rates are 
also confirming the phenotype of all 3 murine variants used, with 34Leu mice 
showing faster FXIII activation than 34Val mice, and FXIII-/- mice showing no 
FXIII activation at all. Some clotting parameters, like lysis time and clot fibre 
thickness were different than expected based on the existing literature, 
however the differences were not statistically significant. It was unpredictable 
to not detect many of the expected differences between the 34Val and 34Leu 
variant in ex vivo studies and perhaps some of these differences were lost 
due to the sensitivity of the assays chosen. However, the main interest of the 
comparison lies in in vivo thrombosis models and that was investigated next. 
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Chapter 5 In vivo murine FeCl3 
induced pulmonary and cerebral 
thromboembolism models  
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5.1 Introduction 
Studies showing that the FXIII-A V34L variant has effects on thrombotic 
disease have been appearing frequently in the last two decades, sparking an 
increased interest in FXIII. In particular, those studies that showed a 
protective effect of FXIII V34L in deep vein thrombosis (Wells et al., 2006, 
Pourgheysari et al., 2014), stroke (Elbaz et al., 2000), coronary artery 
disease (Voko et al., 2007) and myocardial infarction (Shafey et al., 2007) 
have raised a lot of interest. These clinical studies were largely 
observational, and the mechanism by which the 34Leu sequence variant 
exerts its protective effect(s) has not yet been elucidated. It was decided to 
investigate the differences in both venous and arterial thromboembolism 
dynamics between Wild-Type (34Leu), 34Val and FXIII-/- mice by 
establishing a murine thromboembolism model, to then elucidate the in vivo 
effects of different FXIII activity levels in stroke and pulmonary embolism.  
In order to investigate the differences in clot embolisation dynamics between 
FXIII-/-, 34Leu and 34Val mice in both lungs and brains, we employed a 
FeCl3 vascular injury technique. This method was first described by Kurz et 
al. (1990) and is now a widely used tool for thrombi generation (Neeves, 
2015, Schoenwaelder and Jackson, 2015). Once filter paper soaked in FeCl3 
is applied onto the exterior of the blood vessel, FeCl3 diffuses through the 
cell wall and damages the endothelium (Li et al., 2013). The nature of FeCl3 
effects, however, remains poorly understood. Initially, it was thought that iron 
from FeCl3 accumulates inside the endothelium cells, promotes reactive 
oxygen species generation, raises cytotoxicity, causes endothelium 
denudation, which in turn exposes subendothelial elements and promotes 
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thrombus generation via extrinsic pathway of the coagulation cascade (Kurz 
et al., 1990). Later, numerous studies have shown that endothelial 
denudation is actually minimal and could not be the main reason for 
thrombus generation (Eckly et al., 2011, Barr et al., 2013, Woollard et al., 
2009). It was also shown that presence of RBC’s is crucial, because RBC 
haemolysis and subsequent haemoglobin oxidation promoted vascular injury 
and thrombosis (Woollard et al., 2009, Barr et al., 2013). Eckly and 
colleagues have revealed that ferric ion-rich spherical bodies form on the 
endothelium and promote tissue factor expression (Eckly et al., 2011). 
Subsequent studies have suggested that blood cell adhesion to the 
endothelium provides the reactive surface for platelet aggregation and 
coagulation, necessary for stable thrombus formation locally (Ciciliano et al., 
2015). In this case, vascular injury is suggested to be a secondary 
propagator of coagulation and not the initiator. This, however, still remains to 
be confirmed and further looked into, in order to further define the FeCl3 
mechanism of action more precisely (Schoenwaelder and Jackson, 2015). 
Regardless, FeCl3 remains the most widely used model for inducing 
thrombosis (Neeves, 2015), providing a strong and reproducible thrombotic 
response, mostly used for arterial thrombosis (Whinna, 2008, Ghosh et al., 
2008, Owens et al., 2011, Tseng et al., 2006, Zhang et al., 2017), and less 
commonly for venous thrombosis (Wang et al., 2006, Marsh Lyle et al., 1998, 
Martinod et al., 2013, Aghourian et al., 2012). 
By gently applying FeCl3 soaked filter paper to the murine inferior vena cava 
(IVC) we generated clots that embolised and occluded blood vessels inside 
the lung, thus causing pulmonary embolism. To model embolism in the 
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cerebral circulation (stroke), we applied FeCl3 onto the murine carotid artery 
to generate clots, which embolised to the brain and occluded the cerebral 
vasculature. Before the procedure, mice were injected with fluorescent 
fibrinogen (tagged with AlexaFluor647), which allowed visualisation of the 
emboli. Mice vasculature was also made fluorescent by perfusing them with 
a gelatine mix containing FITC-conjugated albumin. Post-procedure brains or 
lungs were harvested, fixed, dehydrated in alcohol solution and optically 
cleared with ether based organic solvent. The resulting organs were 
transparent and ready to be imaged using a light sheet microscope.  
This optical clearing method was first described by Erturk et al (Erturk et al., 
2012) and was named Three-Dimensional Imaging of Solvent-Cleared 
Organs (3DISCO). Initially, the dehydration chemical used was 
tetrahydrofuran (TTF) and its use resulted in tissue distortion. Later, another 
team figured out that TTF can be substituted by methanol and 
dichloromethane (DCM), which not only eliminates the distortive tissue 
shrinkage problem, but also reduces natural tissue autofluorescence for 
reduced background noise (Renier et al., 2014, Renier et al., 2016). The 
team termed the method immuno-DISCO-plus (iDISCO+), which we adapted 
for our experimental protocol. Our method involved using increasing 
methanol concentrations for dehydration; DCM for further dehydration, 
background fluorescence reduction and tissue preparation for correct 
refractive index; and, finally, dibenzyl ether for optical tissue clearing by 
delipidation. 
The principal of light sheet microscope is that a focused light sheet excites a 
single 5 µm thick plane of sample, and light is emitted from the sample 
132 
 
perpendicularly where it gets collected in the objective. With the help of 
lenses, laser light coming from the source is focused into a flat 5 µm thick 
light sheet, and therefore, at one time illuminates only a small amount of the 
organ keeping photodamage and fluorophore bleaching to a minimum. 
During imaging, both the sample and the objective lens are submerged in the 
pool of organic solvent which has the same refractive index as the cleared 
sample. Two sided excitation of the sample improves signal strength and 
detail, since light only needs to travel through half of the organ at most and is 
able to preserve the excitation strength and not get absorbed / scattered as 
much. Double sided imaging is repeated every time the control stage moves 
the sample up by 5 µm. Image stacks are then combined together to recreate 
a three-dimentional image of the organ. Multiple channel capture allows the 
final organ model to contain differently coloured structures, which can be 
distinguished or colocalised in both two and three dimensions. 
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Figure 5.1 Schematic depicting a light sheet microscopy principle. 
The cartoon depicts a mouse brain sample getting first excited with a light 
sheet from both sides (A). Then, excited sample emits fluorescence 
perpendicular to the excitation direction, which is collected in the objective 
lens (B). 
 
Since the light sheet microscope is able to image the organ in 5 µm sheets, 
and do so at 5 µm steps, it is effectively able to capture all the emboli within 
the organ. The ability of light sheet images to be then compiled into a stack 
reconstructing a three dimensional organ was a critical part of this project. 
Newly established organ clearing procedures and high resolution light sheet 
microscope allowed us not only to establish the methodology, but also to 
investigate multiple murine variants in both venous and arterial 
thromboembolism within the last year of the project. The acquired imaging 
data was then analysed using image analysis software, where the embolism 
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occurrence (number of emboli), and severity (emboli volume) were 
determined.  
 
5.2 Aims 
To establish a murine thromboembolism model and elucidate the effects of 
different FXIII activity levels in stroke and pulmonary embolism in vivo. 
 
5.3 Methods 
5.3.1 Pulmonary embolism 
10 mice (5 males, 5 females) per 34Leu, 34Val and FXIII-/- variant were 
anaesthetised, and FeCl3 application to the inferior vena cava (IVC) was 
performed as detailed in section 2.26.1. Photographs depicting the 
application of FeCl3 can be seen in Figure 5.2.  
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Figure 5.2 FeCl3 inferior vena cava injury model surgery photographs.  
Panel A shows the IVC being exposed, prepared for injury. Panel B shows a 
1.5mm X 4.5mm filter paper soaked in 2.5% FeCl3 placed on the exposed 
IVC. Panel C shows IVC after the filter paper is removed and the injury site is 
flooded by saline in order to wash excess FeCl3 away. 
 
Lungs were then harvested, dehydrated and optically cleared as described in 
section 2.26.1. After at least 72 hours post optical clearing, lungs were 
imaged by light sheet microscopy as detailed in section 2.26.2. After 
microscopy image acquisition, image stacks were loaded onto the Imaris 
image analysis software and organ 3D model reconstruction as well as 
embolism analysis was carried out as described in section 2.26.3.  
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5.3.2 Cerebral embolism 
10 mice (5 males, 5 females) per 34Leu, 34Val and FXIII-/- variant were 
anaesthetised and FeCl3 was applied to the carotid artery as detailed in 
section 2.26.1. Photographs depicting the FeCl3 application can be seen in 
Figure 5.3.  
 
 
Figure 5.3 FeCl3 carotid artery injury model surgery photographs.  
Panel A shows left carotid artery being isolated with a plastic strip, made 
ready for injury. Panel B shows a 1.5mm X 4.5mm filter paper soaked in 10% 
FeCl3 and placed on the isolated carotid artery. Panel C shows carotid artery 
after the filter paper is removed and the injury site is flooded by saline in 
order to wash excess FeCl3 away. 
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After the injury, the brains were harvested, dehydrated and optically cleared 
as described in section 2.26.1. At least 72 hours after brain optical clearing, 
organs were imaged by light sheet microscopy as detailed in section 2.26.2. 
After microscopy acquisition, image stacks were loaded onto the Imaris 
image analysis software and organ 3D model reconstruction as well as 
embolism analysis was carried out as described in section 2.26.3.  
For brain samples however, instead of software volumetric analysis, a 
manual emboli counting was carried out as described in section 2.26.4. The 
reason for manual counting was that the majority of brain samples contained 
high intensity large artefacts. Artefacts came from various origins, such as a 
stain of blood on the surface of the organ, surgical trauma, air bubbles inside 
the organ or strongly auto fluorescing overlapping tissue structures. The 
issue of selecting the full range of possible emboli in such samples proved to 
be problematic, because the intensity threshold adjustment was not able to 
eliminate the artefacts due to them being of a higher intensity than some of 
the smaller emboli. Under such circumstances, performing software 
calculation of emboli count always included fragments of artefacts and 
rendered the analysis flawed. Efforts were made to eliminate and 
compensate for the amount of artefact present, however the software 
analysis of brain embolism still contained some of the inaccuracies 
mentioned. It was then decided to do the manual counting of the emboli 
present in the brain. Manual counting meant that it was possible to 
distinguish artefacts from emboli, improving consistency with the sizes of 
emboli analysed (visibly by eye using the same sample magnification). 
Figure 5.4 shows an example of such analysis, with black circles indicating 
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some of the emboli chosen and red oval indicating one of the larger 
artefacts. 
 
Figure 5.4 AlexaFluor647 fluorescence channel light sheet microscope 
image reconstruction of the brain. 
Black circles show examples of emboli that were counted manually. Red oval 
indicates one of the large artefacts that made accurate automatic software 
counting impossible. 
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5.4 Results 
5.4.1 Pulmonary embolism 
Total clot volumes and emboli counts were derived for each mouse by 
adding clot volumes and counts from left and right lungs. Examples of both 
left and right lung 3D reconstructions can be seen in Figure 5.5 as top-down 
snapshots. 
 
 
Figure 5.5 Top-down snapshots of left and right lung 3D reconstruction 
post IVC FeCl3 injury and light sheet microscopy imaging. 
Yellow colour marks vasculature filled with FITC-albumin gelatin (emitting 
488 nm), while blue represents emboli containing AlexaFluor647 tagged 
fibrinogen (emitting 647 nm).  
 
 
 
 
Left Right 
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Imaris software counting of emboli larger than 50 µm3 revealed that 
increased FXIII cross-linking increased pulmonary emboli count (761.4 ± 
99.2 average emboli for FXIII-/-, 1106.0 ± 131.2 for 34Val, and 1364.0 ± 86.3 
for 34Leu mice) (Figure 5.6). The emboli count was significantly increased by 
79.1% (p= 0.0019) in 34Leu compared with FXIII-/- mice. While the other 
comparisons did not show statistical significance, there was a clear trend for 
increasing number of emboli with increased cross-linking, with 34Leu mice 
having 23.3% more total pulmonary emboli than 34Val mice, and 34Val mice 
showing 45.3% more emboli than FXIII-/- mice. 
 
 
Figure 5.6 FXIII-/-, 34Val and 34Leu mice total pulmonary emboli count 
following IVC FeCl3 injury.  
34Leu mice had significantly more pulmonary emboli than FXIII-/- mice (** 
p<0.01), whilst there were no significant differences between other mice 
variants (FXIII-/- vs. 34Val and 34Leu vs. 34Val). Statistical analysis: One-
Way ANOVA and Tukey's multiple comparisons tests. Data shown as mean 
± SEM. n=8.  
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Imaris software volumetric analysis of emboli larger than 50 µm3 revealed 
that increasing FXIII cross-linking increased total pulmonary emboli volume 
(1.05e7 ± 1.3e6 µm3 for FXIII-/-, 1.78e7 ± 2.5e6 µm3 for 34Val and 2.45e7 ± 
3.3e6 µm3 for 34Leu mice) (Figure 5.7). The total emboli volume was 
significantly increased by 133% (p=0.0021) in 34Leu compared with FXIII-/- 
mice. While the other comparisons did not show statistical significance, there 
was a clear trend for increasing total volume of emboli with increased cross-
linking, with 34Leu mice having 37.6% more total pulmonary emboli volume 
than 34Val mice, and 34Val mice showing 69.5% more total emboli volume 
than FXIII-/- mice. 
 
 
Figure 5.7 FXIII-/-, 34Val and 34Leu mice total pulmonary emboli volume 
following IVC FeCl3 injury.  
34Leu mice had significantly higher total pulmonary emboli volume than 
FXIII-/- mice (** p<0.01), whilst there were no significant differences between 
other mice variants (FXIII-/- vs. 34Val and 34Leu vs. 34Val). Statistical 
analysis: One-Way ANOVA and Tukey's multiple comparisons tests. Data 
shown as mean ± SEM. n=8.  
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Next, pulmonary embolism occurrence was also analysed by including only 
the data associated with emboli larger than 7000 µm3, which was on average 
the 25th percentile largest emboli based on volume. The same analysis was 
also performed using the 25th percentile smallest emboli data (<200 µm3). 
The large emboli data revealed that the trend of increasing emboli count with 
increasing cross-linking was still present with larger emboli, as seen in Figure 
5.8. 34Leu mice (347.1 ± 29.0) had more large emboli than FXIII-/- (210.5 ± 
33.8) and 34Val (234.1 ± 29.5) mice, which was nearly a 50% increase. 
34Val and FXIII-/- mice, however, had nearly identical larger emboli counts.  
Emboli smaller than 200 µm3 data show no statistical difference between 
FXIII-/- (229.8 ± 50.0 emboli), 34Val (309.4 ± 47.9 emboli) and 34Leu mice 
(337.0 ± 21.8 emboli). However a trend of small emboli generation increase 
was still evident with increasing FXIII cross-linking: moving from FXIII-/- to 
34Val mice (34.6%), and 34Val to 34Leu mice (8.9%). 
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Figure 5.8 FXIII-/-, 34Val and 34Leu mice large (>7000 µm3) and small 
(<200 µm3) pulmonary emboli count following IVC FeCl3 injury.  
A: 34Leu mice had significantly more pulmonary emboli than FXIII-/- and 
34Val mice (* p<0.05). There was no difference between FXIII-/- and 34Val 
mice large emboli count. Smallest large emboli size: 7000 µm3. B: There was 
no statistically significant difference between FXIII-/-, 34Val and 34Leu mice 
in small emboli count. Largest small emboli size: 200 µm3. Statistical 
analysis: One-Way ANOVA and Tukey's multiple comparisons tests. Data 
shown as mean ± SEM. n=8.  
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5.4.2 Cerebral embolism 
Emboli count was derived for each mouse by manually counting emboli in 3D 
brain reconstructions. Examples of such organ model can be seen in Figure 
5.9 as a top-down snapshot. 
 
 
Figure 5.9 Top-down snapshot of mouse brain 3D reconstruction post 
carotid artery FeCl3 injury and light sheet microscopy imaging. 
Red colour marks vasculature filled with FITC-albumin gelatin (emitting 488 
nm), while dark blue are the emboli containing AlexaFluor647 tagged 
fibrinogen (emitting 647 nm).  
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Manual counting of murine brain emboli revealed that increased FXIII cross-
linking inconsistently affected cerebral embolism occurrence (182.5 ± 14.4 
cerebral emboli for FXIII-/-, 136.8 ± 20.0 for 34Val, and 166.0 ± 10.7 for 
34Leu mice) (Figure 5.10). Although not statistically significant, 34Leu mice 
showed an increase of 21.3% in emboli count over 34Val mice and a 9% 
decrease when compared to FXIII-/- mice. 34Val mice showed a 25% emboli 
count reduction when compared to FXIII-/- mice. Also not statistically 
significant, however notable difference was that 34Val female mice had 60% 
more cerebral emboli than the 34Val male mice (168.4 ± 34.3 emboli vs. 
105.2 ± 11.4 emboli respectively). 
 
 
Figure 5.10 FXIII-/-, 34Val and 34Leu mice total cerebral emboli count 
following carotid artery FeCl3 injury.  
There was no statistically significant difference between FXIII-/-, 34Val and 
34Leu mice in cerebral emboli count. Statistical analysis: One-Way ANOVA 
and Tukey's multiple comparisons tests. Data shown as mean ± SEM. n=10.  
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5.4.3 Brain clearing optimisation 
Attempts were made to enhance brain clearing in order to increase the 
emboli-to-background intensity ratio. However, neither the addition of 0.2% 
TWEEN20 (Sigma-Aldrich) to the dehydration solutions (to aid delipidation), 
nor the extension of the clearing time beyond a standard 72h period yielded 
any visible improvements in brain tissue clearing. 
5.5 Discussion 
The 2.5% FeCl3 IVC injury pulmonary embolism model showed a clear trend, 
that increasing FXIII activity leads to an increased number of lung emboli 
occurring, along with the occurrence of larger clot emboli (increased total 
emboli volume in the lungs). A cut-off for emboli larger than 7000 µm3 was 
used in order to see whether there is a difference in small or large emboli 
generation between the murine FXIII variants. This particular size cut-off was 
chosen, because it is, on average, a 25th percentile of largest emboli and 
7000 µm3 is the point at which emboli volume starts to increase 
exponentially. Smaller than 200 µm3 emboli cut-off was also used for a small 
emboli subgroup, which represented the 25th percentile of lower overall clot 
volume. Interestingly, large emboli data show similar 34Val and FXIII-/- 
emboli counts, although in all emboli data, 34Val had 45% more emboli and 
69% more total emboli volume. It is worth noting that the 7000 µm3 cut-off 
emboli are categorised by fixed emboli volume alone, therefore having the 
same amount of larger emboli, but far more total (all sized) emboli volume 
means that 34Val mice generate smaller emboli than FXIII-/- mice. This is 
also indicated by FXIII-/- mice having noticeably less of the small (<200 µm3) 
emboli (-25.7%) than the 34Val mice, however statistically not significant. 
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This could be an indication that the presence of cross-linking by FXIII 
increases the generation of smaller pulmonary emboli, but not larger emboli. 
Structural enhancement of the blood clot by FXIII cross-linking could help to 
keep a thrombus better anchored at the site of formation, preventing large 
emboli from occuring, but not preventing smaller emboli dislodging from the 
luminal side of the thrombus. At the same time, FXIII-/- thrombi could be 
more susceptible to losing larger chunks of the formed thrombus from the 
injury site due to a weaker fibrin mesh, therefore generating larger clots more 
often than the smaller ones. This trend and hypothesis of FXIII-/- generating 
larger emboli than the 34Val variant was not completely translatable to the 
comparison of the FXIII-/- and 34Leu mice. 34Leu mice generated 
considerably more large (+64.9%) and small (+46.6%) emboli when 
compared to the FXIII-/- mice. The marked emboli count increase was also 
consistent with total emboli count increase (+79.1%) and total emboli volume 
increase (+133.3%) when comparing 34Leu and FXIII-/- mice. Overall, 
increasing FXIII-A activity associated with increased all size venous emboli 
count and total emboli volume in the case of 34Leu mice, and the effect 
between 34Val and 34Leu mice was most noticeable in large venous emboli 
generation (48.3%) and least pronounced in small emboli generation (8.9% 
increase). A possible hypothesis to explain this apparent contradiction could 
be that the increased activation rate of 34Leu variant increases cross-linking 
of fibrinolysis inhibitors to fibrin, and therefore make the venous emboli that 
do occur, more resilient to fibrinolysis, and so increasing their number and 
volume over time. 
148 
 
The FeCl3 carotid artery injury model for cerebral thromboembolism required 
optimisation in order to obtain a sufficient number of emboli occurring in the 
brain. The optimised 10% FeCl3 injury for 3 minutes was close to the higher 
end of concentration used (4.0 - 12.5%) by other research teams (Chen et 
al., 2011, Bonnard and Hagemeyer, 2015, Chen et al., 2008, Robertson et 
al., 2009), as well as a study investigating FeCl3 concentrations (2.5 – 
12.5%) for carotid artery thrombosis (Li et al., 2013). However, the 
experimental conditions resulted in closely grouped data for all mice variants. 
Interestingly, cerebral embolism data did not establish a clear FXIII cross-
linking-dependent trend, but rather showed an inconsistent relationship with 
cross-linking activity (FXIII-/- > 34Leu > 34Val). Similar to the pulmonary 
embolism data, FXIII 34Leu mice had 21% more cerebral emboli when 
compared to 34Val variant, however also showed 9% less emboli when 
compared to FXIII-/- variant. These data suggest that cross-linking by FXIII 
does not have a clear pro-thromboembolic effect as seen in the venous 
environment, since FXIII-/- mice produced the most cerebral emboli in the 
arterial model. A possible explanation for this apparent inconsistency could 
be that FXIII cross-linking stabilises the arterial clots at the vascular injury 
site, thereby reducing possible emboli from being formed. Mechanical 
strengthening of the clot through FXIII cross-linking could be stabilising the 
thrombi against a high shear, fast flowing arterial environment, where clots 
are affected by a strong force of flow. This clot stabilisation effect could, in 
turn, counteract any antifibrinolytic effects of cross-linking by FXIII by 
reducing the level at which emboli dislodge and embolise in the high shear 
arterial flow. Furthermore, due to the higher flow rates in the arterial 
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circulation, the time of transit of emboli from the site of vascular injury to the 
site of occlusion is less than in the venous circulation, reducing the time for 
fibrinolysis of emboli to occur prior to occlusion. Hence, it is possible that the 
mechanical clot stabilisation due to cross-linking in the high flow rate, high 
shear arterial circulation outweighs the antifibrinolytic effect of cross-linking, 
while the opposite occurs in the low flow rate, low shear venous 
environment. 
One limitation of the carotid cerebral embolism model is the use of manual 
emboli counting. Manual counting made it impossible to measure emboli 
volume and detect small emboli that were invisible to the eye at the 
magnification and zoom displayed on the computer screen. This technical 
shortcoming made it impossible to tell whether the total emboli volume in the 
brain is changed with varying amounts of FXIII activity. Attempts were made 
to reduce the subjectivity when manually choosing and counting the emboli, 
by employing a consistency of selecting the emboli at a certain visual 
perception level (such as position of the screen, zoom level and colour 
intensity levels). In addition, blinding of the origin of the samples (FXIII-/-, 
34Val or 34Leu) during analysis also contributed to the reliability of this data. 
An additional limitation is that the FeCl3 vascular injury model for thrombi 
generation represents a stimulus that is supra-physiological, and a poor 
reflection of the natural, slowly developing thrombosis pathophysiology in 
patients (Neeves, 2015). This is particularly relevant for deep vein 
thrombosis (Albadawi et al., 2017), where thrombi form due to blood stasis, 
pooling, hypercoalgulability and endothelial dysfunction (Kumar et al., 2010). 
However, due to FeCl3 being a highly reproducible and reliable thrombus 
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generation method, it is widely used in different studies of arterial and 
venous thrombosis (Schoenwaelder and Jackson, 2015, Neeves, 2015). 
Moreover, my studies were not focussed on factors that cause thrombosis, 
but rather the stability of the thrombi formed. Future studies would benefit by 
a further optimisation of in vivo thrombosis models and consider more 
disease-like environment reproducing models for venous thrombosis, such 
as a suture ligation stasis or stenosis models of the inferior vena cava 
(Albadawi et al., 2017, Diaz et al., 2012, Payne and Brill, 2017).  
Notwithstanding the limitations mentioned above, the data collected from 
both arterial and venous models are tightly grouped and trend-setting. 
Concerning both cerebral and pulmonary embolism occurrence data 
between 34Leu and 34Val mice, the results are in agreement, 34Leu mice 
generating 23.3% more pulmonary emboli and 21.3% more cerebral emboli, 
when compared to 34Val mice. However, from a FXIII-A activation rate point 
of view, the cerebral embolism data does not follow a dependency trend of 
more FXIII activation (and activity) leading to more embolism. The 
observations of a pro-thromboembolic effect of increasing FXIII activity in 
arterial thromboembolism could indeed be counteracted by a stabilising 
effect of the cross-linking of thrombi at their arterial anchoring site. However, 
it is difficult to determine whether the combination of these effects actually 
translate into altered stroke severity without knowing the total emboli volume 
generated and emboli size (their occlusive capability). In the published 
clinical literature, the potential role of FXIII V34L in ischaemic stroke has also 
been controversial. In the year 2000, a French study on 456 patients 
concluded a protective effect of 34Leu variant in ischaemic stroke (Elbaz et 
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al., 2000). Later, a study in Italy showed an opposite effect of increased 
stroke risk associated with the 34Leu variant (Rubattu et al., 2005). Further 
studies have added to this controversy, showing an inconclusive relationship 
of FXIII 34Leu variant with stroke (Endler et al., 2003, Moskau et al., 2010). 
Two major meta-analysis studies have since concluded a lack of association 
between FXIII-A V34L and ischaemic stroke (Li et al., 2012, Wei et al., 
2019). However, a particular study has suggested that, while the 34Leu 
sequence variant did not increase occurrence of ischaemic stroke, it did 
increase severity of the outcome, making fatality from ischaemic stroke three 
times more likely then compared to 34Val patients (Shemirani et al., 2014). 
Therefore, the study from Shemirani et al. findings suggest that stroke 
occurrence might not paint the full picture of the role of FXIII in ischaemic 
stroke, and that FXIII could potentially influence further development, and 
ultimately, the outcome of the disease, possibly by altering the fibrinolytic 
resistance of emboli.  
In apparent contrast to the above, the venous pulmonary embolism data 
showed that both the emboli total volume and number of emboli produced 
were increased with increasing FXIII activity, indicating more severe venous 
thromboembolism. The data is again in apparent contradiction with a large 
meta-analysis study showing that FXIII-A 34Leu may be protective against 
venous thromboembolism (VTE) (Wells et al., 2006). However, when 
comparing naturally developed VTE, where clots formed in static, 
hypercoagulable environment, and not due to the acute endothelial damage 
caused by FeCl3, we are likely seeing different mechanisms of action getting 
influenced by FXIII activity. In a high shear stress arterial environment, FXIII 
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cross-linking activity could stabilise the thrombus at the site of injury and 
therefore be protective against embolism, while in lower shear stress 
environment in the venous circulation, clot stabilisation could not be as 
important. In the venous environment, the antifibrinolytic effect of FXIII could 
perhaps be more influential than mechanical clot stability, where protection 
from fibrinolysis is protecting and clot emboli that are generated, thereby 
providing a larger total volume of emboli generated. This very effect could be 
less noticeable in arterial environment since clots undergo higher shear 
stress and dislodge much earlier in their formation, therefore not being 
affected by the fibrinolytic system as much yet.  
A recent study, using a 12 minute 4% FeCl3 injury model on the femoral vein, 
suggested that FXIII activity may be protective against pulmonary embolism 
in mice by stabilising venous thrombi (Shaya et al., 2019). C57BL/6 
background mice that received FXIII supplementation showed reduced 
number of embolic events captured by intravital microscopy and reduced 
emboli numbers in histologically sectioned lungs, when compared to control 
mice. However, in this study, the mice were FXIII sufficient, were injected 
with human FXIII, and also received a number of anticoagulants. Therefore, 
the comparison of these data with the data presented in this thesis has to be 
made very carefully as the two studies employed very different models to 
study pulmonary embolism. In order to investigate these apparent 
contradictions further, a comparison of data from an IVC ligation model, 
creating a reduced venous flow environment, would be very interesting and 
beneficial in understanding the role of FXIII in a venous thrombotic 
environment development.  
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Chapter 6 Discussion 
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6.1 Summary of data 
The work carried out in this PhD thesis was aimed at achieving the following 
main goals: 1) to develop and characterise a newly developed, world-first, 
murine FXIII-A V34L model; 2) to establish murine FeCl3 vascular injury 
models for studying both arterial and venous thromboembolism; 3) to use 
these newly developed models alongside light sheet microscopy in order to 
observe systemic in vivo effects of FXIII-A V34L sequence variant on CVD. 
Various in vitro techniques were utilised to obtain murine FXIII-A 34Leu and 
34Val recombinant proteins, ex vivo L34V mice characterisation assays were 
performed in order to determine the newly acquired mouse variant 
phenotype, and several new in vivo surgical and imaging techniques were 
developed and characterised to investigate effects of the FXIII-A V34L 
sequence variant on thrombosis. 
My studies and experimental design started with the production of 
recombinant murine FXIII variants. The series of E. coli bacteria 
transformations, culturing and mFXIII-A DNA generation was successful at 
each step carried out, and the correct gene insert sequences were confirmed 
by sequencing along the way. Using site-directed mutagenesis the L34V 
variant DNA construct was successfully generated without introducing any 
unwanted mutations. Both the 34Val and 34Leu recombinant mFXIII-A DNA 
was inserted in the mammalian expression vector pLIVE and bacterial 
expression vector pGEX-6P-1. There was no longer a need to utilise pLIVE 
mFXIII-A for injection into FXIII-A Knock-Out (FXIII-/-) mice in order to 
generate L34V mice through hydrodynamic gene transfer, a method that 
usually leads to only transient and highly variable recombinant FXIII 
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expression at best. Instead, CRISPR generated L34V mice were obtained 
from the GEMM MRC Harwell Institute in Oxford during the second year of 
my PhD project, which replaced the need for hydrodynamic gene transfer 
with two robust and non-variable mouse strains of each genotype.  
Both variants of recombinant mFXIII-A were expressed in E. coli and purified 
with GST tag either attached or removed from the protein. With the cleaved 
version, I originally planned to perform in vitro investigations comparing 
34Val and 34Leu variants, however purification yields and protein purities 
were insufficient. Recombinant protein expression and purification for in vitro 
experimentation was chosen over FXIII-purification from mice plasma due to 
FXIII plasma purification resulting in low yields of FXIII and requiring 
thousands of mice to be bled in order to achieve required amounts as tested 
previously by my colleagues in the group. GST-bound mFXIII-A fusion 
protein was used to perform activation peptide cleavage assay, which 
revealed that 34Leu variant is activated 18% faster than the 34Val variant. 
The 18% increase is lower than the previously published 43% increase, 
using recombinant human FXIII-A injected in FXIII-A Knock-Out mice (Duval 
et al., 2016), which could be due to high levels of impurities in my purified 
protein samples, or due to the fact that the GST tag was still present in the 
purified protein. 
Since the CRISPR generated C57BL/6 background mFXIII-A L34V mice 
were received during the second year of my PhD project, I carried out their 
phenotypical characterisation. The FXIII-A 34Leu variant is the only existing 
variant in laboratory mice, therefore the newly generated 34Val mice enabled 
the comparison between Wild-Type 34Leu and generated 34Val mFXIII-A 
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variants. These newly acquired mice were compared not only to the C57BL/6 
background Wild-Type 34Leu mice, but also to C57BL/6 background FXIII-A 
Knock-Out mice in order to have a negative control for FXIII activity. 
Furthermore, FXIII-/- mice data served as a useful addition in order to 
analyse the data sets from all three mice variants as a gradient of FXIII 
activation and activity: FXIII-/- << 34Val < 34Leu.  
The 34Val and 34Leu mice were breeding, feeding and growing at a similar 
rate and their plasma fibrinogen levels, plasma FXIII-A antigen levels and 
plasma turbidity profiles were similar. Moreover, whole blood clot contraction, 
clot supernatant haemoglobin levels, clot weights and rotational 
thromboelastometry profiles were similar too. According to the expectation, 
plasma FXIII-A activation rates were different by 40%, 34Leu variant being 
faster activated, completely in agreement with a previous study using human 
recombinant FXII V34L variants injected in FXIII-/- mice (ref to Duval et al.). 
Although less pronounced, both these findings are in agreement with 
published human plasma FXIII-A activation rate difference between 34Val 
and 34Leu variants, showing a 2-fold rate difference (Ariens et al., 2000). 
These ex vivo results show that 34Val and 34Leu mice can be accurately 
compared, based on their difference solely on FXIII-A activation rate, using in 
vivo thrombosis model experiments. 
The ex vivo data from the FXIII-/- mice showed as expected no plasma FXIII-
A antigen levels present, negligible plasma cross-linking activity, clots taking 
longer to form, fibrin fibres being thicker, less stiff and easier to lyse than 
compared to the FXIII-A bearing mice data. Clots from FXIII-/- mice showed 
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less RBC incorporation and were therefore lighter than their WT 
counterparts.  
The final year of my PhD project was dedicated primarily to the development 
of new in vivo thrombosis and thromboembolism models. Utilising the reliable 
and reproducible FeCl3 vascular injury technique, I established both venous 
and arterial thromboembolism models; choosing the Inferior Vena Cava 
(IVC) for pulmonary emboli generation, and the carotid artery injury for 
cerebral emboli generation. In light of the published literature, it was 
originally hypothesised that the 34Leu mice would show reduced pulmonary 
emboli, while probably showing inconclusive effects in ischaemic stroke. 
However, increasing FXIII activation rate (FXIII-/- << 34Val < 34Leu), and 
therefore increasing early cross-linking activity, increased pulmonary emboli 
count and total emboli volume, while showing inconclusive effects on the 
counts and volumes of cerebral emboli.  
6.2 Overall discussion 
An 18% activation speed increase of 34Leu FXIII-A variant over the 34Val 
variant confirmed the expected and previously established difference (Ariens 
et al., 2000), however the speed increase was lower than that showed by 
Duval et al. (2016) using human variant in vitro (81%) and in FXIII-/- mice 
(43%). The reason for a smaller difference in activation rates could lie in low 
purity of my murine FXIII samples and host cell proteins interfering with 
thrombin activation of FXIII. It could also be the case that the GST-tag, 
attached to the N-terminus of the activation peptide of FXIII-A is interfering 
with thrombin enzymatic activity being only 37 amino acids away from the 
thrombin cleavage site (Figure 6.1). 
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Figure 6.1 Depiction of GST-FXIII-A fusion protein. 
GST-FXIII-A fusion protein structure starting from N-terminus: GST tag, 
activation peptide (amino acids 1-37), β-sandwich (38-184), catalytic core 
(185-515), β-barrel 1 (516-628) and β-barrel 2 (629-727). Key sites, thrombin 
cleavage site and reactive catalytic cysteine314 residue, are marked with V 
insertion signs. 
 
Nevertheless, the findings confirmed that the murine FXIII-A variant behaves 
in the similar trend when compared to human FXIII-A variants, with the 
34Leu variant showing enhanced activation rate over the 34Val variant.  
The mouse characterisation results confirmed that the three mice variants 
investigated (FXIII-/-, 34Leu and 34Val) are phenotypically similar in general 
parameters, such as growth rate and weight, which may influence 
coagulation as shown in a study with 377 patients, where obese patients 
were more hypercoagulable after an injury (Kornblith et al., 2015) and a 
study with 100 obese patients showing that weight reduction modulates 
systemic inflammation and coagulation (Kobayashi et al., 2004). It was also 
shown that mice were growing at the similar rate and had similar levels of 
fibrinogen in their plasma, similar levels of FXIII-A antigen in their plasma 
(FXIII-/- mice have none) and once again confirmed that FXIII-A activation is 
increased for 34Leu variant, when compared to 34Val (and FXIII-/-) variant. 
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This time the activation rate difference was captured by measuring the 
kinetics of biotin incorporation into fibrin by FXIII, which is indicative of FXIII-
A activation rate, while fully pre-activated 34Leu and 34Val mFXIII-A 
eventually show the same catalytic activity (Wartiovaara et al., 2000). 
Plasma FXIII-A from 34Leu mice showed 139.5% activity of the 34Val variant 
while FXIII-/- variant mice showed only 2.5% of the 34Val activity. Knowing 
that all three mice variants were phenotypically similar and the only 
difference between them was FXIII activation rate, we were confident moving 
forward, that experimental ex vivo and in vivo thrombosis model differences 
would be dependent solely on FXIII-A activation rate differences. 
Interestingly, ex vivo results in plasma turbidity, whole blood 
thromboelastometry, clot contraction, clot supernatant haemoglobin levels 
and clot weight measurement experiments were similar between 34Val and 
34Leu mice, and showed no statistical differences across the board. The 
turbidity assay was expected to show that murine 34Leu variant clots have a 
shorter lag time and form thinner fibrin fibres, as shown by Ariens et al., 
2000. Thromboelastometry was expected to show 34Leu clots to be firmer 
and to lyse slower, as shown in whole blood thromboelastometry studies 
inhibiting FXIII (Jambor et al., 2009) and 34Val vs. 34Leu turbidity lysis 
studies (Duval et al., 2016). 34Leu clot contraction was also expected to be 
enhanced, with increased red blood cell retention and higher clot weight. 
These expectations were based on the studies showing that FXIII activity is 
responsible for clot retraction in both mice (Kasahara et al., 2010) and 
humans (Tutwiler et al., 2016), RBC retention (Aleman et al., 2014, Byrnes et 
al., 2015) and clot weight (Kattula et al., 2018). Therefore, if FXIII activity is 
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responsible for these effects, FXIII activation rate resulting in more cross-
linking activity was expected to have similar effects as well. The lack of 
differences between 34Leu and 34Val ex vivo results could stem from 
multiple reasons discussed below.  
The 34Leu effects on coagulation could manifest only in a flowing circulatory 
environment, where both coagulation and fibrinolytic agents are being 
constantly refreshed to the site of clot formation. In a glass tube, turbidity 
plate well or ROTEM cup the blood is static and clotting factors are prone to 
depletion, therefore potentially masking FXIII activation rate effects otherwise 
present in vivo. Another reason could be that most of the expected 
differences arise from differences in fibrin α-chain cross-linking carried out by 
the FXIII variants, which could be happening at different times when 
comparing human and murine clotting. Preliminary data collected by Dr 
Cedric Duval shows that α-chain cross-linking in mice started and finished 
much earlier in time (and is complete within 10 min after initiation of clotting) 
when compared to the human variants (complete in 60-120 min). Any effects 
of differences in FXIII activation rates on clot structure could be overruled or 
cancelled by the much faster alpha-chain cross-linking rates in mice.  
Ex vivo FXIII-/- values however were mostly different from both 34Val and 
34Leu values, and agreed with published literature confirming the expected 
phenotype. In FXIII-/- data, clots took longer to form in ROTEM, as 
previously shown in published FXIII-poor human plasma 
thromboelastography studies (Schroeder et al., 2001). Additionally, ROTEM 
FXIII-/- data showed a decreased time to lysis, which agreed with published 
human whole blood experiments, showing that inhibiting cross-linking of 
161 
 
fibrin made clots more susceptible to lysis (Lorand et al., 1966). ROTEM clot 
firmness results also pointed to FXIII-/- clots being less firm, agreeing with an 
in vitro study inhibiting FXIII and showing that lack of FXIII activity makes 
whole blood clots less firm (Jambor et al., 2009). Moreover, turbidity data 
acquired showed that FXIII-/- plasma forms clots with increased fibrin fibres 
thickness when compared to FXIII sufficient mice, which agrees with 
scanning electron microscopy (SEM) study showing that increased FXIII 
activation (34Leu variant) forms thinner fibrin fibres (than 34Val variant) (Lim 
et al., 2003). FXIII-/- clots have also retained fewer red blood cells during clot 
contraction, which made the clots lighter. These findings are in agreement 
with previously published clot contraction studies using both mice (Aleman et 
al., 2014) and human (Byrnes et al., 2015) whole blood.  
Even though ex vivo experiments did not show differences in clot structure, 
the activation rates were significantly different between 34Leu and 34Val 
variants and therefore could translate into different thromboembolism 
dynamics. Consequently, this provided sufficient rationale for the PhD project 
to next revolve around arterial and venous thrombosis model development 
and thromboembolism quantification. 
During the final year of the PhD project both arterial and venous 
thromboembolism models were established, as well as light sheet 
microscopy image acquisition and emboli quantification methods were 
optimised. The choice of thrombus generation method, the FeCl3 vascular 
injury technique, came from the particular focus of the project, clot 
embolisation. It could be argued that FeCl3 vascular injury thrombi 
generation method represents a stimulus that is supra-physiological, and a 
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poor reflection of the natural, slowly developing thrombosis pathophysiology 
in patients (Neeves, 2015). This is particularly relevant for deep vein 
thrombosis (Albadawi et al., 2017), where thrombi form due to blood stasis, 
pooling, hypercoagulability and endothelial dysfunction (Kumar et al., 2010). 
Even though these concerns are valid while studying thrombosis itself and 
the origins of thrombus development, they are less of an issue when 
focusing on embolisation alone. This PhD project aimed to investigate the 
mechanisms by which FXIII-A 34Leu sequence variant affects embolisation 
dynamics, but not the thrombus development itself. It could be argued that 
the origins of the thrombus formation (endothelial damage, stasis or 
hypercoagulability) would influence the constitution of the clot itself, and 
therefore, affect embolisation as well, however as an initial murine 34Val vs. 
34Leu embolisation investigation, constrained by project time limits, FeCl3 
vascular injury model was deemed to be the best fit for the purposes of the 
study. Subsequently, the in vivo thromboembolism data resulted in closely 
grouped datasets for all mice variants, proving the accuracy of the 
methodology developed. In vivo model findings also established a clear FXIII 
cross-linking-dependent pulmonary embolism trend, as well as interesting 
cerebral embolism observations.  
The findings from both in vivo thromboembolism models showed that 
increasing activation rate of FXIII-A influenced arterial and venous 
thromboembolism differently. The differences observed could be primarily 
due to the shear stress differences between these two circulatory 
environments. In the venous circulation, more FXIII cross-linking activity 
increased pulmonary emboli generation in both total volume and count. It 
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could be argued that the antifibrinolytic effect of FXIII cross-linking activity 
was a major mechanism responsible for this. FXIII-/- mice generated clots 
that are likely more susceptible to fibrinolysis and could lose a considerable 
amount of thrombus volume before and during the embolisation, which 
reduced the emboli count. Even if a clot embolus is formed, faster lysis may 
completely dissolve the embolus during its transit from the vena cava to the 
pulmonary circulation, thereby reducing emboli counts. FXIII sufficient mice 
show increased resistance to fibrinolysis due to the cross-linking activity of 
FXIII, and therefore, preserved more thrombus volume available to embolise, 
and also preserved more clot emboli during their transit from the vena cava 
to the lungs, increasing pulmonary emboli counts. 34Leu mice, which had a 
faster activated FXIII, may show accelerated and enhanced antifibrinolytic 
activity of FXIII cross-linking, preserving even more thrombus volume able to 
progress into enhanced pulmonary embolism. This is in agreement with 
previous studies showing increased cross-linking of fibrinolysis inhibitors 
such as 2-antiplasmin into fibrin by FXIII 34Leu (Schroder and Kohler, 
2000, Duval et al., 2016). Interestingly, thromboelastometry results gathered 
in this project did not show an increased resistance to lysis for 34Leu clots 
when compared to the 34Val variant, however FXIII-/- clots did lyse faster 
than FXIII sufficient clots. It may be that the thromboelastometry analysis is 
not sensitive enough to pick up subtle but significant differences between the 
two FXIII 34Leu and 34Val variants, or perhaps these differences only occur 
under flow conditions, where thrombotic and haemostatic agents are being 
refreshed at the thrombus formation site. 
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In the arterial environment, the high shear stress of blood flow invokes far 
more force on the forming thrombi than the low shear stress venous 
circulation environment. Fast flowing blood exerts pressure and shear 
stresses on the thrombus, making it potentially break and dislodging 
thrombus fragments to embolise downstream. Therefore, a mechanical 
strengthening of the fibrin clot by increased FXIII cross-linking activity could 
stabilise the arterial thrombus at the formation site, and reduce the amount of 
emboli generating and dislodging from the thrombus. This stabilisation effect 
could have potentially counteracted the antifibrinolytic effect of FXIII, where 
resistance to lysis could have promoted thrombus volume prevention, 
however at the same time could have enhanced thrombus stability and 
reduced chances of embolisation.  Additionally, due to high shear of arterial 
circulation, thrombi could be spending less time at the formation site before 
traveling downstream than venous thrombi have, in addition to spending less 
time in transit from the thrombus site to the brain due to the high shear 
arterial circulation, and therefore, could have been influenced by thrombus-
preserving antifibrinolytic effect of FXIII far less than those in the venous 
circulation. Consequently, fibrinolysis would have had less time to reduce the 
number and size of emboli reaching the brain. 
The fact that 34Val mice generate less arterial emboli than FXIII-/- mice, may 
suggest that FXIII cross-linking greatly enhances the stability of arterial 
thrombi. However, 34Leu mice showed slightly increased emboli generation 
when compared to 34Val mice, suggesting that the faster activated 34Leu 
variant does not provide meaningful additional clot stability over 34Val 
variant, but perhaps rather provides additional fibrinolysis inhibition. The 
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reason that this counteracting effect was not observed in the venous 
circulation could be that a low shear stress of venous flow does not invoke 
enough force on the thrombus for the additional clot stability effect of 34Leu 
variant to be meaningful. Interestingly, thromboelastometry results have not 
shown 34Leu variant clots to be firmer than 34Val clots, however both FXIII 
sufficient variant clots were far firmer than the FXIII-/- clots. A published 
study with 313 post-surgery patients used ROTEM and shown that clot 
firmness was higher for the patients which had thromboembolic 
complications after the surgery (Hincker et al., 2014). Moreover, a French 
study (Collet et al., 2006) has shown that MI patient clots were more rigid as 
well. Therefore, it could be that the stabilisation effects of arterial thrombi are 
not related to the rigidity or firmness of the clot, but rather the elasticity of 
them. Further experiments investigating viscoelastic properties of arterial 
thrombi could elucidate these mechanical distinctions at play. Published 
literature conclusively point towards arterial thrombi being more resistant to 
lysis in pathology bearing patients. It has been reported (Undas and Ariens, 
2011) that clots coming from advanced CAD (Fatah et al., 1992, Undas et 
al., 2007), acute MI (Undas et al., 2008), previous MI (Fatah et al., 1996, 
Collet et al., 2006, Meltzer et al., 2010, Guimaraes et al., 2009), acute stroke 
(Rooth et al., 2011, Undas et al., 2011) and previous stroke (Undas et al., 
2009, Guimaraes et al., 2009) patients are taking longer to lyse, are less 
permeable and also take less time to initiate clotting. This suggests that, 
similarly to venous thrombosis, clots in arterial pathology are denser and 
more resistant to lysis (Undas, 2017), which are an established effects of 
FXIII activity (Hethershaw et al., 2014, Ariens et al., 2002). However, when 
166 
 
considering ischaemic stroke, meta-analysis studies point to inconclusive 
results of FXIII activity, concluding no direct correlation between the faster 
activated 34Leu variant and ischaemic stroke (Li et al., 2012, Wei et al., 
2019), suggesting that in arterial thrombosis opposing mechanisms could be 
at play, balancing prothrombotic (enhanced clot density and resistance to 
lysis) effects of FXIII against the speculated anti-embolic effects of FXIII (clot 
stabilisation).  
These dynamics between antifibrinolytic and stabilising effects of FXIII cross-
linking could be the reason why FXIII activation rates affected venous 
thrombi generation in a clear FXIII-dependent manner, while arterial thrombi 
generation remained inconclusive (Figure 6.2). 
The fact that pulmonary embolism shows a clear FXIII-dependent 
characteristic can potentially be therapeutically utilised. High PE risk 
patients, e.g. DVT or VTE patients, could be prophylactically given FXIII 
inhibitors (Lee and Ansell, 2011). Currently FXIII activation can be indirectly 
modulated by thrombin inhibitors, however if further research confirms a 
strong link between the severity of PE and FXIII activity, this research could 
lead into the new therapeutic development, whether a pharmacological one, 
such as FXIII inhibitory peptide, or perhaps gene therapy (possibly a L34V 
mutation) for the families with an established history of venous thrombosis. 
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Figure 6.2 Vascular injury data interpretation schematic. 
Bold “<” and “>” signs show the direction of decreasing and increasing embolism amount when moving from FXIII-/-, to 34Val, to 
34Leu mice data. Top three panels show the interpretation of arterial thromboembolism data, while the bottom three relate to 
venous thromboembolism. Black box on the right hand side discusses why cross-linking effects seen are specific to either arterial 
or venous environments. 
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An interesting detail from the data collected during the PhD project comes 
from analysing gender differences. Almost in every occasion male and 
female mice had no significant difference in any of the parameters between 
gender groups, apart from one. Female FXIII-/- mice had 36.8% less median 
plasma fibrinogen (P<0.01) than the male mice. This could suggest a 
probable link between FXIII, sex hormones and fibrinogen. However, the 
consensus about fibrinogen levels being dependent on gender is not clear 
throughout the literature. A large meta-analytic study (Kamath and Lip, 2003) 
has concluded that most studies throughout Europe show that women have 
higher fibrinogen levels than men, even in adolescence (Prisco et al., 1996), 
while some studies failed to provide any significant differences (Tarallo et al., 
1992). Furthermore, any other parameters were not indicative of any 
differences between FXIII-/- male and female mice.  
Another gender difference, although not statistically significant, is clearly 
visible; 34Val female mice had 60% more cerebral emboli than the 34Val 
male mice. Interestingly, the difference between male and female 34Val mice 
in stroke occurrence is supported by multiple published studies; for example, 
a study with 1025 patients showing that the coagulation system (but not 
fibrinolytic system), signified by elevated prothrombin fragments, is 
accelerated with aging in female subjects (Inokuchi et al., 2017). Additionally, 
a study on rats following normothermic cardiopulmonary bypass has shown 
that female rats also have elevated prothrombin fragments 1+2 when 
compared to male rats (Kellermann et al., 2014). Another study with 546 
Caucasian patients showed that in a group of subjects, which only had acute 
ischaemic stroke, but no atrial fibrillation, females had lower levels of 
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fibrinogen and elevated prothrombotic agents PAI-1, FVII and FVIII when 
compared to males (Kain et al., 2003). And finally, the CHADS score, 
designed to evaluate ischaemic stroke risk treats the female gender as a risk 
factor (Gage et al., 2001). Although the reported gender differences are few, 
in selected cases and weak, their potential links to coagulation should still be 
considered when investigating thrombosis further in the future endeavours 
beyond this PhD project. 
6.3 Limitations and improvements 
6.3.1 mFXIII-A purification 
The GST-FXIII-A fusion protein samples were equally impure between 34Val 
and 34Leu. Similar impurity profiles and similar protein concentrations made 
the activation rate comparison viable, however high impurity levels in the 
samples could have interfered with activation peptide cleavage by thrombin 
and, therefore, masked some of the activation rate difference (showing 18% 
as opposed to 43% in Duval et al. 2016 study). Acquiring a purer 
recombinant mFXIII-A samples could help elucidate whether E. coli 
impurities play a role in impairing/modulating or masking differences in FXIII-
A activation. 
6.3.2 Rotational thromboelastometry and flow 
It is entirely possible, that differences between murine FXIII-A 34Leu and 
34Val affected clots in terms of fibrinolysis and stiffening reveal themselves 
under flow conditions only. Inside a ROTEM cup, calcium, t-PA and tissue 
factor are spiked-in once at the beginning of the experiment, while in 
circulation, both coagulation and fibrinolytic agents are being constantly 
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refreshed. Therefore, if the effects of different FXIII variants are dependent 
on FXIII and other haemostatic factors being maintained and constantly 
delivered to the site of clot formation, only a flowing model of clotting and 
lysis would fully reveal that. 
6.3.3 FeCl3 vascular injury model 
FeCl3 endothelial injury model on IVC does not mimic the natural VTE 
environment in human patients, where thrombi develop in a static, 
hypercoagulable environment as opposed to acute endothelial damage. 
More physiological IVC ligation and stenosis models could be employed to 
closer mimic naturally occurring pathology. 
6.3.4 Brain image software analysis 
The Imaris image analysis software struggled to take relatively dim emboli 
into the account when larger artefacts were present. When compared with 
lung samples, even with 10% FeCl3 (as opposed to 2.5% for lungs), the brain 
samples showed less emboli which were far dimmer and emitted lower 
fluorescence intensities. The brain is reported to be the most difficult to clear 
for light sheet microscopy, and all clearing protocols published for clearing 
the brain point towards the longest times for this process (Erturk et al., 2012, 
Renier et al., 2014). Therefore, the fact that emboli are not as clearly visible 
in cleared brain samples when compared to lungs is not surprising. Perhaps 
injecting a higher labelled fibrinogen concentration before the carotid artery 
injury, therefore producing emboli that contain a higher concentration of 
AlexaFluor647 dye, could potentially increase the contrast of the emboli. 
Another possibility could be to divide the brain in half prior to clearing, so that 
the DBE encounters less thickness of the brain to perfuse through. However, 
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the core of the brain is very similarly cleared when compared to the edges of 
the brain, therefore this may not help to improve the clearing efficiency. 
Since brains are high in lipids, some clearing protocols (Richardson and 
Lichtman, 2015) suggest adding a detergent, such as 0.2% TWEEN20 
(Sigma-Aldrich) to the dehydration methanol solutions in order to improve 
lipid clearing if extra clarity is needed. However, testing with addition of the 
detergent has not yielded any noticeable improvements. Finally, longer 
clearing times were suggested in the literature, however extending it over a 
standard 72 hours of DBE clearing did not yield visible clarity increase. 
6.4 Future work 
6.4.1 Thrombin concentrations 
Ex vivo assays could be rerun using lower concentrations of thrombin, to see 
if the differences between FXIII-A 34Val and 34Leu mice would be more 
pronounced. This was realised after discovering a previously published study 
showing that with increasing concentrations of thrombin the activation rate 
difference between FXIII-A 34Leu and 34Val variants diminishes (Balogh et 
al. 2000).  
6.4.2 Confocal lysis 
Clot lysis experiments using confocal microscopy would provide a more in-
depth insight about the differences between mFXIII-A 34Leu and 34Val clots 
in resisting fibrinolysis.  
6.4.3 Magnetic tweezers 
An in depth knowledge of how mFXIII-A 34Leu and 34Val affected clots differ 
in their viscoelastic properties could come from magnetic tweezers 
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experiments, where magnetic beads are trapped inside the clot and being 
pulled in different frequencies by utilising a magnetic field. Collected data 
would tell if 34Leu clots are more capable of storing the force applied to them 
(elasticity) by the high shear stress of arterial environment or are they more 
prone to permanent deformation (viscosity). A recent article published by my 
colleagues showed that recurrent VTE patients form clots that are less 
elastic and less viscous than clots from non-recurrent VTE patients (Baker et 
al., 2019), therefore showing that viscoelastic properties of clots are 
important in thromboembolism occurrence. 
6.4.4 Atomic force microscopy single fibrin fibre measurements 
By puling onto a single fibrin fibre with an atomic force microscope cantilever, 
it is possible to measure the force required to break the fibre, as well as the 
force required to permanently deform it. This would allow investigating 
differences in fibrin fibre stiffness and extensibility between the mFXIII-A 
34Leu and 34Val clots. 
6.4.5 Scanning electron microscopy 
Scanning electron microscopy could provide a close up look at the fibrin fibre 
thickness, density, clot mesh branching and porosity. mFXIII-A 34Leu and 
34Val clot structural differences could potentially be revealed up close. 
6.4.6 Alternative fibrin cross-linking proteins 
A low fibrin cross-linking activity observed during FXIII-/- plasma biotin 
incorporation assay run was postulated to be either a background reading or 
perhaps TG1 or TG2 present in the plasma. This could be elucidated by 
repeating the assay on FXIII-/- plasma with TG inhibitors present. 
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6.4.7 Non-thrombin FXIII activators 
34Leu and 34Val mFXIII-A activation and cross-linking activity could be 
looked into by using alternative FXIII activators, such as human neutrophil 
elastase (HNE). Since HNE proteolytic cleavage site on FXIII-A is different to 
that of thrombin, the activation rate difference between FXIII-A sequence 
variants could manifest differently and provide insight into characteristics of 
these FXIII-A variants. 
6.4.8 IVC stenosis model 
Future pulmonary embolism experiments and studies would benefit from 
using an inferior vena cava stenosis model. The stenosis model, in which a 
suture is ligated around the vein, obstructing the blood flow by ~90% (Brill et 
al., 2011), better mimics the natural venous thrombotic pathology in VTE 
patients’ veins, where blood flow is restricted and becomes static. A closer 
reproduction to human thrombosis pathology could mean a more accurate 
simulation of thromboembolism as well. 
6.4.9 Inflammation 
Inflammation is a common contributing mechanism and cause of thrombosis 
in both arterial and venous environments. Embolism data in combination with 
inflammation present would be of interest from a human pathophysiology 
point of view. Therefore, a lipopolysaccharide (LPS)-induced systemic 
inflammation model, utilising an abdominal osmotic pump implant would be a 
plausible future investigation. Dr Cédric Duval is carrying out the 
investigation in IVC FeCl3 injury leading to PE in presence of LPS-induced 
systemic inflammation at the present time. 
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6.4.10 Pulmonary burden  
Mice breathing pattern investigation during the one hour inferior vena cava 
emboli generation could be investigated in order to study pulmonary burden 
and PE damage translation to the loss of pulmonary function.  
6.4.11 Stroke severity  
Mice brains affected by cerebral embolism could be investigated for their 
tissue oxygen deprivation and hypoxia damage, providing an insight into how 
differently 34Leu and 34Val FXIII-A variants affect the severity of stroke.  
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8.1 Appendix 1 
Clustal Omega web tool alignment of a portion CMV-SPORT6 vector 
containing WT mFXIII-A sequence with a PCR amplification product. 
 
CMV-SPORT6      cttttgaggaagtacccagaggcacacagagagactaccagagcaccctctcaggagcac 
pCR2.1 - WT     ------------------------------------------------------------ 
                                                                             
 
CMV-SPORT6      aagcaggatccagtaaagctgagaATGtcagatactccagcaagcacctttggggggagg 
pCR2.1 - WT     ------------------------ATGTCAGATACTCCAGCAAGCACCTTTGGGGGGAGG 
                                        ************************************ 
 
CMV-SPORT6      CGAGCAGTCCCGCCCAATAACTCCAATGCTGCAGAAGTGGACCTCCCAACTGAGGAGCTA 
pCR2.1 - WT     CGAGCAGTCCCGCCCAATAACTCCAATGCTGCAGAAGTGGACCTCCCAACTGAGGAGCTA 
                ************************************************************ 
 
CMV-SPORT6      CAAGGCCTGGTGCCAAGGGGTGTCAACCTGAAAGATTACCTGAATGTCACAGCTGTTCAC 
pCR2.1 - WT     CAAGGCCTGGTGCCAAGGGGTGTCAACCTGAAAGATTACCTGAATGTCACAGCTGTTCAC 
                ************************************************************ 
 
CMV-SPORT6      CTGTTCAAGGAGAGATGGGACAGTAACAAGATTGATCACCACACAGACAAATATGACAAC 
pCR2.1 - WT     CTGTTCAAGGAGAGATGGGACAGTAACAAGATTGATCACCACACAGACAAATATGACAAC 
                ************************************************************ 
 
CMV-SPORT6      AATAAGTTGATTGTCCGCAGAGGGCAGACCTTCTACATCCAGATTGACTTCAACCGTCCC 
pCR2.1 - WT     AATAAGTTGATTGTCCGCAGAGGGCAGACCTTCTACATCCAGATTGACTTCAACCGTCCC 
                ************************************************************ 
 
CMV-SPORT6      TATGACCCCAGGAAGGATCTCTTCAGAGTGGAATATGTCATTGGTCGCTACCCTCAGGAG 
pCR2.1 - WT     TATGACCCCAGGAAGGATCTCTTCAGAGTGGAATATGTCATTGGTCGCTACCCTCAGGAG 
                ************************************************************ 
 
CMV-SPORT6      AACAAGGGCACCTACATCCCTGTGCCTGTAGTGAAAGAGCTGCAAAGCGGAAAGTGGGGA 
pCR2.1 - WT     AACAAGGGCACCTACATCCCTGTGCCTGTAGTGAAAGAGCTGCAAAGCGGAAAGTGGGGA 
                ************************************************************ 
 
CMV-SPORT6      GCCAAGGTTATCATGAATGAGGACCGGTCGGTGCGACTTTCCGTTCAGTCTTCTCCGGAA 
pCR2.1 - WT     GCCAAGGTTATCATGAATGAGGACCGGTCGGTGCGACTTTCCGTTCAGTCTTCTCCGGAA 
                ************************************************************ 
 
CMV-SPORT6      TGCATTGTGGGGAAATTCCGCATGTATGTTGCAGTCTGGACTCCCTATGGCATCCTGCGT 
pCR2.1 - WT     TGCATTGTGGGGAAATTCCGCATGTATGTTGCAGTCTGGACTCCCTATGGCATCCTGCGT 
                ************************************************************ 
 
CMV-SPORT6      ACTCGAAGAGACCCAGAAACAGACACATATATTCTCTTCAACCCTTGGTGTGAAGAGGAC 
pCR2.1 - WT     ACTCGAAGAGACCCAGAAACAGACACATATATTCTCTTCAACCCTTGGTGTGAAGAGGAC 
                ************************************************************ 
 
CMV-SPORT6      GCTGTGTATCTGGATGATGAGAAGGAAAGAGAAGAGTACGTCCTGAATGACATTGGAGTG 
pCR2.1 - WT     GCTGTGTATCTGGATGATGAGAAGGAAAGAGAAGAGTACGTCCTGAATGACATTGGAGTG 
                ************************************************************ 
 
CMV-SPORT6      ATATTTTATGGGGACTTCAAAGACATCAAGAGCAGAAGCTGGAGCTATGGCCAGTTCGAA 
pCR2.1 - WT     ATATTTTATGGGGACTTCAAAGACATCAAGAGCAGAAGCTGGAGCTATGGCCAGTTCGAA 
                ************************************************************ 
 
CMV-SPORT6      GACGGCATCCTGGATACTTGCTTGTATGTGATGGACAAAGCTGAGATGGACCTTTCTGGC 
pCR2.1 - WT     GACGGCATCCTGGATACTTGCTTGTATGTGATGGACAAAGCTGAGATGGACCTTTCTGGC 
                ************************************************************ 
 
CMV-SPORT6      AGAGGCAACCCCATCAAAGTCAGCCGAGTTGGATCAGCAATGGTGAATGCCAAGGATGAT 
pCR2.1 - WT     AGAGGCAACCCCATCAAAGTCAGCCGAGTTGGATCAGCAATGGTGAATGCCAAGGATGAT 
                ************************************************************ 
 
CMV-SPORT6      GAAGGTGTTCTTGTTGGATCATGGGACAATGTCTATGCCTACGGCATCCCTCCATCAGCC 
pCR2.1 - WT     GAAGGTGTTCTTGTTGGATCATGGGACAATGTCTATGCCTACGGCATCCCTCCATCAGCC 
                ************************************************************ 
 
CMV-SPORT6      TGGACAGGAAGTGTTGACATTCTACTAGAATACAGAAGCTCGGAAACACCAGTCCGATAT 
pCR2.1 - WT     TGGACAGGAAGTGTTGACATTCTACTAGAATACAGAAGCTCGGAAACACCAGTCCGATAT 
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                ************************************************************ 
 
CMV-SPORT6      GGCCAGTGTTGGGTTTTTGCTGGTGTCTTTAACACATTTTTAAGATGCCTTGGAATCCCT 
pCR2.1 - WT     GGCCAGTGTTGGGTTTTTGCTGGTGTCTTTAACACATTTTTAAGATGCCTTGGAATCCCT 
                ************************************************************ 
 
CMV-SPORT6      GCACGAGTCATTACCAATTACTTCTCGGCCCACGACAATGATGCCAATCTGCAAATGGAC 
pCR2.1 - WT     GCACGAGTCATTACCAATTACTTCTCGGCCCACGACAATGATGCCAATCTGCAAATGGAC 
                ************************************************************ 
 
CMV-SPORT6      ATCTTCCTGGAAGAAGATGGGAATGTGAGCTCCAAACTCACCAAGGATTCGGTGTGGAAC 
pCR2.1 - WT     ATCTTCCTGGAAGAAGATGGGAATGTGAGCTCCAAACTCACCAAGGATTCGGTGTGGAAC 
                ************************************************************ 
 
CMV-SPORT6      TACCACTGCTGGAACGAAGCGTGGATGACAAGGCCTGATCTTCCTGTTGGATTTGGAGGC 
pCR2.1 - WT     TACCACTGCTGGAACGAAGCGTGGATGACAAGGCCTGATCTTCCTGTTGGATTTGGAGGC 
                ************************************************************ 
 
CMV-SPORT6      TGGCAAGCTGTGGACAGCACACCCCAGGAAAACAGTGATGGCATGTACCGCTGTGGCCCT 
pCR2.1 - WT     TGGCAAGCTGTGGACAGCACACCCCAGGAAAACAGTGATGGCATGTACCGCTGTGGCCCT 
                ************************************************************ 
 
CMV-SPORT6      GCCTCTGTCCAAGCCGTTAAGCATGGCCATGTCTGCTTCCAGTTTGATGCCCCGTTTGTT 
pCR2.1 - WT     GCCTCTGTCCAAGCCGTTAAGCATGGCCATGTCTGCTTCCAGTTTGATGCCCCGTTTGTT 
                ************************************************************ 
 
CMV-SPORT6      TTTGCAGAGGTCAACAGTGATCTTGTTTACATCACAGCTAAGCAAGATGGCACTCACGTG 
pCR2.1 - WT     TTTGCAGAGGTCAACAGTGATCTTGTTTACATCACAGCTAAGCAAGATGGCACTCACGTG 
                ************************************************************ 
 
CMV-SPORT6      GTGGAAGCCGTGGATGCCACCCATATCGGGAAGCTAATTGTGACCAAGCAAATTGGAGGA 
pCR2.1 - WT     GTGGAAGCCGTGGATGCCACCCATATCGGGAAGCTAATTGTGACCAAGCAAATTGGAGGA 
                ************************************************************ 
 
CMV-SPORT6      GATGGCATGCAGGATATCACGGATACTTACAAATTTCAAGAAGGCCAAGAAGAAGAGAGA 
pCR2.1 - WT     GATGGCATGCAGGATATCACGGATACTTACAAATTTCAAGAAGGCCAAGAAGAAGAGAGA 
                ************************************************************ 
 
CMV-SPORT6      CTAGCCCTTGAAACTGCTCTGATGTATGGAGCCAAGAAGACCCTCAACACTGAAGGTGTT 
pCR2.1 - WT     CTAGCCCTTGAAACTGCTCTGATGTATGGAGCCAAGAAGACCCTCAACACTGAAGGTGTT 
                ************************************************************ 
 
CMV-SPORT6      GTCAAATCAAGGTCTGATGTGACCATGAACTTTGATGTGGAAAATGCTGTGCTGGGAAAG 
pCR2.1 - WT     GTCAAATCAAGGTCTGATGTGACCATGAACTTTGATGTGGAAAATGCTGTGCTGGGAAAG 
                ************************************************************ 
 
CMV-SPORT6      GACTTCAAAGTGACTATCACCTTCCAGAACAATAGCTCCAATCTGTACACCATCCTGGCC 
pCR2.1 - WT     GACTTCAAAGTGACTATCACCTTCCAGAACAATAGCTCCAATCTGTACACCATCCTGGCC 
                ************************************************************ 
 
CMV-SPORT6      TATCTTTCTGGCAACATCACCTTCTACACTGGGGTATCCAAGAAAGAGTTCAAGAAGGAG 
pCR2.1 - WT     TATCTTTCTGGCAACATCACCTTCTACACTGGGGTATCCAAGAAAGAGTTCAAGAAGGAG 
                ************************************************************ 
 
CMV-SPORT6      TCCTTTGAAGAGACGCTGGATCCCTTTTCCTCCAAGAAAAAGGAGGTGCTGGTCAGAGCG 
pCR2.1 - WT     TCCTTTGAAGAGACGCTGGATCCCTTTTCCTCCAAGAAAAAGGAGGTGCTGGTCAGAGCG 
                ************************************************************ 
 
CMV-SPORT6      GGCGAGTACATGAGCCACCTTCTAGAACAGGGCTTCTTGCACTTCTTCGTCACGGCACGC 
pCR2.1 - WT     GGCGAGTACATGAGCCACCTTCTAGAACAGGGCTTCTTGCACTTCTTCGTCACGGCACGC 
                ************************************************************ 
 
CMV-SPORT6      ATCAACGAGTCCAGGGATGTCCTGGCCAAACAAAAGTCCATAATACTGACTATCCCCAAG 
pCR2.1 - WT     ATCAACGAGTCCAGGGATGTCCTGGCCAAACAAAAGTCCATAATACTGACTATCCCCAAG 
                ************************************************************ 
 
CMV-SPORT6      ATCACCATCAAGGTCCGAGGTGCTGCCATGGTTGGCTCTGATATGGTTGTGACTGTTGAG 
pCR2.1 - WT     ATCACCATCAAGGTCCGAGGTGCTGCCATGGTTGGCTCTGATATGGTTGTGACTGTTGAG 
                ************************************************************ 
 
CMV-SPORT6      TTCACTAATCCTTTAAAAGAAACACTACAAAATGTCTGGATTCATTTGGATGGTCCTGGA 
pCR2.1 - WT     TTCACTAATCCTTTAAAAGAAACACTACAAAATGTCTGGATTCATTTGGATGGTCCTGGA 
                ************************************************************ 
 
CMV-SPORT6      GTGATGAGACCCAAGAGAAAGGTGTTCCGTGAAATCCGGCCCAACACCACGGTGCAGTGG 
pCR2.1 - WT     GTGATGAGACCCAAGAGAAAGGTGTTCCGTGAAATCCGGCCCAACACCACGGTGCAGTGG 
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                ************************************************************ 
 
CMV-SPORT6      GAAGAAGTCTGTCGGCCTTGGGTCTCTGGCCATCGGAAGCTGATTGCCAGCATGACCAGT 
pCR2.1 - WT     GAAGAAGTCTGTCGGCCTTGGGTCTCTGGCCATCGGAAGCTGATTGCCAGCATGACCAGT 
                ************************************************************ 
 
CMV-SPORT6      GACTCCCTGAGACATGTGTATGGAGAGCTGGATCTTCAGATTCAAAGACGACCTACTATG 
pCR2.1 - WT     GACTCCCTGAGACATGTGTATGGAGAGCTGGATCTTCAGATTCAAAGACGACCTACTATG 
                ************************************************************ 
 
CMV-SPORT6      TAAATTCCCAGAAGGCTCAAGTGGGCTGGGGCACATGGCCTCTTGCAGTCTTGGCTATGG 
pCR2.1 - WT     TAA--------------------------------------------------------- 
                ***                                                          
 
CMV-SPORT6      agattctaatgcaaaacatagctagctcttgctttaatttgggtgtgaagactgagaccg 
pCR2.1 - WT     ------------------------------------------------------------ 
                                                                            
 
8.2 Appendix 2 
Clustal Omega web tool alignment of WT mFXIII-A insert in pLIVE 
vector with a pLIVE+mFXIII-A DNA template. 
pLIVE+mFXIII-A       aaaattttcatgatgttttcttttttgctaaaactaaagaattattcttttacatttcag 
mFXIII-A             ------------------------------------------------------------ 
                                                                                  
 
pLIVE+mFXIII-A       tttttctgctagcaggatccagtaaagctgagaATGTCAGATACTCCAGCAAGCACCTTT 
mFXIII-A             ---------------------------------ATGTCAGATACTCCAGCAAGCACCTTT 
                                                      *************************** 
 
pLIVE+mFXIII-A       GGGGGGAGGCGAGCAGTCCCGCCCAATAACTCCAATGCTGCAGAAGTGGACCTCCCAACT 
mFXIII-A             GGGGGGAGGCGAGCAGTCCCGCCCAATAACTCCAATGCTGCAGAAGTGGACCTCCCAACT 
                     ************************************************************ 
 
pLIVE+mFXIII-A       GAGGAGCTACAAGGCCTGGTGCCAAGGGGTGTCAACCTGAAAGATTACCTGAATGTCACA 
mFXIII-A             GAGGAGCTACAAGGCCTGGTGCCAAGGGGTGTCAACCTGAAAGATTACCTGAATGTCACA 
                     ************************************************************ 
 
pLIVE+mFXIII-A       GCTGTTCACCTGTTCAAGGAGAGATGGGACAGTAACAAGATTGATCACCACACAGACAAA 
mFXIII-A             GCTGTTCACCTGTTCAAGGAGAGATGGGACAGTAACAAGATTGATCACCACACAGACAAA 
                     ************************************************************ 
 
pLIVE+mFXIII-A       TATGACAACAATAAGTTGATTGTCCGCAGAGGGCAGACCTTCTACATCCAGATTGACTTC 
mFXIII-A             TATGACAACAATAAGTTGATTGTCCGCAGAGGGCAGACCTTCTACATCCAGATTGACTTC 
                     ************************************************************ 
 
pLIVE+mFXIII-A       AACCGTCCCTATGACCCCAGGAAGGATCTCTTCAGAGTGGAATATGTCATTGGTCGCTAC 
mFXIII-A             AACCGTCCCTATGACCCCAGGAAGGATCTCTTCAGAGTGGAATATGTCATTGGTCGCTAC 
                     ************************************************************ 
 
pLIVE+mFXIII-A       CCTCAGGAGAACAAGGGCACCTACATCCCTGTGCCTGTAGTGAAAGAGCTGCAAAGCGGA 
mFXIII-A             CCTCAGGAGAACAAGGGCACCTACATCCCTGTGCCTGTAGTGAAAGAGCTGCAAAGCGGA 
                     ************************************************************ 
 
pLIVE+mFXIII-A       AAGTGGGGAGCCAAGGTTATCATGAATGAGGACCGGTCGGTGCGACTTTCCGTTCAGTCT 
mFXIII-A             AAGTGGGGAGCCAAGGTTATCATGAATGAGGACCGGTCGGTGCGACTTTCCGTTCAGTCT 
                     ************************************************************ 
 
pLIVE+mFXIII-A       TCTCCGGAATGCATTGTGGGGAAATTCCGCATGTATGTTGCAGTCTGGACTCCCTATGGC 
mFXIII-A             TCTCCGGAATGCATTGTGGGGAAATTCCGCATGTATGTTGCAGTCTGGACTCCCTATGGC 
                     ************************************************************ 
 
pLIVE+mFXIII-A       ATCCTGCGTACTCGAAGAGACCCAGAAACAGACACATATATTCTCTTCAACCCTTGGTGT 
mFXIII-A             ATCCTGCGTACTCGAAGAGACCCAGAAACAGACACATATATTCTCTTCAACCCTTGGTGT 
                     ************************************************************ 
 
pLIVE+mFXIII-A       GAAGAGGACGCTGTGTATCTGGATGATGAGAAGGAAAGAGAAGAGTACGTCCTGAATGAC 
200 
 
mFXIII-A             GAAGAGGACGCTGTGTATCTGGATGATGAGAAGGAAAGAGAAGAGTACGTCCTGAATGAC 
                     ************************************************************ 
 
pLIVE+mFXIII-A       ATTGGAGTGATATTTTATGGGGACTTCAAAGACATCAAGAGCAGAAGCTGGAGCTATGGC 
mFXIII-A             ATTGGAGTGATATTTTATGGGGACTTCAAAGACATCAAGAGCAGAAGCTGGAGCTATGGC 
                     ************************************************************ 
 
pLIVE+mFXIII-A       CAGTTCGAAGACGGCATCCTGGATACTTGCTTGTATGTGATGGACAAAGCTGAGATGGAC 
mFXIII-A             CAGTTCGAAGACGGCATCCTGGATACTTGCTTGTATGTGATGGACAAAGCTGAGATGGAC 
                     ************************************************************ 
 
pLIVE+mFXIII-A       CTTTCTGGCAGAGGCAACCCCATCAAAGTCAGCCGAGTTGGATCAGCAATGGTGAATGCC 
mFXIII-A            CTTTCTGGCAGAGGCAACCCCATCAAAGTCAGCCGAGTTGGATCAGCAATGGTGAATGCC 
                     ************************************************************ 
 
pLIVE+mFXIII-A       AAGGATGATGAAGGTGTTCTTGTTGGATCATGGGACAATGTCTATGCCTACGGCATCCCT 
mFXIII-A             AAGGATGATGAAGGTGTTCTTGTTGGATCATGGGACAATGTCTATGCCTACGGCATCCCT 
                     ************************************************************ 
 
pLIVE+mFXIII-A       CCATCAGCCTGGACAGGAAGTGTTGACATTCTACTAGAATACAGAAGCTCGGAAACACCA 
mFXIII-A             CCATCAGCCTGGACAGGAAGTGTTGACATTCTACTAGAATACAGAAGCTCGGAAACACCA 
                     ************************************************************ 
 
pLIVE+mFXIII-A       GTCCGATATGGCCAGTGTTGGGTTTTTGCTGGTGTCTTTAACACATTTTTAAGATGCCTT 
mFXIII-A             GTCCGATATGGCCAGTGTTGGGTTTTTGCTGGTGTCTTTAACACATTTTTAAGATGCCTT 
                     ************************************************************ 
 
pLIVE+mFXIII-A       GGAATCCCTGCACGAGTCATTACCAATTACTTCTCGGCCCACGACAATGATGCCAATCTG 
mFXIII-A             GGAATCCCTGCACGAGTCATTACCAATTACTTCTCGGCCCACGACAATGATGCCAATCTG 
                     ************************************************************ 
 
pLIVE+mFXIII-A       CAAATGGACATCTTCCTGGAAGAAGATGGGAATGTGAGCTCCAAACTCACCAAGGATTCG 
mFXIII-A             CAAATGGACATCTTCCTGGAAGAAGATGGGAATGTGAGCTCCAAACTCACCAAGGATTCG 
                     ************************************************************ 
 
pLIVE+mFXIII-A       GTGTGGAACTACCACTGCTGGAACGAAGCGTGGATGACAAGGCCTGATCTTCCTGTTGGA 
mFXIII-A             GTGTGGAACTACCACTGCTGGAACGAAGCGTGGATGACAAGGCCTGATCTTCCTGTTGGA 
                     ************************************************************ 
 
pLIVE+mFXIII-A       TTTGGAGGCTGGCAAGCTGTGGACAGCACACCCCAGGAAAACAGTGATGGCATGTACCGC 
mFXIII-A             TTTGGAGGCTGGCAAGCTGTGGACAGCACACCCCAGGAAAACAGTGATGGCATGTACCGC 
                     ************************************************************ 
 
pLIVE+mFXIII-A       TGTGGCCCTGCCTCTGTCCAAGCCGTTAAGCATGGCCATGTCTGCTTCCAGTTTGATGCC 
mFXIII-A             TGTGGCCCTGCCTCTGTCCAAGCCGTTAAGCATGGCCATGTCTGCTTCCAGTTTGATGCC 
                     ************************************************************ 
 
pLIVE+mFXIII-A       CCGTTTGTTTTTGCAGAGGTCAACAGTGATCTTGTTTACATCACAGCTAAGCAAGATGGC 
mFXIII-A             CCGTTTGTTTTTGCAGAGGTCAACAGTGATCTTGTTTACATCACAGCTAAGCAAGATGGC 
                     ************************************************************ 
 
pLIVE+mFXIII-A       ACTCACGTGGTGGAAGCCGTGGATGCCACCCATATCGGGAAGCTAATTGTGACCAAGCAA 
mFXIII-A             ACTCACGTGGTGGAAGCCGTGGATGCCACCCATATCGGGAAGCTAATTGTGACCAAGCAA 
                     ************************************************************ 
 
pLIVE+mFXIII-A       ATTGGAGGAGATGGCATGCAGGATATCACGGATACTTACAAATTTCAAGAAGGCCAAGAA 
mFXIII-A             ATTGGAGGAGATGGCATGCAGGATATCACGGATACTTACAAATTTCAAGAAGGCCAAGAA 
                     ************************************************************ 
 
pLIVE+mFXIII-A       GAAGAGAGACTAGCCCTTGAAACTGCTCTGATGTATGGAGCCAAGAAGACCCTCAACACT 
mFXIII-A             GAAGAGAGACTAGCCCTTGAAACTGCTCTGATGTATGGAGCCAAGAAGACCCTCAACACT 
                     ************************************************************ 
 
pLIVE+mFXIII-A       GAAGGTGTTGTCAAATCAAGGTCTGATGTGACCATGAACTTTGATGTGGAAAATGCTGTG 
mFXIII-A             GAAGGTGTTGTCAAATCAAGGTCTGATGTGACCATGAACTTTGATGTGGAAAATGCTGTG 
                     ************************************************************ 
 
pLIVE+mFXIII-A       CTGGGAAAGGACTTCAAAGTGACTATCACCTTCCAGAACAATAGCTCCAATCTGTACACC 
mFXIII-A             CTGGGAAAGGACTTCAAAGTGACTATCACCTTCCAGAACAATAGCTCCAATCTGTACACC 
                     ************************************************************ 
 
pLIVE+mFXIII-A       ATCCTGGCCTATCTTTCTGGCAACATCACCTTCTACACTGGGGTATCCAAGAAAGAGTTC 
mFXIII-A             ATCCTGGCCTATCTTTCTGGCAACATCACCTTCTACACTGGGGTATCCAAGAAAGAGTTC 
                     ************************************************************ 
 
pLIVE+mFXIII-A       AAGAAGGAGTCCTTTGAAGAGACGCTGGATCCCTTTTCCTCCAAGAAAAAGGAGGTGCTG 
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mFXIII-A             AAGAAGGAGTCCTTTGAAGAGACGCTGGATCCCTTTTCCTCCAAGAAAAAGGAGGTGCTG 
                     ************************************************************ 
 
pLIVE+mFXIII-A       GTCAGAGCGGGCGAGTACATGAGCCACCTTCTAGAACAGGGCTTCTTGCACTTCTTCGTC 
mFXIII-A             GTCAGAGCGGGCGAGTACATGAGCCACCTTCTAGAACAGGGCTTCTTGCACTTCTTCGTC 
                     ************************************************************ 
 
pLIVE+mFXIII-A       ACGGCACGCATCAACGAGTCCAGGGATGTCCTGGCCAAACAAAAGTCCATAATACTGACT 
mFXIII-A             ACGGCACGCATCAACGAGTCCAGGGATGTCCTGGCCAAACAAAAGTCCATAATACTGACT 
                     ************************************************************ 
 
pLIVE+mFXIII-A       ATCCCCAAGATCACCATCAAGGTCCGAGGTGCTGCCATGGTTGGCTCTGATATGGTTGTG 
mFXIII-A             ATCCCCAAGATCACCATCAAGGTCCGAGGTGCTGCCATGGTTGGCTCTGATATGGTTGTG 
                     ************************************************************ 
 
pLIVE+mFXIII-A       ACTGTTGAGTTCACTAATCCTTTAAAAGAAACACTACAAAATGTCTGGATTCATTTGGAT 
mFXIII-A             ACTGTTGAGTTCACTAATCCTTTAAAAGAAACACTACAAAATGTCTGGATTCATTTGGAT 
                     ************************************************************ 
 
pLIVE+mFXIII-A       GGTCCTGGAGTGATGAGACCCAAGAGAAAGGTGTTCCGTGAAATCCGGCCCAACACCACG 
mFXIII-A             GGTCCTGGAGTGATGAGACCCAAGAGAAAGGTGTTCCGTGAAATCCGGCCCAACACCACG 
                     ************************************************************ 
 
pLIVE+mFXIII-A       GTGCAGTGGGAAGAAGTCTGTCGGCCTTGGGTCTCTGGCCATCGGAAGCTGATTGCCAGC 
mFXIII-A             GTGCAGTGGGAAGAAGTCTGTCGGCCTTGGGTCTCTGGCCATCGGAAGCTGATTGCCAGC 
                     ************************************************************ 
 
pLIVE+mFXIII-A       ATGACCAGTGACTCCCTGAGACATGTGTATGGAGAGCTGGATCTTCAGATTCAAAGACGA 
mFXIII-A             ATGACCAGTGACTCCCTGAGACATGTGTATGGAGAGCTGGATCTTCAGATTCAAAGACGA 
                     ************************************************************ 
 
pLIVE+mFXIII-A       CCTACTATGTAAattcccagaaggctcgagtaacatcacatttaaaagcatctcaggtaa 
mFXIII-A             CCTACTATGTAA------------------------------------------------ 
                     ************                                                 
 
pLIVE+mFXIII-A       ctatattttgaattttttaaaaaagtaactgtaatagttattattaaaatagcaaagatt 
mFXIII-A             ------------------------------------------------------------                                                                                 
 
8.3 Appendix 3 
Clustal Omega alignment of a portion of pLIVE vector containing WT 
(34Leu) and 34Val mFXIII-A sequences. mFXIII-A L34V mutagenesis from 
WT FXIII-A in pLIVE vector with L34V point mutation highlighted. Underlined 
is the location of mFXIII-A amino acid codon number 34. 
 
pLIVE-WT        aaaattttcatgatgttttcttttttgctaaaactaaagaattattcttttacatttcag 
pLIVE-L34V      ------------------------------------------------------------ 
                                                                             
 
pLIVE-WT        tttttctgctagcaggatccagtaaagctgagaATGTCAGATACTCCAGCAAGCACCTTT 
pLIVE-L34V      ---------------------------------ATGTCAGATACTCCAGCAAGCACCTTT 
                                                 *************************** 
 
pLIVE-WT        GGGGGGAGGCGAGCAGTCCCGCCCAATAACTCCAATGCTGCAGAAGTGGACCTCCCAACT 
pLIVE-L34V      GGGGGGAGGCGAGCAGTCCCGCCCAATAACTCCAATGCTGCAGAAGTGGACCTCCCAACT 
                ************************************************************ 
 
pLIVE-WT        GAGGAGCTACAAGGCCTGGTGCCAAGGGGTGTCAACCTGAAAGATTACCTGAATGTCACA 
pLIVE-L34V      GAGGAGCTACAAGGCGTGGTGCCAAGGGGTGTCAACCTGAAAGATTACCTGAATGTCACA 
                *************** ******************************************** 
 
pLIVE-WT        GCTGTTCACCTGTTCAAGGAGAGATGGGACAGTAACAAGATTGATCACCACACAGACAAA 
pLIVE-L34V      GCTGTTCACCTGTTCAAGGAGAGATGGGACAGTAACAAGATTGATCACCACACAGACAAA 
                ************************************************************ 
 
202 
 
pLIVE-WT        TATGACAACAATAAGTTGATTGTCCGCAGAGGGCAGACCTTCTACATCCAGATTGACTTC 
pLIVE-L34V      TATGACAACAATAAGTTGATTGTCCGCAGAGGGCAGACCTTCTACATCCAGATTGACTTC 
                ************************************************************ 
 
pLIVE-WT        AACCGTCCCTATGACCCCAGGAAGGATCTCTTCAGAGTGGAATATGTCATTGGTCGCTAC 
pLIVE-L34V      AACCGTCCCTATGACCCCAGGAAGGATCTCTTCAGAGTGGAATATGTCATTGGTCGCTAC 
                ************************************************************ 
 
pLIVE-WT        CCTCAGGAGAACAAGGGCACCTACATCCCTGTGCCTGTAGTGAAAGAGCTGCAAAGCGGA 
pLIVE-L34V      CCTCAGGAGAACAAGGGCACCTACATCCCTGTGCCTGTAGTGAAAGAGCTGCAAAGCGGA 
                ************************************************************ 
 
pLIVE-WT        AAGTGGGGAGCCAAGGTTATCATGAATGAGGACCGGTCGGTGCGACTTTCCGTTCAGTCT 
pLIVE-L34V      AAGTGGGGAGCCAAGGTTATCATGAATGAGGACCGGTCGGTGCGACTTTCCGTTCAGTCT 
                ************************************************************ 
 
pLIVE-WT        TCTCCGGAATGCATTGTGGGGAAATTCCGCATGTATGTTGCAGTCTGGACTCCCTATGGC 
pLIVE-L34V      TCTCCGGAATGCATTGTGGGGAAATTCCGCATGTATGTTGCAGTCTGGACTCCCTATGGC 
                ************************************************************ 
 
pLIVE-WT        ATCCTGCGTACTCGAAGAGACCCAGAAACAGACACATATATTCTCTTCAACCCTTGGTGT 
pLIVE-L34V      ATCCTGCGTACTCGAAGAGACCCAGAAACAGACACATATATTCTCTTCAACCCTTGGTGT 
                ************************************************************ 
 
pLIVE-WT        GAAGAGGACGCTGTGTATCTGGATGATGAGAAGGAAAGAGAAGAGTACGTCCTGAATGAC 
pLIVE-L34V      GAAGAGGACGCTGTGTATCTGGATGATGAGAAGGAAAGAGAAGAGTACGTCCTGAATGAC 
                ************************************************************ 
 
pLIVE-WT        ATTGGAGTGATATTTTATGGGGACTTCAAAGACATCAAGAGCAGAAGCTGGAGCTATGGC 
pLIVE-L34V      ATTGGAGTGATATTTTATGGGGACTTCAAAGACATCAAGAGCAGAAGCTGGAGCTATGGC 
                ************************************************************ 
 
pLIVE-WT        CAGTTCGAAGACGGCATCCTGGATACTTGCTTGTATGTGATGGACAAAGCTGAGATGGAC 
pLIVE-L34V      CAGTTCGAAGACGGCATCCTGGATACTTGCTTGTATGTGATGGACAAAGCTGAGATGGAC 
                ************************************************************ 
 
pLIVE-WT        CTTTCTGGCAGAGGCAACCCCATCAAAGTCAGCCGAGTTGGATCAGCAATGGTGAATGCC 
pLIVE-L34V      CTTTCTGGCAGAGGCAACCCCATCAAAGTCAGCCGAGTTGGATCAGCAATGGTGAATGCC 
                ************************************************************ 
 
pLIVE-WT        AAGGATGATGAAGGTGTTCTTGTTGGATCATGGGACAATGTCTATGCCTACGGCATCCCT 
pLIVE-L34V      AAGGATGATGAAGGTGTTCTTGTTGGATCATGGGACAATGTCTATGCCTACGGCATCCCT 
                ************************************************************ 
 
pLIVE-WT        CCATCAGCCTGGACAGGAAGTGTTGACATTCTACTAGAATACAGAAGCTCGGAAACACCA 
pLIVE-L34V      CCATCAGCCTGGACAGGAAGTGTTGACATTCTACTAGAATACAGAAGCTCGGAAACACCA 
                ************************************************************ 
 
pLIVE-WT        GTCCGATATGGCCAGTGTTGGGTTTTTGCTGGTGTCTTTAACACATTTTTAAGATGCCTT 
pLIVE-L34V      GTCCGATATGGCCAGTGTTGGGTTTTTGCTGGTGTCTTTAACACATTTTTAAGATGCCTT 
                ************************************************************ 
 
pLIVE-WT        GGAATCCCTGCACGAGTCATTACCAATTACTTCTCGGCCCACGACAATGATGCCAATCTG 
pLIVE-L34V      GGAATCCCTGCACGAGTCATTACCAATTACTTCTCGGCCCACGACAATGATGCCAATCTG 
                ************************************************************ 
 
pLIVE-WT        CAAATGGACATCTTCCTGGAAGAAGATGGGAATGTGAGCTCCAAACTCACCAAGGATTCG 
pLIVE-L34V      CAAATGGACATCTTCCTGGAAGAAGATGGGAATGTGAGCTCCAAACTCACCAAGGATTCG 
                ************************************************************ 
 
pLIVE-WT        GTGTGGAACTACCACTGCTGGAACGAAGCGTGGATGACAAGGCCTGATCTTCCTGTTGGA 
pLIVE-L34V      GTGTGGAACTACCACTGCTGGAACGAAGCGTGGATGACAAGGCCTGATCTTCCTGTTGGA 
                ************************************************************ 
 
pLIVE-WT        TTTGGAGGCTGGCAAGCTGTGGACAGCACACCCCAGGAAAACAGTGATGGCATGTACCGC 
pLIVE-L34V      TTTGGAGGCTGGCAAGCTGTGGACAGCACACCCCAGGAAAACAGTGATGGCATGTACCGC 
                ************************************************************ 
 
pLIVE-WT        TGTGGCCCTGCCTCTGTCCAAGCCGTTAAGCATGGCCATGTCTGCTTCCAGTTTGATGCC 
pLIVE-L34V      TGTGGCCCTGCCTCTGTCCAAGCCGTTAAGCATGGCCATGTCTGCTTCCAGTTTGATGCC 
                ************************************************************ 
 
pLIVE-WT        CCGTTTGTTTTTGCAGAGGTCAACAGTGATCTTGTTTACATCACAGCTAAGCAAGATGGC 
pLIVE-L34V      CCGTTTGTTTTTGCAGAGGTCAACAGTGATCTTGTTTACATCACAGCTAAGCAAGATGGC 
                ************************************************************ 
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pLIVE-WT        ACTCACGTGGTGGAAGCCGTGGATGCCACCCATATCGGGAAGCTAATTGTGACCAAGCAA 
pLIVE-L34V      ACTCACGTGGTGGAAGCCGTGGATGCCACCCATATCGGGAAGCTAATTGTGACCAAGCAA 
                ************************************************************ 
 
pLIVE-WT        ATTGGAGGAGATGGCATGCAGGATATCACGGATACTTACAAATTTCAAGAAGGCCAAGAA 
pLIVE-L34V      ATTGGAGGAGATGGCATGCAGGATATCACGGATACTTACAAATTTCAAGAAGGCCAAGAA 
                ************************************************************ 
 
pLIVE-WT        GAAGAGAGACTAGCCCTTGAAACTGCTCTGATGTATGGAGCCAAGAAGACCCTCAACACT 
pLIVE-L34V      GAAGAGAGACTAGCCCTTGAAACTGCTCTGATGTATGGAGCCAAGAAGACCCTCAACACT 
                ************************************************************ 
 
pLIVE-WT        GAAGGTGTTGTCAAATCAAGGTCTGATGTGACCATGAACTTTGATGTGGAAAATGCTGTG 
pLIVE-L34V      GAAGGTGTTGTCAAATCAAGGTCTGATGTGACCATGAACTTTGATGTGGAAAATGCTGTG 
                ************************************************************ 
 
pLIVE-WT        CTGGGAAAGGACTTCAAAGTGACTATCACCTTCCAGAACAATAGCTCCAATCTGTACACC 
pLIVE-L34V      CTGGGAAAGGACTTCAAAGTGACTATCACCTTCCAGAACAATAGCTCCAATCTGTACACC 
                ************************************************************ 
 
pLIVE-WT        ATCCTGGCCTATCTTTCTGGCAACATCACCTTCTACACTGGGGTATCCAAGAAAGAGTTC 
pLIVE-L34V      ATCCTGGCCTATCTTTCTGGCAACATCACCTTCTACACTGGGGTATCCAAGAAAGAGTTC 
                ************************************************************ 
 
pLIVE-WT        AAGAAGGAGTCCTTTGAAGAGACGCTGGATCCCTTTTCCTCCAAGAAAAAGGAGGTGCTG 
pLIVE-L34V      AAGAAGGAGTCCTTTGAAGAGACGCTGGATCCCTTTTCCTCCAAGAAAAAGGAGGTGCTG 
                ************************************************************ 
 
pLIVE-WT        GTCAGAGCGGGCGAGTACATGAGCCACCTTCTAGAACAGGGCTTCTTGCACTTCTTCGTC 
pLIVE-L34V      GTCAGAGCGGGCGAGTACATGAGCCACCTTCTAGAACAGGGCTTCTTGCACTTCTTCGTC 
                ************************************************************ 
 
pLIVE-WT        ACGGCACGCATCAACGAGTCCAGGGATGTCCTGGCCAAACAAAAGTCCATAATACTGACT 
pLIVE-L34V      ACGGCACGCATCAACGAGTCCAGGGATGTCCTGGCCAAACAAAAGTCCATAATACTGACT 
                ************************************************************ 
 
pLIVE-WT        ATCCCCAAGATCACCATCAAGGTCCGAGGTGCTGCCATGGTTGGCTCTGATATGGTTGTG 
pLIVE-L34V      ATCCCCAAGATCACCATCAAGGTCCGAGGTGCTGCCATGGTTGGCTCTGATATGGTTGTG 
                ************************************************************ 
 
pLIVE-WT        ACTGTTGAGTTCACTAATCCTTTAAAAGAAACACTACAAAATGTCTGGATTCATTTGGAT 
pLIVE-L34V      ACTGTTGAGTTCACTAATCCTTTAAAAGAAACACTACAAAATGTCTGGATTCATTTGGAT 
                ************************************************************ 
 
pLIVE-WT        GGTCCTGGAGTGATGAGACCCAAGAGAAAGGTGTTCCGTGAAATCCGGCCCAACACCACG 
pLIVE-L34V      GGTCCTGGAGTGATGAGACCCAAGAGAAAGGTGTTCCGTGAAATCCGGCCCAACACCACG 
                ************************************************************ 
 
pLIVE-WT        GTGCAGTGGGAAGAAGTCTGTCGGCCTTGGGTCTCTGGCCATCGGAAGCTGATTGCCAGC 
pLIVE-L34V      GTGCAGTGGGAAGAAGTCTGTCGGCCTTGGGTCTCTGGCCATCGGAAGCTGATTGCCAGC 
                ************************************************************ 
 
pLIVE-WT        ATGACCAGTGACTCCCTGAGACATGTGTATGGAGAGCTGGATCTTCAGATTCAAAGACGA 
pLIVE-L34V      ATGACCAGTGACTCCCTGAGACATGTGTATGGAGAGCTGGATCTTCAGATTCAAAGACGA 
                ************************************************************ 
 
pLIVE-WT        CCTACTATGTAAattcccagaaggctcgagtaacatcacatttaaaagcatctcaggtaa 
pLIVE-L34V      CCTACTATGTAA------------------------------------------------ 
                ************                                                 
 
pLIVE-WT        ctatattttgaattttttaaaaaagtaactgtaatagttattattaaaatagcaaagatt 
pLIVE-L34V      ------------------------------------------------------------ 
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8.4 Appendix 4 
Clustal Omega web tool alignment of inserted WT and L34V mFXIII-A 
sequences into pGEX-6P-1 vector.  
Included pGEX-6P-1 sequence alongside WT mFXIII-A sequence is shown 
for vector demonstration purposes. L34V point mutation is highlighted, while 
underlined is the location of mFXIII-A amino acid codon number 34. 
 
pGEX6P1-WT        atcctccaaaatcggatctggaagttctgttccaggggcccctgggatccccggaattcA 
pGEX6P1-L34V      -----------------------------------------------------------A 
                                                                             * 
 
pGEX6P1-WT        TGTCAGATACTCCAGCAAGCACCTTTGGGGGGAGGCGAGCAGTCCCGCCCAATAACTCCA 
pGEX6P1-L34V      TGTCAGATACTCCAGCAAGCACCTTTGGGGGGAGGCGAGCAGTCCCGCCCAATAACTCCA 
                  ************************************************************ 
 
pGEX6P1-WT        ATGCTGCAGAAGTGGACCTCCCAACTGAGGAGCTACAAGGCCTGGTGCCAAGGGGTGTCA 
pGEX6P1-L34V      ATGCTGCAGAAGTGGACCTCCCAACTGAGGAGCTACAAGGCGTGGTGCCAAGGGGTGTCA 
                  ***************************************** ****************** 
 
pGEX6P1-WT        ACCTGAAAGATTACCTGAATGTCACAGCTGTTCACCTGTTCAAGGAGAGATGGGACAGTA 
pGEX6P1-L34V      ACCTGAAAGATTACCTGAATGTCACAGCTGTTCACCTGTTCAAGGAGAGATGGGACAGTA 
                  ************************************************************ 
 
pGEX6P1-WT        ACAAGATTGATCACCACACAGACAAATATGACAACAATAAGTTGATTGTCCGCAGAGGGC 
pGEX6P1-L34V      ACAAGATTGATCACCACACAGACAAATATGACAACAATAAGTTGATTGTCCGCAGAGGGC 
                  ************************************************************ 
 
pGEX6P1-WT        AGACCTTCTACATCCAGATTGACTTCAACCGTCCCTATGACCCCAGGAAGGATCTCTTCA 
pGEX6P1-L34V      AGACCTTCTACATCCAGATTGACTTCAACCGTCCCTATGACCCCAGGAAGGATCTCTTCA 
                  ************************************************************ 
 
pGEX6P1-WT        GAGTGGAATATGTCATTGGTCGCTACCCTCAGGAGAACAAGGGCACCTACATCCCTGTGC 
pGEX6P1-L34V      GAGTGGAATATGTCATTGGTCGCTACCCTCAGGAGAACAAGGGCACCTACATCCCTGTGC 
                  ************************************************************ 
 
pGEX6P1-WT        CTGTAGTGAAAGAGCTGCAAAGCGGAAAGTGGGGAGCCAAGGTTATCATGAATGAGGACC 
pGEX6P1-L34V      CTGTAGTGAAAGAGCTGCAAAGCGGAAAGTGGGGAGCCAAGGTTATCATGAATGAGGACC 
                  ************************************************************ 
 
pGEX6P1-WT        GGTCGGTGCGACTTTCCGTTCAGTCTTCTCCGGAATGCATTGTGGGGAAATTCCGCATGT 
pGEX6P1-L34V      GGTCGGTGCGACTTTCCGTTCAGTCTTCTCCGGAATGCATTGTGGGGAAATTCCGCATGT 
                  ************************************************************ 
 
pGEX6P1-WT        ATGTTGCAGTCTGGACTCCCTATGGCATCCTGCGTACTCGAAGAGACCCAGAAACAGACA 
pGEX6P1-L34V      ATGTTGCAGTCTGGACTCCCTATGGCATCCTGCGTACTCGAAGAGACCCAGAAACAGACA 
                  ************************************************************ 
 
pGEX6P1-WT        CATATATTCTCTTCAACCCTTGGTGTGAAGAGGACGCTGTGTATCTGGATGATGAGAAGG 
pGEX6P1-L34V      CATATATTCTCTTCAACCCTTGGTGTGAAGAGGACGCTGTGTATCTGGATGATGAGAAGG 
                  ************************************************************ 
 
pGEX6P1-WT        AAAGAGAAGAGTACGTCCTGAATGACATTGGAGTGATATTTTATGGGGACTTCAAAGACA 
pGEX6P1-L34V      AAAGAGAAGAGTACGTCCTGAATGACATTGGAGTGATATTTTATGGGGACTTCAAAGACA 
                  ************************************************************ 
 
pGEX6P1-WT        TCAAGAGCAGAAGCTGGAGCTATGGCCAGTTCGAAGACGGCATCCTGGATACTTGCTTGT 
pGEX6P1-L34V      TCAAGAGCAGAAGCTGGAGCTATGGCCAGTTCGAAGACGGCATCCTGGATACTTGCTTGT 
                  ************************************************************ 
 
pGEX6P1-WT        ATGTGATGGACAAAGCTGAGATGGACCTTTCTGGCAGAGGCAACCCCATCAAAGTCAGCC 
pGEX6P1-L34V      ATGTGATGGACAAAGCTGAGATGGACCTTTCTGGCAGAGGCAACCCCATCAAAGTCAGCC 
                  ************************************************************ 
 
pGEX6P1-WT        GAGTTGGATCAGCAATGGTGAATGCCAAGGATGATGAAGGTGTTCTTGTTGGATCATGGG 
pGEX6P1-L34V      GAGTTGGATCAGCAATGGTGAATGCCAAGGATGATGAAGGTGTTCTTGTTGGATCATGGG 
                  ************************************************************ 
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pGEX6P1-WT        ACAATGTCTATGCCTACGGCATCCCTCCATCAGCCTGGACAGGAAGTGTTGACATTCTAC 
pGEX6P1-L34V      ACAATGTCTATGCCTACGGCATCCCTCCATCAGCCTGGACAGGAAGTGTTGACATTCTAC 
                  ************************************************************ 
 
pGEX6P1-WT        TAGAATACAGAAGCTCGGAAACACCAGTCCGATATGGCCAGTGTTGGGTTTTTGCTGGTG 
pGEX6P1-L34V      TAGAATACAGAAGCTCGGAAACACCAGTCCGATATGGCCAGTGTTGGGTTTTTGCTGGTG 
                  ************************************************************ 
 
pGEX6P1-WT        TCTTTAACACATTTTTAAGATGCCTTGGAATCCCTGCACGAGTCATTACCAATTACTTCT 
pGEX6P1-L34V      TCTTTAACACATTTTTAAGATGCCTTGGAATCCCTGCACGAGTCATTACCAATTACTTCT 
                  ************************************************************ 
 
pGEX6P1-WT        CGGCCCACGACAATGATGCCAATCTGCAAATGGACATCTTCCTGGAAGAAGATGGGAATG 
pGEX6P1-L34V      CGGCCCACGACAATGATGCCAATCTGCAAATGGACATCTTCCTGGAAGAAGATGGGAATG 
                  ************************************************************ 
 
pGEX6P1-WT        TGAGCTCCAAACTCACCAAGGATTCGGTGTGGAACTACCACTGCTGGAACGAAGCGTGGA 
pGEX6P1-L34V      TGAGCTCCAAACTCACCAAGGATTCGGTGTGGAACTACCACTGCTGGAACGAAGCGTGGA 
                  ************************************************************ 
 
pGEX6P1-WT        TGACAAGGCCTGATCTTCCTGTTGGATTTGGAGGCTGGCAAGCTGTGGACAGCACACCCC 
pGEX6P1-L34V      TGACAAGGCCTGATCTTCCTGTTGGATTTGGAGGCTGGCAAGCTGTGGACAGCACACCCC 
                  ************************************************************ 
 
pGEX6P1-WT        AGGAAAACAGTGATGGCATGTACCGCTGTGGCCCTGCCTCTGTCCAAGCCGTTAAGCATG 
pGEX6P1-L34V      AGGAAAACAGTGATGGCATGTACCGCTGTGGCCCTGCCTCTGTCCAAGCCGTTAAGCATG 
                  ************************************************************ 
 
pGEX6P1-WT        GCCATGTCTGCTTCCAGTTTGATGCCCCGTTTGTTTTTGCAGAGGTCAACAGTGATCTTG 
pGEX6P1-L34V      GCCATGTCTGCTTCCAGTTTGATGCCCCGTTTGTTTTTGCAGAGGTCAACAGTGATCTTG 
                  ************************************************************ 
 
pGEX6P1-WT        TTTACATCACAGCTAAGCAAGATGGCACTCACGTGGTGGAAGCCGTGGATGCCACCCATA 
pGEX6P1-L34V      TTTACATCACAGCTAAGCAAGATGGCACTCACGTGGTGGAAGCCGTGGATGCCACCCATA 
                  ************************************************************ 
 
pGEX6P1-WT        TCGGGAAGCTAATTGTGACCAAGCAAATTGGAGGAGATGGCATGCAGGATATCACGGATA 
pGEX6P1-L34V      TCGGGAAGCTAATTGTGACCAAGCAAATTGGAGGAGATGGCATGCAGGATATCACGGATA 
                  ************************************************************ 
 
pGEX6P1-WT        CTTACAAATTTCAAGAAGGCCAAGAAGAAGAGAGACTAGCCCTTGAAACTGCTCTGATGT 
pGEX6P1-L34V      CTTACAAATTTCAAGAAGGCCAAGAAGAAGAGAGACTAGCCCTTGAAACTGCTCTGATGT 
                  ************************************************************ 
 
pGEX6P1-WT        ATGGAGCCAAGAAGACCCTCAACACTGAAGGTGTTGTCAAATCAAGGTCTGATGTGACCA 
pGEX6P1-L34V      ATGGAGCCAAGAAGACCCTCAACACTGAAGGTGTTGTCAAATCAAGGTCTGATGTGACCA 
                  ************************************************************ 
 
pGEX6P1-WT        TGAACTTTGATGTGGAAAATGCTGTGCTGGGAAAGGACTTCAAAGTGACTATCACCTTCC 
pGEX6P1-L34V      TGAACTTTGATGTGGAAAATGCTGTGCTGGGAAAGGACTTCAAAGTGACTATCACCTTCC 
                  ************************************************************ 
 
pGEX6P1-WT        AGAACAATAGCTCCAATCTGTACACCATCCTGGCCTATCTTTCTGGCAACATCACCTTCT 
pGEX6P1-L34V      AGAACAATAGCTCCAATCTGTACACCATCCTGGCCTATCTTTCTGGCAACATCACCTTCT 
                  ************************************************************ 
 
pGEX6P1-WT        ACACTGGGGTATCCAAGAAAGAGTTCAAGAAGGAGTCCTTTGAAGAGACGCTGGATCCCT 
pGEX6P1-L34V      ACACTGGGGTATCCAAGAAAGAGTTCAAGAAGGAGTCCTTTGAAGAGACGCTGGATCCCT 
                  ************************************************************ 
 
pGEX6P1-WT        TTTCCTCCAAGAAAAAGGAGGTGCTGGTCAGAGCGGGCGAGTACATGAGCCACCTTCTAG 
pGEX6P1-L34V      TTTCCTCCAAGAAAAAGGAGGTGCTGGTCAGAGCGGGCGAGTACATGAGCCACCTTCTAG 
                  ************************************************************ 
 
pGEX6P1-WT        AACAGGGCTTCTTGCACTTCTTCGTCACGGCACGCATCAACGAGTCCAGGGATGTCCTGG 
pGEX6P1-L34V      AACAGGGCTTCTTGCACTTCTTCGTCACGGCACGCATCAACGAGTCCAGGGATGTCCTGG 
                  ************************************************************ 
 
pGEX6P1-WT        CCAAACAAAAGTCCATAATACTGACTATCCCCAAGATCACCATCAAGGTCCGAGGTGCTG 
pGEX6P1-L34V      CCAAACAAAAGTCCATAATACTGACTATCCCCAAGATCACCATCAAGGTCCGAGGTGCTG 
                  ************************************************************ 
 
pGEX6P1-WT        CCATGGTTGGCTCTGATATGGTTGTGACTGTTGAGTTCACTAATCCTTTAAAAGAAACAC 
pGEX6P1-L34V      CCATGGTTGGCTCTGATATGGTTGTGACTGTTGAGTTCACTAATCCTTTAAAAGAAACAC 
                  ************************************************************ 
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pGEX6P1-WT        TACAAAATGTCTGGATTCATTTGGATGGTCCTGGAGTGATGAGACCCAAGAGAAAGGTGT 
pGEX6P1-L34V      TACAAAATGTCTGGATTCATTTGGATGGTCCTGGAGTGATGAGACCCAAGAGAAAGGTGT 
                  ************************************************************ 
 
pGEX6P1-WT        TCCGTGAAATCCGGCCCAACACCACGGTGCAGTGGGAAGAAGTCTGTCGGCCTTGGGTCT 
pGEX6P1-L34V      TCCGTGAAATCCGGCCCAACACCACGGTGCAGTGGGAAGAAGTCTGTCGGCCTTGGGTCT 
                  ************************************************************ 
 
pGEX6P1-WT        CTGGCCATCGGAAGCTGATTGCCAGCATGACCAGTGACTCCCTGAGACATGTGTATGGAG 
pGEX6P1-L34V      CTGGCCATCGGAAGCTGATTGCCAGCATGACCAGTGACTCCCTGAGACATGTGTATGGAG 
                  ************************************************************ 
 
pGEX6P1-WT        AGCTGGATCTTCAGATTCAAAGACGACCTACTATGTAAattcccagaaggctcgagcggc 
pGEX6P1-L34V      AGCTGGATCTTCAGATTCAAAGACGACCTACTATGTAA---------------------- 
                  **************************************                       
 
pGEX6P1-WT        cgcatcgtgactgactgacgatctgcctcgcgcgtttcggtgatgacggtgaaaacctct 
pGEX6P1-L34V      ------------------------------------------------------------ 
                                                                               
 
